The	O
objective	O
of	O
this	O
paper	O
is	O
to	O
evaluate	O
the	O
influence	O
of	O
patient	O
risk	O
status	O
on	O
the	O
incidence	O
of	O
and	O
indications	O
for	O
cesarean	O
delivery	O
.	O
All	O
live	O
births	O
greater	O
than	O
or	O
=	O
23	O
weeks	O
at	O
the	O
University	O
of	O
Vermont	O
in	O
1995	O
(	O
n	O
=	O
2395	O
)	O
were	O
retrospectively	O
analyzed	O
for	O
delivery	O
route	O
,	O
indication	O
for	O
cesarean	O
,	O
gestational	O
age	O
,	O
parity	O
,	O
and	O
practice	O
group	O
(	O
to	O
reflect	O
risk	O
status	O
)	O
.	O
The	O
total	O
cesarean	O
rate	O
was	O
14.4	O
%	O
(	O
344	O
of	O
2395	O
)	O
,	O
and	O
the	O
primary	O
rate	O
was	O
11.4	O
%	O
(	O
244	O
of	O
2144	O
)	O
.	O
Abnormal	O
presentation	O
was	O
the	O
most	O
common	O
indication	O
(	O
25.6	O
%	O
,	O
88	O
of	O
344	O
)	O
.	O
The	O
``	O
corrected	O
''	O
cesarean	O
rate	O
(	O
maternal-fetal	O
medicine	O
and	O
transported	O
patients	O
excluded	O
)	O
was	O
12.4	O
%	O
(	O
273	O
of	O
2194	O
)	O
,	O
and	O
the	O
``	O
corrected	O
''	O
primary	O
rate	O
was	O
9.6	O
%	O
(	O
190	O
of	O
1975	O
)	O
.	O
Furthermore	O
,	O
when	O
all	O
deliveries	O
were	O
analyzed	O
,	O
regardless	O
of	O
risk	O
status	O
but	O
limited	O
to	O
gestational	O
age	O
greater	O
than	O
or	O
=	O
36	O
weeks	O
,	O
the	O
rates	O
did	O
not	O
change	O
(	O
12.6	O
%	O
,	O
280	O
of	O
2214	O
;	O
primary	O
9.2	O
%	O
,	O
183	O
of	O
1994	O
)	O
.	O
Arrest	O
of	O
dilation	O
was	O
the	O
most	O
common	O
indication	O
in	O
both	O
``	O
corrected	O
''	O
subgroups	O
(	O
23.4	O
and	O
24.6	O
%	O
,	O
respectively	O
)	O
.	O
Cesarean	O
rates	O
at	O
tertiary	O
care	O
hospitals	O
should	O
be	O
compared	O
with	O
rates	O
at	O
community	O
hospitals	O
only	O
after	O
correcting	O
for	O
dissimilar	O
patient	O
groups	O
or	O
gestational	O
age	O
.	O
In	O
the	O
third	O
trimester	O
,	O
the	O
amniotic	O
fluid	O
index	O
(	O
AFI	O
)	O
may	O
be	O
affected	O
by	O
maternal	O
fluid	O
status	O
.	O
As	O
the	O
ambient	O
temperature	O
increases	O
,	O
there	O
is	O
an	O
increase	O
in	O
insensible	O
fluid	O
loss	O
and	O
the	O
potential	O
for	O
dehydration	O
.	O
We	O
hypothesize	O
that	O
as	O
temperature	O
increases	O
there	O
would	O
be	O
a	O
concomitant	O
decrease	O
in	O
AFI	O
.	O
From	O
June	O
11	O
to	O
August	O
16	O
,	O
1993	O
,	O
during	O
a	O
period	O
of	O
unusual	O
high	O
heat	O
,	O
42	O
women	O
with	O
singleton	O
pregnancies	O
between	O
27	O
and	O
40	O
weeks	O
'	O
gestation	O
undergoing	O
serial	O
antenatal	O
testing	O
had	O
AFI	O
determinations	O
recorded	O
at	O
least	O
weekly	O
.	O
The	O
daily	O
high	O
ambient	O
temperature	O
in	O
our	O
urban	O
area	O
was	O
subsequently	O
obtained	O
.	O
A	O
2-	O
,	O
3-	O
,	O
and	O
4-day	O
mean	O
temperature	O
prior	O
to	O
the	O
test	O
date	O
was	O
compared	O
to	O
AFI	O
using	O
a	O
Spearman-rank	O
Correlation	O
.	O
The	O
daily	O
high	O
temperature	O
ranged	O
from	O
71	O
to	O
104	O
degrees	O
F	O
and	O
AFI	O
values	O
ranged	O
from	O
1.7	O
to	O
24.7	O
cm	O
during	O
the	O
study	O
period	O
.	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
2-	O
,	O
3-	O
,	O
and	O
4-day	O
mean	O
temperature	O
and	O
AFI	O
,	O
with	O
the	O
4-day	O
mean	O
being	O
the	O
most	O
significant	O
(	O
r	O
=	O
0.31	O
,	O
p	O
&	O
#	O
60	O
;	O
0.001	O
)	O
.	O
Fluctuations	O
in	O
ambient	O
temperature	O
are	O
inversely	O
correlated	O
to	O
changes	O
in	O
AFI	O
.	O
This	O
relationship	O
should	O
be	O
taken	O
into	O
account	O
when	O
interpreting	O
the	O
AFI	O
as	O
a	O
measure	O
of	O
fetal	O
well-being	O
.	O
This	O
study	O
tested	O
the	O
hypothesis	O
that	O
to	O
reduce	O
the	O
rate	O
of	O
macrosomic	O
infants	O
in	O
gestational	O
diabetes	O
cases	O
,	O
good	O
glycemic	O
control	O
should	O
be	O
initiated	O
before	O
34	O
completed	O
gestational	O
weeks	O
.	O
The	O
study	O
population	O
included	O
84	O
women	O
with	O
gestational	SYMP
diabetes	SYMP
,	O
ascertained	O
by	O
universal	O
screening	O
of	O
all	O
women	O
attending	O
the	O
antenatal	O
clinic	O
of	O
the	O
Hadassah	O
Medical	O
Center	O
,	O
over	O
a	O
2-year	O
period	O
.	O
The	O
60	O
women	O
(	O
71	O
%	O
)	O
,	O
who	O
initiated	O
treatment	O
before	O
34	O
completed	O
weeks	O
,	O
composed	O
the	O
``	O
early	O
''	O
group	O
.	O
The	O
24	O
women	O
(	O
29	O
%	O
)	O
,	O
who	O
initiated	O
treatment	O
after	O
the	O
34th	O
week	O
,	O
composed	O
the	O
``	O
late	O
''	O
group	O
.	O
All	O
patients	O
were	O
managed	O
by	O
an	O
intensified	O
protocol	O
,	O
including	O
stringent	O
glycemic	SYMP
control	SYMP
.	O
In	O
the	O
``	O
early	O
''	O
and	O
``	O
late	O
''	O
groups	O
,	O
mean	O
gestational	O
age	O
at	O
the	O
beginning	O
of	O
treatment	O
was	O
30.0	O
+/-	O
3.8	O
and	O
36.2	O
+/-	O
1.2	O
weeks	O
,	O
and	O
duration	O
of	O
treatment	O
was	O
9.6	O
+/-	O
4.1	O
and	O
3.7	O
+/-	O
1.8	O
weeks	O
,	O
respectively	O
.	O
Maternal	O
characteristics	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O
The	O
rate	O
of	O
macrosomic	O
and	O
large-for-gestational-age	O
infants	O
were	O
5	O
and	O
11	O
%	O
,	O
respectively	O
,	O
in	O
the	O
early	O
group	O
as	O
compared	O
to	O
25	O
and	O
29	O
%	O
in	O
the	O
``	O
late	O
''	O
group	O
(	O
p	O
&	O
#	O
60	O
;	O
0.05	O
)	O
.	O
No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
groups	O
in	O
the	O
mode	O
of	O
delivery	O
or	O
Apgar	O
scores	O
.	O
We	O
conclude	O
that	O
to	O
reduce	O
the	O
rate	O
of	O
macrosomic	SYMP
infants	SYMP
in	SYMP
gestational	SYMP
diabetes	SYMP
cases	SYMP
,	O
good	SYMP
glycemic	SYMP
control	SYMP
should	O
be	O
initiated	O
before	O
34	O
completed	O
gestational	O
weeks	O
.	O
Our	O
aim	O
was	O
to	O
investigate	O
the	O
contribution	O
of	O
certain	O
antenatally	O
detectable	O
markers	O
leading	O
to	O
the	O
diagnosis	O
of	O
trisomic	O
fetuses	O
we	O
observed	O
over	O
a	O
period	O
of	O
6	O
years	O
.	O
In	O
our	O
study	O
,	O
we	O
specifically	O
analyzed	O
the	O
role	O
played	O
by	O
advanced	O
maternal	O
age	O
and	O
sonographically	O
discovered	O
abnormalities	O
in	O
the	O
detection	O
of	O
autosomal	SYMP
trisomies	SYMP
.	O
All	O
together	O
,	O
27	O
fetuses	O
had	O
this	O
disorder	O
,	O
representing	O
28.7	O
%	O
(	O
27	O
of	O
94	O
)	O
of	O
all	O
cytogenetic	SYMP
aberrations	SYMP
detected	O
at	O
our	O
center	O
over	O
the	O
same	O
period	O
.	O
Down	SYMP
syndrome	SYMP
(	O
12	O
cases	O
)	O
and	O
Edward	SYMP
syndrome	SYMP
(	O
11	O
cases	O
)	O
were	O
the	O
most	O
common	O
trisomies	SYMP
,	O
while	O
4	O
cases	O
of	O
Patau	SYMP
syndrome	SYMP
were	O
also	O
diagnosed	O
.	O
The	O
most	O
common	O
indication	O
leading	O
to	O
diagnosis	O
was	O
abnormal	O
ultrasound	O
finding	O
(	O
48.2	O
%	O
)	O
,	O
followed	O
by	O
advanced	O
maternal	O
age	O
(	O
44.4	O
%	O
)	O
.	O
However	O
,	O
63	O
%	O
of	O
the	O
trisomic	O
fetuses	O
belonged	O
to	O
mothers	O
aged	O
35	O
years	O
and	O
above	O
.	O
Down	SYMP
syndrome	SYMP
fetuses	O
(	O
41.7	O
%	O
)	O
had	O
prenatally	O
detected	O
sonographic	O
anomalies	O
,	O
63.6	O
%	O
for	O
Edward	SYMP
syndrome	SYMP
,	O
and	O
all	O
fetuses	O
with	O
Patau	SYMP
syndrome	SYMP
(	O
4	O
of	O
4	O
)	O
showed	O
abnormal	O
sonographic	O
signs	O
.	O
Trisomy	SYMP
21	SYMP
presented	O
with	O
the	O
following	O
features	O
:	O
hydramnios	O
,	O
complex	O
malformations	O
,	O
pyelectasis	SYMP
,	O
and	O
duodenal	SYMP
atresia	SYMP
.	O
Trisomy	SYMP
18	SYMP
fetuses	O
showed	O
hydramnios	O
,	O
intrauterine	O
growth	O
retardation	O
,	O
microcephaly	SYMP
,	O
spina	SYMP
bifida	SYMP
,	O
and	O
nonimmune	SYMP
hydrops	SYMP
fetalis	SYMP
.	O
Signs	O
observed	O
in	O
fetuses	O
with	O
trisomy	SYMP
13	SYMP
were	O
:	O
hydrocephalus	O
,	O
intrauterine	O
growth	O
retardation	O
,	O
oligoanhydramnios	O
,	O
complex	O
malformations	O
,	O
severe	O
fetal	O
bradycardia	SYMP
and	O
hydronephrosis	SYMP
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
rate	O
of	O
preeclampsia	SYMP
is	O
increased	O
in	O
triplet	O
as	O
compared	O
to	O
twin	O
gestations	O
.	O
Fifty-three	O
triplet	O
pregnancies	O
between	O
1986	O
and	O
1993	O
at	O
The	O
New	O
York	O
Hospital-Cornell	O
Medical	O
Center	O
were	O
reviewed	O
.	O
These	O
were	O
matched	O
for	O
maternal	O
age	O
,	O
parity	O
,	O
and	O
race	O
to	O
twin	O
gestations	O
(	O
N	O
=	O
53	O
)	O
from	O
the	O
same	O
population	O
.	O
Severe	O
preeclampsia	SYMP
was	O
defined	O
by	O
standard	O
criteria	O
.	O
Student	O
's	O
t-test	O
,	O
Fisher	O
exact	O
test	O
,	O
and	O
Chi-square	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O
The	O
rate	O
of	O
severe	O
preeclampsia	SYMP
was	O
increased	O
significantly	O
in	O
the	O
triplet	O
group	O
12	O
of	O
53	O
(	O
22.6	O
%	O
)	O
as	O
compared	O
with	O
the	O
twin	O
group	O
3	O
of	O
53	O
(	O
5.7	O
%	O
)	O
(	O
OR	O
=	O
4.9	O
,	O
95	O
%	O
CI	O
1.2-23.5	O
,	O
p	O
=	O
0.02	O
)	O
.	O
The	O
rate	O
of	O
overall	O
preeclampsia	SYMP
was	O
not	O
significantly	O
different	O
in	O
the	O
triplet	O
18	O
of	O
53	O
(	O
33.96	O
%	O
)	O
or	O
twin	O
12	O
of	O
53	O
(	O
22.6	O
%	O
)	O
groups	O
.	O
In	O
this	O
retrospective	O
,	O
case-controlled	O
study	O
,	O
the	O
rate	O
of	O
severe	O
pre-eclampsia	SYMP
was	O
significantly	O
increased	O
in	O
triplet	O
gestations	O
as	O
compared	O
to	O
twins	O
although	O
the	O
overall	O
rate	O
of	O
preeclampsia	SYMP
was	O
not	O
.	O
This	O
information	O
may	O
be	O
useful	O
in	O
counseling	O
patients	O
with	O
high	O
order	O
multifetal	O
gestations	O
.	O
We	O
conducted	O
a	O
survey	O
and	O
audit	O
of	O
thermal	O
equipment	O
use	O
in	O
very	O
low-birth-weight	O
infants	O
in	O
five	O
Ohio	O
neonatal	O
intensive	O
care	O
units	O
(	O
NICUs	O
)	O
to	O
document	O
regional	O
practice	O
.	O
The	O
survey	O
indicated	O
a	O
variety	O
of	O
thermal	O
care	O
styles	O
.	O
Two	O
NICUs	O
preferred	O
to	O
admit	O
infants	O
to	O
incubators	O
,	O
the	O
other	O
three	O
favoring	O
radiant	O
warmers	O
.	O
These	O
three	O
NICUs	O
moved	O
infants	O
from	O
radiant	O
warmers	O
into	O
incubators	O
at	O
significantly	O
different	O
mean	O
ages	O
.	O
The	O
audit	O
demonstrated	O
inconsistent	O
use	O
of	O
plastic	O
covers	O
,	O
warming	O
mattresses	O
,	O
and	O
added	O
humidity	O
under	O
radiant	O
warmers	O
,	O
and	O
discrepancies	O
between	O
survey	O
responses	O
and	O
actual	O
use	O
within	O
NICUs	O
.	O
Inter-NICU	O
variability	O
of	O
thermal	O
equipment	O
use	O
may	O
complicate	O
fluid	O
management	O
.	O
This	O
report	O
describes	O
a	O
full-term	O
newborn	O
with	O
massive	SYMP
fetomaternal	SYMP
hemorrhage	SYMP
.	O
Fetal	O
movements	O
were	O
decreased	O
48	O
hr	O
prior	O
to	O
delivery	O
.	O
On	O
the	O
day	O
of	O
delivery	O
,	O
they	O
were	O
absent	O
.	O
The	O
nonstress	O
test	O
was	O
abnormal	O
with	O
low	O
biophysical	O
profile	O
and	O
decreased	O
beat-to-beat	O
variability	O
.	O
The	O
infant	O
presented	O
with	O
extreme	O
pallor	O
,	O
hypotonia	SYMP
,	O
hepatosplenomegaly	SYMP
,	O
and	O
ascites	SYMP
.	O
The	O
initial	O
hemoglobin	O
was	O
2.2	O
g/dL	O
,	O
the	O
Kleihauer-Betke	O
stain	O
was	O
27.6	O
%	O
(	O
highest	O
level	O
ever	O
reported	O
)	O
.	O
Right	O
temporal	O
and	O
cerebellar	O
hemorrhages	O
were	O
present	O
.	O
Sequelae	O
include	O
severe	O
developmental	O
delay	O
and	O
asymmetric	O
double	O
hemiplegia	SYMP
.	O
Omphalocele-Exstrophy-Imperforate	SYMP
anus-Spinal	SYMP
defects	SYMP
(	SYMP
OEIS	SYMP
complex	SYMP
)	SYMP
,	O
a	O
combination	O
of	O
omphalocele	SYMP
,	O
exstrophy	SYMP
of	SYMP
the	SYMP
bladder	SYMP
,	O
an	O
imperforate	O
anus	O
and	O
spinal	SYMP
defects	SYMP
,	O
arises	O
from	O
a	O
single	O
localized	O
defect	O
in	O
the	O
early	O
development	O
of	O
the	O
mesoderm	O
that	O
will	O
later	O
contribute	O
to	O
infraumbilical	O
mesenchyme	O
,	O
cloacal	O
septum	O
,	O
and	O
caudal	O
vertebrae	O
.	O
In	O
this	O
report	O
,	O
we	O
document	O
the	O
perinatal	O
features	O
of	O
two	O
cases	O
of	O
OEIS	SYMP
complex	SYMP
associated	O
with	O
meningomyeloceles	SYMP
and	O
severe	O
lower	O
limb	O
defects	O
,	O
and	O
discuss	O
the	O
prenatal	O
diagnosis	O
,	O
inheritance	O
,	O
and	O
differential	O
diagnosis	O
of	O
this	O
association	O
of	O
malformations	O
.	O
Although	O
long-term	O
survival	O
can	O
be	O
achieved	O
by	O
successful	O
corrective	SYMP
surgery	SYMP
,	O
the	O
associated	O
structural	O
defects	O
such	O
as	O
large	SYMP
meningomyelocele	SYMP
and	O
severe	O
limb	SYMP
aplasia	SYMP
or	O
hypoplasia	SYMP
,	O
as	O
seen	O
in	O
our	O
patient	O
,	O
can	O
influence	O
the	O
patient	O
's	O
quality	O
of	O
life	O
.	O
We	O
would	O
like	O
to	O
emphasize	O
that	O
an	O
accurate	O
prenatal	O
diagnosis	O
of	O
OEIS	SYMP
complex	SYMP
and	O
associated	O
malformations	O
is	O
important	O
for	O
the	O
detailed	O
counseling	O
of	O
the	O
family	O
as	O
well	O
as	O
appropriate	O
perinatal	O
management	O
by	O
the	O
obstetricians	O
,	O
pediatric	O
surgeons	O
,	O
urologists	O
,	O
neurosurgeons	O
,	O
and	O
neonatologists	O
.	O
Nonimmune	SYMP
hydrops	SYMP
fetails	SYMP
diagnosed	O
at	O
21	O
weeks	O
'	O
gestation	O
with	O
profound	O
ascites	SYMP
,	O
hydrothorax	SYMP
,	O
and	O
pericardial	SYMP
effusion	SYMP
receded	O
gradually	O
with	O
regression	O
of	O
a	O
subchorial	O
placental	O
lucencies	O
immediately	O
below	O
the	O
umbilical	O
cord	O
insertion	O
.	O
Careful	O
inspection	O
of	O
the	O
delivered	O
placenta	O
revealed	O
that	O
there	O
was	O
a	O
yellowish	O
lesion	O
of	O
fibrin	O
deposits	O
below	O
the	O
cord	O
insertion	O
site	O
,	O
which	O
resulted	O
from	O
the	O
absorption	O
of	O
hematoma	O
.	O
A	O
subchorial	O
placental	O
hematoma	SYMP
,	O
which	O
detected	O
as	O
a	O
subchorial	O
placental	O
lucencies	SYMP
by	O
ultrasonography	O
,	O
can	O
be	O
a	O
cause	O
of	O
reversible	O
nonimmune	SYMP
hydrops	SYMP
fetalis	SYMP
.	O
The	O
mitochondrial	SYMP
diseases	SYMP
are	O
uncommon	O
multisystem	O
disorders	O
characterized	O
by	O
the	O
presence	O
of	O
functionally	O
and/or	O
structurally	O
abnormal	O
mitochondria	O
.	O
As	O
there	O
have	O
been	O
few	O
reports	O
of	O
the	O
obstetrical	O
care	O
of	O
affected	O
patients	O
,	O
we	O
wish	O
to	O
document	O
two	O
pregnancies	O
in	O
a	O
woman	O
with	O
a	O
Chronic	SYMP
Progressive	SYMP
External	SYMP
Ophthalmoplegia	SYMP
(	SYMP
Kearns-Sayre-like	SYMP
syndrome	SYMP
)	SYMP
.	O
Both	O
pregnancies	O
were	O
complicated	O
by	O
preterm	O
labor	O
and	O
hypertension	SYMP
.	O
CONTEXT	O
:	O
Four	O
genetic	O
loci	O
have	O
been	O
identified	O
as	O
contributing	O
to	O
Alzheimer	SYMP
disease	SYMP
(	SYMP
AD	SYMP
)	SYMP
,	O
including	O
the	O
amyloid	O
precursor	O
protein	O
gene	O
,	O
the	O
presenilin	O
1	O
gene	O
,	O
the	O
presenilin	O
2	O
gene	O
,	O
and	O
the	O
apolipoprotein	O
E	O
gene	O
,	O
but	O
do	O
not	O
account	O
for	O
all	O
the	O
genetic	O
risk	O
for	O
AD	O
.	O
OBJECTIVE	O
:	O
To	O
identify	O
additional	O
genetic	O
risk	O
factors	O
for	O
late-onset	O
AD	O
.	O
DESIGN	O
:	O
A	O
complete	O
genomic	O
screen	O
was	O
performed	O
(	O
N=280	O
markers	O
)	O
.	O
Critical	O
values	O
for	O
chromosomal	O
regional	O
follow-up	O
were	O
a	O
P	O
value	O
of	O
.05	O
or	O
less	O
for	O
affected	O
relative	O
pair	O
analysis	O
or	O
sibpair	O
analysis	O
,	O
a	O
parametric	O
lod	O
score	O
of	O
1.0	O
or	O
greater	O
,	O
or	O
both	O
.	O
Regional	O
follow-up	O
included	O
analysis	O
of	O
additional	O
markers	O
and	O
a	O
second	O
data	O
set	O
.	O
SETTING	O
:	O
Clinic	O
populations	O
in	O
the	O
continental	O
United	O
States	O
.	O
PATIENTS	O
:	O
greater	O
thanFrom	O
a	O
series	O
of	O
multiplex	O
families	O
affected	O
with	O
late-onset	O
(	O
>	O
or	O
=60	O
years	O
)	O
AD	O
ascertained	O
during	O
the	O
last	O
14	O
years	O
(	O
National	O
Insititute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke-Alzheimer	O
's	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
diagnostic	O
criteria	O
)	O
and	O
for	O
which	O
DNA	O
has	O
been	O
obtained	O
,	O
a	O
subset	O
of	O
16	O
families	O
(	O
135	O
total	O
family	O
members	O
,	O
52	O
of	O
whom	O
were	O
patients	O
with	O
AD	O
)	O
was	O
used	O
for	O
the	O
genomic	O
screen	O
.	O
A	O
second	O
subset	O
of	O
38	O
families	O
(	O
216	O
total	O
family	O
members	O
,	O
89	O
of	O
whom	O
were	O
patients	O
with	O
AD	O
)	O
was	O
used	O
for	O
the	O
follow-up	O
analysis	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Linkage	O
analysis	O
results	O
generated	O
using	O
both	O
genetic	O
model-dependent	O
(	O
lod	O
score	O
)	O
and	O
model-independent	O
methods	O
.	O
RESULTS	O
:	O
Fifteen	O
chromosomal	O
regions	O
warranted	O
initial	O
follow-up	O
.	O
Follow-up	O
analyses	O
revealed	O
4	O
regions	O
of	O
continued	O
interest	O
on	O
chromosomes	O
4	O
,	O
6	O
,	O
12	O
,	O
and	O
20	O
,	O
with	O
the	O
strongest	O
results	O
observed	O
forchromosome	O
12	O
.	O
Peak	O
2-point	O
affecteds-only	O
lod	O
scores	O
(	O
n=54	O
)	O
were	O
1.3	O
,	O
1.6	O
,	O
2.7	O
,	O
and	O
2.2	O
and	O
affected	O
relative	O
pairs	O
P	O
values	O
(	O
n=54	O
)	O
were	O
.04	O
,	O
.03	O
,	O
.14	O
,	O
and	O
.04	O
for	O
D12S373	O
,	O
D12S1057	O
,	O
D12S1042	O
,	O
and	O
D12S390	O
,	O
respectively	O
.	O
Sibpair	O
analysis	O
(	O
n=54	O
)	O
resulted	O
in	O
maximum	O
lod	O
scores	O
(	O
MLSs	O
)	O
of	O
1.5	O
,	O
2.6	O
,	O
3.2	O
,	O
and	O
2.3	O
for	O
these	O
markers	O
,	O
with	O
a	O
peak	O
multipoint	O
MLS	O
of	O
3.5	O
.	O
A	O
priori	O
stratification	O
by	O
APOE	O
genotype	O
identified	O
27	O
families	O
that	O
had	O
at	O
least	O
1	O
member	O
with	O
AD	O
whose	O
genotype	O
did	O
not	O
contain	O
an	O
APOE*4	O
allele	O
.	O
Analysis	O
of	O
these	O
27	O
families	O
resulted	O
in	O
MLSs	O
of	O
1.0	O
,	O
2.4	O
,	O
3.7	O
,	O
and	O
3.3	O
and	O
a	O
peak	O
multipoint	O
MLS	O
of	O
3.9	O
.	O
CONCLUSIONS	O
:	O
A	O
complete	O
genomic	O
screen	O
in	O
families	O
affected	O
with	O
late-onset	O
AD	O
identified	O
4	O
regions	O
of	O
interest	O
after	O
follow-up	O
.	O
Chromosome	O
12	O
gave	O
the	O
strongest	O
and	O
most	O
consistent	O
results	O
with	O
a	O
peak	O
multipoint	O
MLS	O
of	O
3.5	O
,	O
suggesting	O
that	O
this	O
region	O
contains	O
a	O
new	O
susceptibility	O
gene	O
for	O
AD	O
.	O
Additional	O
analyses	O
are	O
necessary	O
to	O
identify	O
the	O
chromosome	O
12	O
susceptibility	O
gene	O
for	O
AD	O
and	O
to	O
follow	O
up	O
the	O
regions	O
of	O
interest	O
on	O
chromosomes	O
4	O
,	O
6	O
,	O
and	O
20	O
.	O
CONTEXT	O
:	O
A	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
may	O
confer	O
substantial	O
risk	O
for	O
breast	O
and/or	O
ovarian	O
cancer	SYMP
.	O
However	O
,	O
knowledge	O
regarding	O
all	O
possible	O
mutations	O
and	O
the	O
relationship	O
between	O
risk	O
factors	O
and	O
mutations	O
is	O
incomplete	O
.	O
OBJECTIVES	O
:	O
To	O
identify	O
BRCA1	O
mutations	O
and	O
to	O
determine	O
factors	O
that	O
best	O
predict	O
presence	O
of	O
a	O
deleterious	O
BRCA1	O
mutation	O
in	O
patients	O
with	O
breast	O
and/or	O
ovarian	O
cancer	SYMP
.	O
DESIGN	O
:	O
A	O
complete	O
sequence	O
analysis	O
of	O
the	O
BRCA1	O
coding	O
sequence	O
and	O
flanking	O
intronic	O
regions	O
was	O
performed	O
in	O
798	O
women	O
in	O
a	O
collaborative	O
effort	O
involving	O
institutions	O
from	O
the	O
United	O
States	O
,	O
Italy	O
,	O
Germany	O
,	O
Finland	O
,	O
and	O
Switzerland	O
.	O
PARTICIPANTS	O
:	O
Institutions	O
selected	O
798	O
persons	O
representing	O
families	O
(	O
1	O
person	O
for	O
each	O
family	O
)	O
thought	O
to	O
be	O
at	O
elevated	O
a	O
priori	O
risk	O
of	O
BRCA1	O
mutation	O
due	O
to	O
potential	O
risk	O
factors	O
,	O
such	O
as	O
multiple	O
cases	O
of	O
breast	SYMP
cancer	SYMP
,	O
early	O
age	O
of	O
breast	SYMP
cancer	SYMP
diagnosis	O
,	O
and	O
cases	O
of	O
ovarian	SYMP
cancer	SYMP
.	O
No	O
participant	O
was	O
from	O
a	O
family	O
in	O
which	O
genetic	O
markers	O
showed	O
linkage	O
to	O
the	O
BRCA1	O
locus	O
.	O
MAJOR	O
OUTCOME	O
MEASURES	O
:	O
Sequence	O
variants	O
detected	O
in	O
this	O
sample	O
are	O
presented	O
along	O
with	O
analyses	O
designed	O
to	O
determine	O
predictive	O
characteristics	O
of	O
those	O
testing	O
positive	O
for	O
BRCA1	O
mutations	O
.	O
RESULTS	O
:	O
In	O
102	O
women	O
(	O
12.8	O
%	O
)	O
,	O
clearly	O
deleterious	O
mutations	O
were	O
detected	O
.	O
Fifty	O
new	O
genetic	O
alterations	O
were	O
found	O
including	O
24	O
deleterious	O
mutations	O
,	O
24	O
variants	O
of	O
unknown	O
significance	O
,	O
and	O
2	O
rare	O
polymorphisms	O
.	O
In	O
a	O
subset	O
of	O
71	O
Ashkenazi	O
Jewish	O
women	O
,	O
only	O
2	O
distinct	O
deleterious	O
mutations	O
were	O
found	O
:	O
185delAG	O
in	O
17	O
cases	O
and	O
5382insC	O
in	O
7	O
cases	O
.	O
A	O
bias	O
in	O
prior	O
reports	O
for	O
mutations	O
in	O
exon	O
11	O
was	O
revealed	O
.	O
Characteristics	O
of	O
a	O
patient	O
's	O
specific	O
diagnosis	O
(	O
unilateral	O
or	O
bilateral	O
breast	SYMP
cancer	SYMP
,	O
with	O
or	O
without	O
ovarian	SYMP
cancer	SYMP
)	O
,	O
early	O
age	O
at	O
diagnosis	O
,	O
Ashkenazi	O
Jewish	O
ethnicity	O
,	O
and	O
family	O
history	O
of	O
cancer	O
were	O
positively	O
associated	O
with	O
the	O
probability	O
of	O
her	O
carrying	O
a	O
deleterious	O
BRCA1	O
mutation	O
.	O
CONCLUSIONS	O
:	O
Using	O
logistic	O
regression	O
analysis	O
,	O
we	O
provide	O
a	O
method	O
for	O
evaluating	O
the	O
probability	O
of	O
a	O
woman	O
's	O
carrying	O
a	O
deleterious	O
BRCA1	O
mutation	O
for	O
a	O
wide	O
range	O
of	O
cases	O
,	O
which	O
can	O
be	O
an	O
important	O
tool	O
for	O
clinicians	O
as	O
they	O
incorporate	O
genetic	O
susceptibility	O
testing	O
into	O
their	O
medical	O
practice	O
.	O
CONTEXT	O
:	O
Approximately	O
9	O
%	O
of	O
prostate	SYMP
cancer	SYMP
cases	O
have	O
been	O
estimated	O
to	O
result	O
from	O
inheritance	O
of	O
mutated	O
prostate	O
cancer	O
susceptibility	O
genes	O
.	O
Few	O
data	O
exist	O
as	O
to	O
whether	O
there	O
are	O
clinical	O
differences	O
between	O
prostate	SYMP
cancers	SYMP
that	O
are	O
inherited	O
and	O
those	O
that	O
occur	O
in	O
the	O
general	O
population	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
phenotypic	O
characteristics	O
of	O
families	O
potentially	O
linked	O
to	O
the	O
hereditary	O
prostate	O
cancer	O
1	O
(	O
HPC1	O
)	O
locus	O
on	O
chromosome	O
1q24-25	O
.	O
DESIGN	O
:	O
Retrospective	O
case	O
study	O
in	O
which	O
clinical	O
data	O
were	O
extracted	O
from	O
medical	O
and	O
pathological	O
records	O
.	O
FAMILIES	O
:	O
A	O
total	O
of	O
74	O
North	O
American	O
families	O
with	O
hereditary	O
prostate	SYMP
cancer	SYMP
.	O
Prostate	O
cancer	O
cases	O
from	O
the	O
National	O
Cancer	O
Data	O
Base	O
were	O
used	O
as	O
a	O
reference	O
population	O
for	O
comparison	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
The	O
families	O
were	O
divided	O
into	O
2	O
groups	O
:	O
either	O
potentially	O
linked	O
(	O
33	O
families	O
with	O
133	O
men	O
with	O
prostate	SYMP
cancer	SYMP
)	O
,	O
and	O
thus	O
likely	O
to	O
be	O
carrying	O
an	O
altered	O
HPC1	O
gene	O
,	O
or	O
potentially	O
unlinked	O
(	O
41	O
families	O
with	O
172	O
men	O
with	O
prostate	SYMP
cancer	SYMP
)	O
,	O
on	O
the	O
basis	O
of	O
haplotype	O
analysis	O
in	O
the	O
region	O
of	O
HPC1	O
.	O
The	O
age	O
at	O
diagnosis	O
of	O
prostate	SYMP
cancer	SYMP
,	O
serum	O
prostate-specific	O
antigen	O
levels	O
,	O
digital	O
rectal	O
examination	O
status	O
,	O
stage	O
,	O
grade	O
,	O
primary	O
treatment	O
of	O
prostate	SYMP
cancers	SYMP
,	O
and	O
occurrence	O
of	O
other	O
cancers	SYMP
were	O
compared	O
between	O
the	O
groups	O
.	O
RESULTS	O
:	O
The	O
mean	O
age	O
at	O
diagnosis	O
of	O
prostate	SYMP
cancer	SYMP
for	O
men	O
in	O
potentially	O
linked	O
families	O
was	O
significantly	O
lower	O
than	O
for	O
men	O
in	O
potentially	O
unlinked	O
families	O
(	O
63.7	O
vs	O
65.9	O
years	O
,	O
respectively	O
,	O
P=.01	O
;	O
mean	O
age	O
at	O
diagnosis	O
in	O
the	O
reference	O
population	O
was	O
71.6	O
years	O
)	O
.	O
Higher-grade	O
cancers	SYMP
(	O
grade	O
3	O
)	O
were	O
more	O
common	O
in	O
potentially	O
linked	O
families	O
,	O
and	O
advanced-stage	O
disease	O
was	O
found	O
in	O
41	O
%	O
of	O
the	O
case	O
patients	O
in	O
potentially	O
linked	O
families	O
compared	O
with	O
31	O
%	O
in	O
both	O
the	O
potentially	O
unlinked	O
families	O
and	O
the	O
reference	O
groups	O
(	O
P=.03	O
for	O
the	O
latter	O
comparison	O
)	O
.	O
In	O
the	O
other	O
clinical	O
parameters	O
,	O
we	O
found	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
.	O
A	O
modest	O
excess	O
of	O
breast	SYMP
cancer	SYMP
and	O
colon	SYMP
cancer	SYMP
was	O
found	O
in	O
potentially	O
linked	O
families	O
in	O
comparison	O
with	O
potentially	O
unlinked	O
families	O
,	O
but	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O
CONCLUSIONS	O
:	O
Families	O
that	O
provide	O
evidence	O
for	O
segregation	O
of	O
an	O
altered	O
HPC1	O
gene	O
are	O
characterized	O
by	O
multiple	O
cases	O
of	O
prostate	SYMP
cancer	SYMP
that	O
,	O
in	O
most	O
respects	O
,	O
are	O
indistinguishable	O
from	O
nonhereditary	O
cases	O
.	O
However	O
,	O
3	O
characteristics	O
were	O
observed	O
:	O
younger	O
age	O
at	O
diagnosis	O
,	O
higher-grade	O
tumors	SYMP
,	O
and	O
more	O
advanced-stage	O
disease	O
.	O
Our	O
study	O
shows	O
that	O
a	O
significant	O
fraction	O
of	O
hereditary	O
prostate	SYMP
cancers	SYMP
are	O
diagnosed	O
in	O
advanced	O
stages	O
,	O
emphasizing	O
the	O
clinical	O
importance	O
of	O
early	O
detection	O
in	O
men	O
potentially	O
carrying	O
prostate	O
cancer	O
susceptibility	O
genes	O
.	O
These	O
findings	O
support	O
the	O
current	O
recommendations	O
to	O
screen	O
men	O
with	O
a	O
positive	O
family	O
history	O
of	O
prostate	SYMP
cancer	SYMP
beginning	O
at	O
age	O
40	O
years	O
.	O
CONTEXT	O
:	O
Susceptibility	O
to	O
multiple	SYMP
sclerosis	SYMP
(	SYMP
MS	SYMP
)	SYMP
involves	O
a	O
genetically	O
complex	O
autoimmune	O
component	O
.	O
However	O
,	O
except	O
for	O
genes	O
in	O
the	O
HLA	O
system	O
,	O
specific	O
susceptibility	O
loci	O
are	O
unknown	O
or	O
unconfirmed	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
several	O
loci	O
spanning	O
3	O
candidate	O
regions	O
for	O
a	O
role	O
in	O
multiple	SYMP
sclerosis	SYMP
(	SYMP
MS	SYMP
)	SYMP
susceptibility	O
in	O
2	O
ethnic	O
groups	O
using	O
both	O
single-locus	O
and	O
haplotype	O
analyses	O
.	O
The	O
3	O
regions	O
include	O
HLA	O
on	O
chromosome	O
6p21.3	O
,	O
APOE	O
on	O
chromosome	O
19ql	O
3.2	O
,	O
and	O
MBP	O
(	O
myelin	O
basic	O
protein	O
)	O
on	O
chromosome	O
18q23	O
.	O
DESIGN	O
:	O
Case-control	O
association	O
testing	O
.	O
SUBJECTS	O
:	O
A	O
total	O
of	O
120	O
Caucasian	O
patients	O
with	O
MS	O
and	O
107	O
unrelated	O
control	O
individuals	O
from	O
California	O
,	O
and	O
32	O
patients	O
and	O
32	O
unrelated	O
control	O
individuals	O
from	O
Beijing	O
,	O
China	O
.	O
All	O
patients	O
with	O
MS	O
were	O
diagnosed	O
as	O
having	O
clinically	O
definite	O
disease	O
according	O
to	O
published	O
criteria	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Chi2	O
Testing	O
of	O
loci	O
and	O
individual	O
alleles	O
and	O
haplotypes	O
.	O
Haplotype	O
frequencies	O
were	O
estimated	O
with	O
standard	O
maximum	O
likelihood	O
methods	O
.	O
RESULTS	O
:	O
The	O
HLA	O
effect	O
is	O
due	O
to	O
the	O
class	O
II	O
DR2	O
haplotype	O
,	O
DRB1*1501-DQA1*0102-DRB1*0602	O
;	O
contributions	O
to	O
MS	O
susceptibility	O
from	O
additional	O
DRB1-DQB1	O
alleles	O
or	O
other	O
HLA	O
region	O
loci	O
were	O
not	O
observed	O
.	O
Variation	O
within	O
the	O
MBP	O
locus	O
on	O
chromosome	O
18q23	O
showed	O
no	O
effect	O
in	O
MS	O
.	O
The	O
distribution	O
of	O
haplotypes	O
from	O
5	O
loci	O
within	O
the	O
chromosome	O
19q13.2	O
region	O
,	O
including	O
D19S178	O
,	O
D19S574	O
,	O
APOE	O
,	O
APOC2	O
,	O
and	O
D19S219	O
,	O
differed	O
between	O
patient	O
and	O
control	O
samples	O
.	O
D19S574	O
showed	O
a	O
significant	O
effect	O
(	O
P=.015	O
)	O
in	O
Caucasian	O
patients	O
with	O
MS	O
due	O
to	O
the	O
increased	O
frequency	O
of	O
a	O
single	O
allele	O
(	O
P=.002	O
)	O
.	O
The	O
APOE	O
variation	O
,	O
prominent	O
in	O
other	O
neurological	O
diseases	O
,	O
showed	O
no	O
influence	O
on	O
MS	O
susceptibility	O
,	O
despite	O
its	O
location	O
within	O
the	O
chromosome	O
19q13.2	O
region	O
.	O
Interaction	O
effects	O
between	O
DR2	O
and	O
chromosome	O
19q13.2	O
or	O
MBP	O
in	O
MS	O
susceptibility	O
were	O
not	O
apparent	O
.	O
CONCLUSIONS	O
:	O
The	O
significant	O
chromosome	O
19q13.2	O
single-locus	O
and	O
multilocus	O
haplotype	O
associations	O
with	O
MS	O
in	O
Caucasian	O
and	O
Chinese	O
patient	O
samples	O
indicate	O
an	O
effect	O
from	O
a	O
nearby	O
disease	O
susceptibility	O
locus	O
.	O
These	O
initial	O
observations	O
are	O
an	O
encouraging	O
step	O
toward	O
the	O
description	O
of	O
non-HLA	O
genetic	O
susceptibility	O
to	O
MS	O
.	O
TO_SEE	O
A	O
radiation	O
dose-response	O
relationship	O
is	O
demonstrated	O
for	O
all	O
sarcomas	O
and	O
,	O
for	O
the	O
first	O
time	O
in	O
humans	O
,	O
for	O
soft	O
tissue	O
sarcomas	O
.	O
Retinoblastoma	SYMP
patients	O
should	O
be	O
examined	O
for	O
new	O
cancers	SYMP
and	O
followed	O
into	O
later	O
life	O
to	O
determine	O
whether	O
their	O
extraordinary	O
cancer	O
risk	O
extends	O
to	O
common	O
cancers	SYMP
of	O
adulthood	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
rate	O
of	O
recent	O
cocaine	O
use	O
among	O
a	O
metropolitan	O
population	O
of	O
predominantly	O
Hispanic	O
and	O
African-American	O
women	O
with	O
preterm	O
premature	SYMP
rupture	SYMP
of	SYMP
the	SYMP
membranes	SYMP
(	SYMP
PROM	SYMP
)	SYMP
and	O
to	O
ascertain	O
the	O
impact	O
of	O
cocaine	O
on	O
the	O
latency	O
period	O
between	O
rupture	O
of	O
membranes	O
and	O
delivery	O
.	O
Urine	O
toxicology	O
screens	O
were	O
prospectively	O
obtained	O
on	O
147	O
women	O
with	O
preterm	SYMP
PROM	SYMP
.	O
The	O
urine	O
screen	O
did	O
not	O
influence	O
management	O
decisions	O
.	O
All	O
women	O
were	O
expectantly	O
managed	O
without	O
tocolytics	O
until	O
37	O
weeks	O
'	O
gestation	O
unless	O
they	O
developed	O
clinical	O
chorioamnionitis	O
,	O
or	O
nonreassuring	O
fetal	O
heart	O
rate	O
tracing	O
or	O
biophysical	O
profile	O
.	O
Demographic	O
information	O
,	O
hours	O
from	O
rupture	O
of	O
membranes	O
to	O
delivery	O
,	O
gestational	O
age	O
,	O
and	O
birth	O
weight	O
at	O
delivery	O
were	O
compared	O
using	O
Fisher	O
's	O
exact	O
,	O
Mann-Whitney	O
U	O
,	O
and	O
randomization	O
tests	O
where	O
appropriate	O
.	O
The	O
rate	O
of	O
positive	O
urine	O
drug	O
screens	O
for	O
cocaine	O
was	O
8.2	O
%	O
.	O
Women	O
in	O
the	O
cocaine	O
positive	O
group	O
were	O
of	O
higher	O
parity	O
(	O
3	O
,	O
[	O
0-7	O
]	O
vs.	O
1	O
,	O
[	O
0-6	O
]	O
,	O
p	O
=	O
0.001	O
)	O
and	O
tended	O
to	O
be	O
older	O
(	O
27	O
,	O
[	O
23-42	O
]	O
vs.	O
25	O
,	O
[	O
14-40	O
]	O
)	O
.	O
There	O
was	O
a	O
higher	O
rate	O
of	O
recent	O
cocaine	O
use	O
among	O
African-American	O
women	O
(	O
20.4	O
%	O
)	O
as	O
compared	O
to	O
non-African-Americans	O
(	O
1.2	O
%	O
,	O
p	O
=	O
0.0001	O
)	O
.	O
Cocaine-positive	O
women	O
presented	O
at	O
an	O
earlier	O
gestational	O
age	O
(	O
32	O
weeks	O
'	O
,	O
[	O
24-34	O
]	O
vs.	O
33	O
weeks	O
'	O
,	O
[	O
23-36	O
]	O
,	O
p	O
=	O
0.02	O
)	O
and	O
had	O
a	O
significantly	O
longer	O
membrane	O
rupture	O
to	O
delivery	O
interval	O
than	O
women	O
with	O
a	O
negative	O
urine	O
drug	O
screen	O
(	O
174	O
hr	O
,	O
[	O
6-475	O
]	O
vs.	O
33	O
hours	O
[	O
1-833	O
]	O
,	O
p	O
=	O
0.01	O
)	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
reason	O
for	O
delivery	O
between	O
the	O
two	O
groups	O
of	O
patients	O
.	O
Recent	O
cocaine	O
use	O
among	O
women	O
with	O
preterm	SYMP
PROM	SYMP
is	O
common	O
in	O
only	O
some	O
segments	O
of	O
an	O
urban	O
population	O
.	O
Women	O
with	O
recent	O
cocaine	O
use	O
present	O
with	O
ruptured	O
membranes	O
at	O
an	O
earlier	O
gestational	O
age	O
and	O
may	O
actually	O
have	O
a	O
longer	O
latency	O
period	O
than	O
women	O
who	O
do	O
not	O
use	O
cocaine	O
.	O
The	O
objective	O
of	O
this	O
article	O
is	O
to	O
explore	O
attitudes	O
of	O
an	O
inner-city	O
,	O
pregnant	O
cohort	O
about	O
general	O
and	O
HIV-related	O
prenatal	O
care	O
.	O
Responses	O
to	O
an	O
interview	O
at	O
initial	O
prenatal	O
care	O
enrollment	O
were	O
compared	O
using	O
Chi-square	O
and	O
Fisher	O
's	O
exact	O
tests	O
.	O
Of	O
75	O
women	O
,	O
drug	O
users	O
(	O
51	O
%	O
)	O
were	O
more	O
likely	O
to	O
say	O
that	O
they	O
would	O
defer	O
initiating	O
prenatal	O
care	O
(	O
P	O
=	O
0.03	O
)	O
and	O
to	O
minimize	O
the	O
risk	O
of	O
drug	O
or	O
alcohol	O
use	O
to	O
the	O
fetus	O
(	O
P	O
=	O
0.04	O
)	O
.	O
Most	O
(	O
85	O
%	O
)	O
viewed	O
pregnancy	O
as	O
inappropriate	O
for	O
HIV	SYMP
infected	O
women	O
and	O
primarily	O
drug	O
users	O
(	O
P	O
=	O
0.06	O
)	O
would	O
abort	O
if	O
HIV	SYMP
infected	O
.	O
Over	O
half	O
thought	O
HIV	SYMP
transmission	O
occurred	O
most	O
times	O
or	O
always	O
.	O
Only	O
20	O
%	O
had	O
heard	O
of	O
a	O
drug	O
to	O
reduce	O
this	O
risk	O
,	O
but	O
95	O
%	O
would	O
take	O
such	O
a	O
therapy	O
.	O
These	O
inner-city	O
,	O
pregnant	O
women	O
disapproved	O
of	O
pregnancy	O
if	O
HIV	SYMP
infected	O
and	O
thought	O
the	O
risk	O
of	O
transmission	O
was	O
high	O
.	O
They	O
knew	O
little	O
of	O
how	O
to	O
reduce	O
this	O
risk	O
but	O
nearly	O
all	O
would	O
accept	O
a	O
drug	O
to	O
prevent	O
transmission	O
.	O
The	O
association	O
of	O
parvovirus	SYMP
B19	SYMP
infection	SYMP
and	O
hydrops	SYMP
fetalis	SYMP
is	O
well	O
known	O
.	O
However	O
,	O
the	O
association	O
of	O
parvovirus	SYMP
and	O
fetal	O
pleural	O
or	O
pericardial	SYMP
effusions	SYMP
has	O
not	O
been	O
reported	O
.	O
We	O
present	O
five	O
cases	O
of	O
isolated	O
pleural	O
or	O
pericardial	SYMP
effusion	SYMP
with	O
documented	O
maternal	O
parvovirus	SYMP
infection	SYMP
in	O
four	O
of	O
these	O
pregnancies	O
.	O
In	O
the	O
absence	O
of	O
structural	O
or	O
karyotypic	O
abnormalities	O
,	O
spontaneous	O
resolution	O
of	O
the	O
effusion	O
portends	O
for	O
a	O
successful	O
pregnancy	O
outcome	O
.	O
BACKGROUND	O
:	O
Cochlear	SYMP
implantation	SYMP
is	O
nowadays	O
a	O
reliable	O
and	O
well-accepted	O
method	O
of	O
auditory	O
rehabilitation	O
in	O
selected	O
adults	O
and	O
children	O
.	O
METHODS	O
:	O
We	O
present	O
rehabilitation	O
data	O
on	O
21	O
adult	O
patients	O
provided	O
with	O
the	O
Nucleus	O
CI22	O
M	O
cochlear	O
implant	O
using	O
the	O
SPEAK	O
strategy	O
.	O
RESULTS	O
:	O
Results	O
of	O
first	O
tune-up	O
show	O
an	O
open	O
set	O
speech	O
understanding	O
in	O
approximately	O
50	O
%	O
of	O
patients	O
.	O
Long-term	O
results	O
also	O
reveal	O
further	O
improvement	O
in	O
patients	O
who	O
had	O
no	O
open	O
set	O
speech	O
understanding	O
.	O
Our	O
data	O
seem	O
to	O
indicate	O
similar	O
results	O
in	O
comparison	O
to	O
other	O
groups	O
using	O
the	O
CIS	O
strategy	O
.	O
CONCLUSIONS	O
:	O
In	O
adults	O
,	O
open	O
set	O
speech	O
understanding	O
can	O
be	O
achieved	O
even	O
at	O
the	O
first	O
tune-up	O
.	O
Results	O
of	O
early	O
rehabilitation	O
seem	O
to	O
be	O
influenced	O
by	O
duration	O
and	O
etiology	O
of	O
deafness	SYMP
,	O
experience	O
with	O
hearing	O
aids	O
,	O
and	O
other	O
factors	O
.	O
Adverse	O
drug	O
effects	O
are	O
manifold	O
and	O
heterogenous	O
.	O
Many	O
situations	O
may	O
hamper	O
the	O
signalling	O
(	O
i.e	O
.	O
the	O
detection	O
of	O
early	O
warning	O
signs	O
)	O
of	O
adverse	O
effects	O
and	O
new	O
signals	O
often	O
differ	O
from	O
previous	O
experiences	O
.	O
Signals	O
have	O
qualitative	O
and	O
quantitative	O
aspects	O
.	O
Different	O
categories	O
of	O
adverse	O
effects	O
need	O
different	O
methods	O
for	O
detection	O
.	O
Current	O
pharmacovigilance	O
is	O
predominantly	O
based	O
on	O
spontaneous	O
reporting	O
and	O
is	O
mainly	O
helpful	O
in	O
detecting	O
type	O
B	O
effects	O
(	O
those	O
effects	O
that	O
are	O
often	O
allergic	O
or	O
idiosyncratic	O
reactions	O
,	O
characteristically	O
occurring	O
in	O
only	O
a	O
minority	O
of	O
patients	O
and	O
usually	O
unrelated	O
to	O
dosage	O
and	O
that	O
are	O
serious	O
,	O
unexpected	O
and	O
unpredictable	O
)	O
and	O
unusual	O
type	O
A	O
effects	O
(	O
those	O
effects	O
that	O
are	O
related	O
to	O
the	O
pharmacological	O
effects	O
of	O
the	O
drug	O
and	O
are	O
dosage-related	O
)	O
.	O
Examples	O
of	O
other	O
sources	O
of	O
signals	O
are	O
prescription	O
event	O
monitoring	O
,	O
large	O
automated	O
data	O
resources	O
on	O
morbidity	O
and	O
drug	O
use	O
(	O
including	O
record	O
linkage	O
)	O
,	O
case-control	O
surveillance	O
and	O
follow-up	O
studies	O
.	O
Type	O
C	O
effects	O
(	O
those	O
effects	O
related	O
to	O
an	O
increased	O
frequency	O
of	O
'spontaneous	O
'	O
disease	O
)	O
are	O
difficult	O
to	O
study	O
,	O
however	O
,	O
and	O
continue	O
to	O
pose	O
a	O
pharmacoepidemiological	O
challenge	O
.	O
Seven	O
basic	O
considerations	O
can	O
be	O
identified	O
that	O
determine	O
the	O
evidence	O
contained	O
in	O
a	O
signal	O
:	O
quantitative	O
strength	O
of	O
the	O
association	O
,	O
consistency	O
of	O
the	O
data	O
,	O
exposure	O
response	O
relationship	O
,	O
biological	O
plausibility	O
,	O
experimental	O
findings	O
,	O
possible	O
analogies	O
and	O
the	O
nature	O
and	O
quality	O
of	O
the	O
data	O
.	O
A	O
proposal	O
is	O
made	O
for	O
a	O
standard	O
signal	O
management	O
procedure	O
at	O
pharmacovigilance	O
centres	O
,	O
including	O
the	O
following	O
steps	O
:	O
signal	O
delineation	O
,	O
literature	O
search	O
,	O
preliminary	O
inventory	O
of	O
data	O
,	O
collection	O
of	O
additional	O
information	O
,	O
consultation	O
with	O
the	O
World	O
Health	O
Organization	O
Centre	O
for	O
International	O
Drug	O
Monitoring	O
and	O
the	O
relevant	O
drug	O
companies	O
,	O
aggregated	O
data	O
assessment	O
and	O
a	O
report	O
in	O
writing	O
.	O
A	O
better	O
understanding	O
of	O
the	O
conditions	O
and	O
mechanisms	O
involved	O
in	O
the	O
detection	O
of	O
adverse	O
drug	O
effects	O
may	O
further	O
improve	O
strategies	O
for	O
pharmacovigilance	O
.	O
YES	O
The	O
temporal	O
properties	O
of	O
semantic	O
and	O
phonological	O
processes	O
in	O
speech	O
production	O
were	O
investigated	O
in	O
a	O
new	O
experimental	O
paradigm	O
using	O
movement-related	O
brain	O
potentials	O
.	O
The	O
main	O
experimental	O
task	O
was	O
picture	O
naming	O
.	O
In	O
addition	O
,	O
a	O
2-choice	O
reaction	O
go/no-go	O
procedure	O
was	O
included	O
,	O
involving	O
a	O
semantic	O
and	O
a	O
phonological	O
categorization	O
of	O
the	O
picture	O
name	O
.	O
Lateralized	O
readiness	O
potentials	O
(	O
LRPs	O
)	O
were	O
derived	O
to	O
test	O
whether	O
semantic	O
and	O
phonological	O
information	O
activated	O
motor	O
processes	O
at	O
separate	O
moments	O
in	O
time	O
.	O
An	O
LRP	O
was	O
only	O
observed	O
on	O
no-go	O
trials	O
when	O
the	O
semantic	O
(	O
not	O
the	O
phonological	O
)	O
decision	O
determined	O
the	O
response	O
hand	O
.	O
Varying	O
the	O
position	O
of	O
the	O
critical	O
phoneme	O
in	O
the	O
picture	O
name	O
did	O
not	O
affect	O
the	O
onset	O
of	O
the	O
LRP	O
but	O
rather	O
influenced	O
when	O
the	O
LRP	O
began	O
to	O
differ	O
on	O
go	O
and	O
no-go	O
trials	O
and	O
allowed	O
the	O
duration	O
of	O
phonological	O
encoding	O
of	O
a	O
word	O
to	O
be	O
estimated	O
.	O
These	O
results	O
provide	O
electrophysiological	O
evidence	O
for	O
early	O
semantic	O
activation	O
and	O
later	O
phonological	O
encoding	O
.	O
The	O
effects	O
of	O
alanine	O
and	O
glycine	O
substitution	O
for	O
tryptophan	O
upon	O
the	O
species	O
heterogeneity	O
of	O
gramicidin	O
A	O
analogs	O
incorporated	O
into	O
SDS	O
micelles	O
have	O
been	O
investigated	O
.	O
The	O
sequential	O
replacement	O
of	O
the	O
four	O
tryptophan	O
residues	O
in	O
gramicidin	O
A	O
at	O
positions	O
15	O
,	O
13	O
,	O
11	O
,	O
and	O
9	O
with	O
glycine	O
showed	O
that	O
there	O
was	O
no	O
detectable	O
effect	O
at	O
position	O
15	O
but	O
increasing	O
heterogeneity	O
of	O
species	O
in	O
the	O
micelles	O
proceeding	O
toward	O
the	O
interior	O
of	O
the	O
micelle	O
at	O
position	O
9	O
.	O
The	O
replacement	O
of	O
tryptophan	O
at	O
positions	O
15	O
and	O
9	O
with	O
alanine	O
was	O
found	O
to	O
produce	O
more	O
species	O
heterogeneity	O
than	O
found	O
with	O
glycine	O
substitution	O
at	O
the	O
same	O
positions	O
.	O
An	O
increase	O
in	O
the	O
SDS	O
concentration	O
reduces	O
the	O
number	O
of	O
different	O
species	O
present	O
in	O
micelles	O
.	O
With	O
the	O
Gly-11	O
,	O
Gly-13	O
,	O
and	O
Gly-15	O
analogs	O
,	O
the	O
increase	O
in	O
SDS	O
concentration	O
results	O
in	O
the	O
formation	O
of	O
a	O
single	O
species	O
;	O
however	O
,	O
for	O
the	O
Gly-9	O
,	O
Ala-9	O
,	O
and	O
Ala-15	O
analogs	O
,	O
heterogeneity	O
remains	O
.	O
Molecular	O
dynamics	O
in	O
torsion-angle	O
space	O
was	O
applied	O
to	O
nuclear	O
magnetic	O
resonance	O
structure	O
calculation	O
using	O
nuclear	O
Overhauser	O
effect-derived	O
distances	O
and	O
J-coupling-constant-derived	O
dihedral	O
angle	O
restraints	O
.	O
Compared	O
to	O
two	O
other	O
commonly	O
used	O
algorithms	O
,	O
molecular	O
dynamics	O
in	O
Cartesian	O
space	O
and	O
metric-matrix	O
geometry	O
combined	O
with	O
Cartesian	O
molecular	O
dynamics	O
,	O
the	O
method	O
shows	O
increased	O
computational	O
efficiency	O
and	O
success	O
rate	O
for	O
large	O
proteins	O
,	O
and	O
it	O
shows	O
a	O
dramatically	O
increased	O
radius	O
of	O
convergence	O
for	O
DNA	O
.	O
The	O
torsion-angle	O
molecular	O
dynamics	O
algorithm	O
starts	O
from	O
an	O
extended	O
strand	O
conformation	O
and	O
proceeds	O
in	O
four	O
stages	O
:	O
high-temperature	O
torsion-angle	O
molecular	O
dynamics	O
,	O
slow-cooling	O
torsion-angle	O
molecular	O
dynamics	O
,	O
Cartesian	O
molecular	O
dynamics	O
,	O
and	O
minimization	O
.	O
Tests	O
were	O
carried	O
out	O
using	O
experimental	O
NMR	O
data	O
for	O
protein	O
G	O
,	O
interleukin-8	O
,	O
villin	O
14T	O
,	O
and	O
a	O
12	O
base-pair	O
duplex	O
of	O
DNA	O
,	O
and	O
simulated	O
NMR	O
data	O
for	O
bovine	O
pancreatic	O
trypsin	O
inhibitor	O
.	O
For	O
villin	O
14T	O
,	O
a	O
monomer	O
consisting	O
of	O
126	O
residues	O
,	O
structure	O
determination	O
by	O
torsion-angle	O
molecular	O
dynamics	O
has	O
a	O
success	O
rate	O
of	O
85	O
%	O
,	O
a	O
more	O
than	O
twofold	O
improvement	O
over	O
other	O
methods	O
.	O
In	O
the	O
case	O
of	O
the	O
12	O
base-pair	O
DNA	O
duplex	O
,	O
torsion-angle	O
molecular	O
dynamics	O
had	O
a	O
success	O
rate	O
of	O
52	O
%	O
while	O
Cartesian	O
molecular	O
dynamics	O
and	O
metric-matrix	O
distance	O
geometry	O
always	O
failed	O
.	O
The	O
wavelet-transform	O
method	O
is	O
used	O
to	O
quantify	O
the	O
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
parameters	O
:	O
chemical	O
shift	O
,	O
apparent	O
relaxation	O
time	O
T2	O
,	O
resonance	O
amplitude	O
,	O
and	O
phase	O
.	O
Wavelet	O
transformation	O
is	O
a	O
time-frequency	O
representation	O
which	O
separates	O
each	O
component	O
from	O
the	O
FID	O
,	O
then	O
successively	O
quantifies	O
it	O
and	O
subtracts	O
it	O
from	O
the	O
raw	O
signal	O
.	O
Two	O
iterative	O
procedures	O
have	O
been	O
developed	O
.	O
They	O
have	O
been	O
combined	O
with	O
a	O
nonlinear	O
regression	O
analysis	O
method	O
and	O
tested	O
on	O
both	O
simulated	O
and	O
real	O
sets	O
of	O
biomedical	O
MRS	O
data	O
selected	O
with	O
respect	O
to	O
the	O
main	O
problems	O
usually	O
encountered	O
in	O
quantifying	O
biomedical	O
MRS	O
,	O
specifically	O
``	O
chemical	O
noise	O
,	O
''	O
resulting	O
from	O
overlapping	O
resonances	O
,	O
and	O
baseline	O
distortion	O
.	O
The	O
results	O
indicate	O
that	O
the	O
wavelet-transform	O
method	O
can	O
provide	O
efficient	O
and	O
accurate	O
quantification	O
of	O
MRS	O
data	O
.	O
YES	O
YES	O
YES	O
Today	O
's	O
technology	O
links	O
health	O
care	O
providers	O
and	O
patients	O
across	O
town	O
,	O
in	O
the	O
next	O
state	O
or	O
even	O
another	O
country	O
.	O
Nursing	O
across	O
state	O
lines	O
poses	O
complications	O
:	O
state-bound	O
regulatory	O
and	O
licensure	O
issues	O
.	O
This	O
article	O
discusses	O
many	O
of	O
the	O
nutritional	O
topics	O
important	O
to	O
the	O
intensivist	O
.	O
Nutritional	O
assessment	O
,	O
substrate	O
immunonutrition	O
,	O
and	O
disease	O
specific	O
issues	O
are	O
presented	O
.	O
Early	O
introduction	O
of	O
enteral	O
feeds	O
and	O
the	O
use	O
of	O
nutritional	O
modulation	O
are	O
emphasized	O
.	O
PROBLEM	O
:	O
To	O
compare	O
the	O
expression	O
by	O
T-lymphocytes	O
of	O
an	O
immunomodulatory	O
protein	O
known	O
as	O
progesterone-induced	O
blocking	O
factor	O
(	O
PIBF	O
)	O
in	O
conception	O
versus	O
non-conception	O
cycles	O
even	O
when	O
there	O
has	O
been	O
definite	O
fertilization	O
and	O
embryo	O
formation	O
.	O
METHOD	O
:	O
PIBF	O
expression	O
on	O
T	O
lymphocytes	O
was	O
measured	O
using	O
an	O
immunohistochemical	O
method	O
with	O
a	O
PIBF-specific	O
polyclonal	O
antibody	O
.	O
These	O
levels	O
were	O
determined	O
in	O
patients	O
undergoing	O
three	O
types	O
of	O
therapy	O
:	O
non-in	O
vitro	O
fertilization	O
(	O
IVF	O
)	O
,	O
IVF-embryo	O
transfer	O
(	O
ET	O
)	O
,	O
and	O
frozen	O
ET	O
.	O
Sera	O
were	O
drawn	O
12	O
days	O
from	O
ovulation	O
in	O
non-IVF	O
cycles	O
or	O
9	O
days	O
after	O
ET	O
and	O
were	O
assayed	O
for	O
PIBF	O
and	O
beta	O
human	O
chorionic	O
gondotropin	O
.	O
Comparison	O
of	O
the	O
frequency	O
of	O
lymphocyte	O
expression	O
of	O
PIBF	O
in	O
pregnant	O
versus	O
non-pregnant	O
women	O
were	O
made	O
.	O
RESULTS	O
:	O
PIBF	O
was	O
detected	O
in	O
29.5	O
%	O
of	O
non-pregnant	O
women	O
and	O
52.5	O
%	O
of	O
pregnant	O
women	O
.	O
There	O
were	O
no	O
differences	O
in	O
PIBF	O
levels	O
by	O
therapy	O
used	O
in	O
non-pregnant	O
cases	O
or	O
in	O
the	O
pregnant	O
group	O
.	O
CONCLUSION	O
:	O
These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
maternal	O
expression	O
of	O
PIBF	O
in	O
T-lymphocytes	O
soon	O
after	O
trophoblast	O
invasion	O
may	O
depend	O
on	O
successful	O
implantation	O
.	O
Many	O
amino	O
acids	O
contain	O
an	O
asymmetric	O
centre	O
,	O
occurring	O
as	O
laevorotatory	O
,	O
L	O
,	O
or	O
dextrorotatory	O
,	O
D	O
,	O
compounds	O
.	O
It	O
is	O
generally	O
assumed	O
that	O
abiotic	O
synthesis	O
of	O
amino	O
acids	O
on	O
the	O
early	O
Earth	O
resulted	O
in	O
racemic	O
mixtures	O
(	O
L-	O
and	O
D-enantiomers	O
in	O
equal	O
abundance	O
)	O
.	O
But	O
the	O
origin	O
of	O
life	O
required	O
,	O
owing	O
to	O
conformational	O
constraints	O
,	O
the	O
almost	O
exclusive	O
selection	O
of	O
either	O
L-	O
or	O
D-enantiomers	O
,	O
and	O
the	O
question	O
of	O
why	O
living	O
systems	O
on	O
the	O
Earth	O
consist	O
of	O
L-enantiomers	O
rather	O
than	O
D-enantiomers	O
is	O
unresolved	O
.	O
A	O
substantial	O
fraction	O
of	O
the	O
organic	O
compounds	O
on	O
the	O
early	O
Earth	O
may	O
have	O
been	O
derived	O
from	O
comet	O
and	O
meteorite	O
impacts	O
.	O
It	O
has	O
been	O
reported	O
previously	O
that	O
amino	O
acids	O
in	O
the	O
Murchison	O
meteorite	O
exhibit	O
an	O
excess	O
of	O
L-enantiomers	O
,	O
raising	O
the	O
possibility	O
that	O
a	O
similar	O
excess	O
was	O
present	O
in	O
the	O
initial	O
inventory	O
of	O
organic	O
compounds	O
on	O
the	O
Earth	O
.	O
The	O
stable	O
carbon	O
isotope	O
compositions	O
of	O
individual	O
amino	O
acids	O
in	O
Murchison	O
support	O
an	O
extraterrestrial	O
origin	O
--	O
rather	O
than	O
a	O
terrestrial	O
overprint	O
of	O
biological	O
amino	O
acids-although	O
reservations	O
have	O
persisted	O
.	O
Here	O
we	O
show	O
that	O
individual	O
amino-acid	O
enantiomers	O
from	O
Murchison	O
are	O
enriched	O
in	O
15N	O
relative	O
to	O
their	O
terrestrial	O
counterparts	O
,	O
so	O
confirming	O
an	O
extraterrestrial	O
source	O
for	O
an	O
L-enantiomer	O
excess	O
in	O
the	O
Solar	O
System	O
that	O
may	O
predate	O
the	O
origin	O
of	O
life	O
on	O
the	O
Earth	O
.	O
Home	O
care	O
workers	O
face	O
an	O
increasing	O
risk	O
for	O
workplace	O
violence	O
.	O
A	O
proactive	O
preventive	O
approach	O
is	O
presented	O
that	O
suggests	O
strategies	O
to	O
use	O
during	O
the	O
previsit	O
phase	O
,	O
the	O
visit	O
experience	O
,	O
and	O
on	O
an	O
ongoing	O
basis	O
.	O
The	O
miracidia	O
of	O
Fasciola	O
hepatica	O
and	O
Trichobilharzia	O
ocellata	O
approach	O
their	O
host	O
snails	O
Lymnaea	O
truncatula	O
and	O
L.	O
stagnalis	O
by	O
increasing	O
their	O
rate	O
of	O
change	O
of	O
direction	O
(	O
RCD	O
)	O
in	O
increasing	O
gradients	O
of	O
snail-conditioned	O
water	O
(	O
SCW	O
)	O
,	O
and	O
they	O
perform	O
a	O
turnback	O
swimming	O
in	O
decreasing	O
gradients	O
.	O
Both	O
hostfinding	O
responses	O
in	O
both	O
species	O
were	O
induced	O
by	O
glycoconjugates	O
with	O
a	O
molecular	O
weight	O
of	O
greater	O
than	O
30	O
kDa	O
that	O
were	O
sensitive	O
to	O
hydrolysis	O
with	O
pronase	O
E	O
and	O
oxidation	O
with	O
NaIO4	O
.	O
Alkaline	O
cleavage	O
revealed	O
that	O
they	O
contained	O
carbohydrates	O
linked	O
O-glycosidically	O
via	O
serine	O
and	O
N-acetylgalactosamine	O
.	O
Miracidia	O
clearly	O
preferred	O
SCW	O
from	O
their	O
specific	O
host	O
snail	O
versus	O
other	O
sympatric	O
snail	O
species	O
and	O
did	O
not	O
respond	O
to	O
water	O
conditioned	O
with	O
fish	O
,	O
tadpoles	O
,	O
or	O
leeches	O
.	O
Differences	O
in	O
the	O
chemical	O
characteristics	O
of	O
SCW	O
from	O
the	O
intermediate	O
hosts	O
L.	O
truncatula	O
and	O
L.	O
stagnalis	O
could	O
be	O
shown	O
by	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
,	O
blotting	O
,	O
and	O
subsequent	O
carbohydrate	O
detection	O
.	O
The	O
first	O
step	O
of	O
purification	O
of	O
the	O
effective	O
signaling	O
SCW	O
components	O
from	O
both	O
snail	O
species	O
was	O
achieved	O
by	O
ion-exchange	O
chromatography	O
.	O
Black	O
patients	O
with	O
colon	SYMP
cancer	SYMP
in	O
the	O
Black/White	O
Cancer	O
Survival	O
Study	O
were	O
found	O
to	O
have	O
a	O
poorer	O
survival	O
than	O
white	O
patients	O
.	O
More	O
advanced-stage	O
disease	O
at	O
diagnosis	O
was	O
the	O
primary	O
determinant	O
,	O
accounting	O
for	O
60	O
%	O
of	O
the	O
excess	O
mortality	O
.	O
After	O
adjusting	O
for	O
stage	O
,	O
factors	O
such	O
as	O
poverty	O
,	O
other	O
socioeconomic	O
conditions	O
,	O
and	O
treatment	O
did	O
not	O
further	O
explain	O
the	O
remaining	O
survival	O
deficit	O
.	O
This	O
study	O
examined	O
the	O
aggressiveness	O
of	O
colon	SYMP
tumors	SYMP
in	O
blacks	O
and	O
whites	O
to	O
explore	O
its	O
role	O
in	O
the	O
racial	O
survival	O
differences	O
.	O
Tumor	O
characteristics	O
of	O
703	O
cases	O
of	O
newly	O
diagnosed	O
invasive	O
colon	O
adenocarcinoma	SYMP
were	O
centrally	O
evaluated	O
by	O
a	O
gastrointestinal	O
pathologist	O
,	O
blinded	O
in	O
regard	O
to	O
the	O
age	O
,	O
race	O
,	O
and	O
sex	O
of	O
the	O
patients	O
.	O
Blacks	O
were	O
less	O
likely	O
to	O
have	O
poorly	O
differentiated	O
(	O
grade	O
3	O
)	O
tumors	SYMP
[	O
odds	O
ratio	O
(	O
OR	O
)	O
,	O
0.44	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.22-0.88	O
]	O
and	O
lymphoid	O
reaction	O
(	O
OR	O
,	O
0.49	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.26-0.90	O
)	O
when	O
compared	O
with	O
whites	O
.	O
These	O
black/white	O
(	O
B/W	O
)	O
differences	O
remained	O
statistically	O
significant	O
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
metropolitan	O
area	O
,	O
summary	O
stage	O
,	O
socioeconomic	O
status	O
,	O
body	O
mass	O
index	O
,	O
and	O
health	O
care	O
access	O
and	O
utilization	O
.	O
In	O
addition	O
,	O
blacks	O
were	O
less	O
likely	O
to	O
have	O
high-grade	O
(	O
grade	O
3	O
)	O
nuclear	SYMP
atypia	SYMP
,	O
mitotic	O
activity	O
,	O
and	O
tubule	O
formation	O
,	O
although	O
these	O
ORs	O
did	O
not	O
reach	O
a	O
statistical	O
significance	O
level	O
of	O
0.05	O
.	O
Similar	O
B/W	O
differences	O
were	O
observed	O
for	O
patients	O
with	O
advanced	O
disease	O
but	O
not	O
with	O
early	O
stage	O
.	O
Comparison	O
by	O
anatomical	O
subsite	O
showed	O
that	O
blacks	O
had	O
statistically	O
significantly	O
better	O
differentiated	O
tumors	SYMP
for	O
cancers	SYMP
of	O
the	O
proximal	O
and	O
transverse	O
colon	O
but	O
not	O
for	O
the	O
distal	O
.	O
No	O
racial	O
differences	O
were	O
found	O
for	O
blood	O
vessel	O
and	O
lymphatic	SYMP
invasion	SYMP
,	O
necrosis	SYMP
,	O
fibrosis	SYMP
,	O
and	O
mucinous	O
type	O
of	O
histology	O
.	O
The	O
findings	O
,	O
therefore	O
,	O
are	O
the	O
opposite	O
of	O
those	O
hypothesized	O
.	O
After	O
adjusting	O
for	O
stage	O
,	O
more	O
aggressive	O
tumor	O
characteristics	O
do	O
not	O
explain	O
the	O
adverse	O
survival	O
differential	O
in	O
blacks	O
.	O
This	O
suggests	O
that	O
there	O
may	O
be	O
racial	O
differences	O
in	O
environmental	O
exposure	O
,	O
and	O
that	O
the	O
intensity	O
and	O
mode	O
of	O
delivery	O
of	O
carcinogen	O
insult	O
as	O
well	O
as	O
host	O
susceptibility	O
may	O
differ	O
by	O
race	O
and	O
anatomical	O
subsite	O
.	O
Future	O
studies	O
should	O
explore	O
the	O
B/W	O
differences	O
in	O
tumor	O
biology	O
using	O
molecular	O
markers	O
that	O
precede	O
the	O
conventional	O
histological	O
parameters	O
evaluated	O
here	O
.	O
A	O
new	O
method	O
is	O
described	O
for	O
detection	O
of	O
mutations	O
in	O
the	O
lysosomal	O
alpha-glucosidase	O
gene	O
(	O
GAA	O
)	O
leading	O
to	O
Glycogen	SYMP
Storage	SYMP
Disease	SYMP
type	SYMP
II	SYMP
(	SYMP
GSDII	SYMP
)	SYMP
.	O
A	O
key	O
feature	O
of	O
the	O
method	O
is	O
isolation	O
and	O
reverse	O
transcription	O
of	O
mRNA	O
followed	O
by	O
PCR	O
amplification	O
of	O
lysosomal	O
alpha-glucosidase	O
cDNA	O
with	O
M13-extended	O
primers	O
.	O
Dye	O
labeled	O
primers	O
are	O
used	O
for	O
cycle	O
sequencing	O
and	O
an	O
ABI	O
PRISM	O
377	O
DNA	O
sequencing	O
system	O
for	O
analysis	O
.	O
The	O
method	O
is	O
rapid	O
and	O
complementary	O
to	O
the	O
automated	O
sequencing	O
of	O
all	O
the	O
19	O
,	O
PCR	O
amplified	O
,	O
coding	O
exons	O
of	O
the	O
GAA	O
gene	O
.	O
The	O
advantages	O
and	O
pitfalls	O
of	O
this	O
new	O
method	O
are	O
discussed	O
in	O
the	O
light	O
of	O
the	O
results	O
obtained	O
with	O
an	O
infantile	O
GSDII	O
patient	O
.	O
A	O
new	O
splice	O
site	O
mutation	O
in	O
the	O
GAA	O
gene	O
of	O
this	O
patient	O
was	O
identified	O
,	O
IVS16	O
(	O
+2T	O
--	O
>	O
C	O
)	O
,	O
resulting	O
in	O
the	O
deletion	O
of	O
16	O
base	O
pairs	O
of	O
exon	O
16	O
.	O
The	O
presence	O
of	O
clinical	O
autonomic	SYMP
dysfunction	SYMP
in	O
patients	O
with	O
neurologic	SYMP
diseases	SYMP
,	O
such	O
as	O
multiple	SYMP
sclerosis	SYMP
,	O
Parkinson	SYMP
's	SYMP
disease	SYMP
,	O
and	O
cerebrovascular	O
accident	O
,	O
has	O
become	O
increasingly	O
recognized	O
in	O
the	O
past	O
decade	O
.	O
Very	O
few	O
autonomic	O
tests	O
have	O
been	O
done	O
on	O
pediatric	O
patients	O
thus	O
far	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
autonomic	O
function	O
in	O
patients	O
with	O
cerebral	SYMP
palsy	SYMP
using	O
two	O
noninvasive	O
tests	O
:	O
sympathetic	O
skin	O
response	O
(	O
SSR	O
)	O
and	O
R-R	O
interval	O
variation	O
(	O
RRIV	O
)	O
.	O
Twenty-four	O
patients	O
with	O
cerebral	SYMP
palsy	SYMP
and	O
24	O
control	O
subjects	O
between	O
the	O
ages	O
of	O
4	O
and	O
12	O
yr	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
There	O
was	O
no	O
significant	O
difference	O
of	O
mean	O
latency	O
,	O
amplitude	O
,	O
or	O
amplitude	O
ratio	O
of	O
SSR	O
between	O
the	O
two	O
groups	O
under	O
electric	O
stimulus	O
,	O
startling	O
stimulus	O
,	O
and	O
deep	O
breathing	O
conditions	O
.	O
No	O
significant	O
difference	O
in	O
frequency	O
of	O
absent	O
response	O
and	O
asymmetric	O
response	O
was	O
also	O
noted	O
.	O
Mean	O
heart	O
rate	O
under	O
relaxed	O
sitting	O
condition	O
was	O
significantly	O
higher	O
in	O
the	O
study	O
group	O
.	O
Significant	O
negative	O
correlation	O
between	O
heart	O
rate	O
and	O
age	O
was	O
noted	O
in	O
the	O
control	O
group	O
but	O
was	O
not	O
present	O
in	O
the	O
study	O
group	O
.	O
Also	O
,	O
there	O
was	O
no	O
statistical	O
difference	O
of	O
mean	O
RRIV	O
between	O
the	O
two	O
groups	O
.	O
No	O
objective	O
evidence	O
of	O
autonomic	O
disturbance	O
in	O
patients	O
with	O
cerebral	SYMP
palsy	SYMP
was	O
found	O
in	O
this	O
study	O
.	O
A	O
two-credits	O
per	O
semester	O
clinical	O
medicine	O
course	O
was	O
established	O
in	O
the	O
Department	O
of	O
Physical	O
Medicine	O
and	O
Rehabilitation	O
(	O
PM	O
&	O
#	O
38	O
;	O
R	O
)	O
in	O
cooperation	O
with	O
the	O
Johns	O
Hopkins	O
University	O
undergraduate	O
Human	O
Biology	O
faculty	O
to	O
present	O
the	O
variety	O
of	O
inpatient	O
consultation	O
personnel	O
,	O
units	O
,	O
patient	O
diagnostic	O
groups	O
,	O
and	O
functional	O
problems	O
.	O
College	O
students	O
spend	O
4	O
hr	O
weekly	O
on	O
the	O
PM	O
&	O
#	O
38	O
;	O
R	O
consultation	O
service	O
as	O
team	O
members	O
under	O
resident	O
supervision	O
.	O
The	O
curriculum	O
emphasizes	O
student	O
understanding	O
of	O
the	O
roles	O
of	O
rehabilitation	O
team	O
members	O
.	O
Objectives	O
include	O
demonstration	O
of	O
working	O
knowledge	O
of	O
the	O
Biopsychosocial	O
Model	O
,	O
the	O
World	O
Health	O
Organization	O
Model	O
of	O
disablement	O
and	O
interdisciplinary	O
rehabilitation	O
intervention	O
.	O
The	O
course	O
includes	O
simulations	O
of	O
physical	O
impairments	O
,	O
demonstrations	O
of	O
adaptive	O
equipment	O
,	O
interactive	O
chart	O
reviews	O
,	O
readings	O
,	O
and	O
audio	O
lectures	O
.	O
A	O
retrospective	O
sequential	O
review	O
was	O
made	O
of	O
the	O
last	O
100	O
physical	O
medicine	O
and	O
rehabilitation	O
consultations	O
with	O
student	O
attendance	O
.	O
The	O
results	O
confirm	O
student	O
exposure	O
to	O
many	O
ward	O
settings	O
(	O
surgery	O
,	O
30	O
%	O
;	O
neurology/neurosurgery	O
,	O
28	O
%	O
;	O
medicine	O
,	O
24	O
%	O
;	O
intensive	O
care	O
,	O
15	O
%	O
;	O
oncology	O
,	O
2	O
%	O
;	O
and	O
psychiatry	O
,	O
1	O
%	O
)	O
,	O
patient	O
complexity	O
(	O
averaging	O
10	O
problems	O
)	O
,	O
and	O
multiple	O
ICD-9	O
diagnosis	O
categories	O
(	O
circulatory	O
,	O
36	O
%	O
;	O
neurologic	O
,	O
22	O
%	O
;	O
musculoskeletal	O
,	O
17	O
%	O
;	O
neoplasms	O
,	O
10	O
%	O
;	O
injury	O
,	O
5	O
%	O
;	O
endocrine	O
,	O
4	O
%	O
;	O
infections	O
,	O
3	O
%	O
;	O
and	O
others	O
,	O
3	O
%	O
)	O
.	O
The	O
rehabilitation	O
consultation	O
service	O
is	O
particularly	O
effective	O
as	O
an	O
introduction	O
to	O
hospital-based	O
medical	O
practice	O
due	O
to	O
the	O
diagnostic	O
variety	O
of	O
the	O
patients	O
,	O
the	O
functional	O
approach	O
of	O
rehabilitation	O
,	O
and	O
student	O
exposure	O
to	O
multiple	O
hospital	O
settings	O
.	O
The	O
Biopsychosocial	O
Model	O
of	O
medical	O
practice	O
is	O
demonstrated	O
through	O
multiple	O
interdisciplinary	O
perspectives	O
of	O
needs	O
and	O
interventions	O
for	O
patients	O
with	O
obvious	O
functional	O
deficits	O
.	O
This	O
process	O
develops	O
a	O
rudimentary	O
understanding	O
of	O
the	O
effect	O
of	O
illness	O
on	O
the	O
person	O
and	O
the	O
variety	O
of	O
medically	O
effective	O
therapeutic	O
modalities	O
.	O
YES	O
Because	O
activity	O
and	O
regular	O
exercise	O
are	O
important	O
factors	O
to	O
maintain	O
general	O
good	O
health	O
in	O
senior	O
citizens	O
,	O
we	O
investigated	O
whether	O
senior	O
dancing	O
has	O
any	O
effect	O
on	O
peripheral	O
or	O
lumbar	O
bone	O
density	O
.	O
We	O
performed	O
a	O
prospective	O
study	O
over	O
a12-mo	O
period	O
on	O
bone	O
density	O
at	O
a	O
spinal	O
and	O
peripheral	O
measuring	O
site	O
in	O
28	O
female	O
senior	O
members	O
(	O
mean	O
age	O
:	O
67	O
+/-	O
2	O
yr	O
)	O
of	O
a	O
dancing	O
group	O
in	O
Vienna	O
.	O
Lumbar	O
bone	O
mineral	O
density	O
was	O
assessed	O
by	O
quantitative	O
computed	O
tomography	O
(	O
qCT	O
)	O
and	O
radial	O
bone	O
density	O
by	O
single	O
photon	O
absorptiometry	O
of	O
the	O
distal	O
forearm	O
.	O
The	O
mean	O
training	O
time	O
per	O
week	O
was	O
3.2	O
+/-	O
0.8	O
h.	O
In	O
the	O
entire	O
group	O
of	O
female	O
dancers	O
,	O
no	O
significant	O
effects	O
of	O
dancing	O
on	O
radial	O
or	O
lumbar	O
bone	O
density	O
could	O
be	O
observed	O
.	O
Linear	O
regression	O
analysis	O
showed	O
that	O
the	O
lower	O
the	O
qCT	O
at	O
the	O
beginning	O
of	O
the	O
observation	O
period	O
,	O
the	O
higher	O
was	O
the	O
percentage	O
increase	O
of	O
spinal	O
qCT	O
in	O
the	O
entire	O
group	O
during	O
12	O
mo	O
of	O
dancing	O
(	O
r	O
=	O
0.52	O
,	O
P	O
&	O
#	O
60	O
;	O
0.0001	O
)	O
.	O
For	O
additional	O
evaluation	O
,	O
females	O
were	O
divided	O
into	O
two	O
subgroups	O
,	O
osteoporotic	O
or	O
nonosteoporotic	O
,	O
based	O
on	O
x-rays	O
and	O
lumbar	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
as	O
measured	O
by	O
qCT	O
.	O
The	O
group	O
classified	O
as	O
dancers	O
with	O
osteoporosis	O
(	O
group	O
I	O
)	O
showed	O
a	O
significant	O
increase	O
in	O
lumbar	O
bone	O
density	O
,	O
whereas	O
in	O
the	O
group	O
of	O
dancers	O
without	O
signs	O
of	O
osteoporosis	SYMP
(	O
group	O
II	O
)	O
,	O
BMD	O
remained	O
unchanged	O
.	O
Additionally	O
,	O
radial	O
bone	O
density	O
did	O
not	O
show	O
any	O
changes	O
in	O
either	O
group	O
.	O
Group	O
I	O
showed	O
a	O
significant	O
correlation	O
between	O
basal	O
spinal	O
BMD	O
and	O
the	O
percentage	O
change	O
of	O
BMD	O
during	O
the	O
observation	O
period	O
(	O
r	O
=	O
0.7	O
,	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O
.	O
Changes	O
of	O
the	O
biochemical	O
parameters	O
were	O
observed	O
in	O
the	O
bone-specific	O
isoenzyme	O
of	O
alkaline	O
phosphatase	O
,	O
a	O
marker	O
of	O
osteoblastic	O
activity	O
,	O
in	O
group	O
I	O
giving	O
additional	O
evidence	O
of	O
increased	O
bone	O
formation	O
.	O
OBJECTIVES	O
:	O
To	O
estimate	O
the	O
prevalence	O
of	O
Chlamydia	SYMP
trachomatis	SYMP
in	O
asymptomatic	O
women	O
attending	O
general	O
practice	O
:	O
to	O
assess	O
the	O
potential	O
of	O
the	O
ligase	O
chain	O
reaction	O
as	O
a	O
screening	O
tool	O
;	O
and	O
to	O
evaluate	O
selective	O
screening	O
criteria	O
.	O
DESIGN	O
:	O
Cross	O
sectional	O
survey	O
.	O
SETTING	O
:	O
Four	O
general	O
practices	O
in	O
northeast	O
London	O
.	O
SUBJECTS	O
:	O
890	O
women	O
aged	O
18-35	O
years	O
attending	O
general	O
practice	O
for	O
a	O
cervical	O
smear	O
or	O
a	O
``	O
young	O
well	O
woman	O
''	O
check	O
between	O
October	O
1994	O
and	O
January	O
1996	O
.	O
The	O
women	O
were	O
tested	O
for	O
C	SYMP
trachomatis	SYMP
with	O
confirmed	O
enzyme	O
immunoassay	O
(	O
endocervical	O
specimens	O
)	O
and	O
ligase	O
chain	O
reaction	O
assay	O
on	O
urine	O
specimens	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Prevalence	O
of	O
C	SYMP
trachomatis	SYMP
infection	SYMP
in	O
women	O
aged	O
18-35	O
on	O
the	O
basis	O
of	O
each	O
test	O
;	O
sensitivity	O
and	O
specificity	O
of	O
both	O
tests	O
in	O
this	O
population	O
.	O
RESULTS	O
:	O
Prevalence	O
of	O
confirmed	O
infection	O
was	O
2.6	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
1.6	O
%	O
to	O
3.6	O
%	O
)	O
in	O
all	O
women	O
.	O
Prevalence	O
on	O
the	O
basis	O
of	O
enzyme	O
immunoassay	O
was	O
1.6	O
%	O
(	O
0.8	O
%	O
to	O
2.7	O
%	O
)	O
,	O
with	O
a	O
sensitivity	O
of	O
60	O
%	O
and	O
a	O
specificity	O
of	O
100	O
%	O
.	O
Prevalence	O
on	O
the	O
basis	O
of	O
ligase	O
chain	O
reaction	O
was	O
2.5	O
%	O
(	O
1.5	O
%	O
to	O
3.9	O
%	O
)	O
,	O
with	O
90	O
%	O
sensitivity	O
and	O
99.8	O
%	O
specificity	O
.	O
Screening	O
all	O
women	O
aged	O
&	O
#	O
60	O
;	O
or	O
=	O
25	O
and	O
all	O
women	O
who	O
had	O
had	O
two	O
or	O
more	O
partners	O
in	O
the	O
past	O
year	O
would	O
have	O
detected	O
87	O
%	O
(	O
20/23	O
)	O
of	O
infections	O
.	O
CONCLUSION	O
:	O
Ligase	O
chain	O
reaction	O
on	O
urine	O
samples	O
performs	O
at	O
least	O
as	O
well	O
as	O
enzyme	O
immunoassay	O
on	O
cervical	O
specimens	O
in	O
this	O
low	O
prevalence	O
population	O
.	O
It	O
offers	O
potential	O
as	O
a	O
non-invasive	O
screening	O
tool	O
.	O
A	O
simple	O
selective	O
screening	O
strategy	O
might	O
be	O
appropriate	O
and	O
would	O
be	O
able	O
to	O
detect	O
most	O
cases	O
of	O
infection	SYMP
.	O
However	O
,	O
a	O
rigorous	O
economic	O
evaluation	O
of	O
possible	O
screening	O
strategies	O
is	O
needed	O
first	O
.	O
Recently	O
,	O
many	O
advances	O
have	O
been	O
made	O
in	O
the	O
study	O
of	O
sexual	O
differentiation	O
,	O
including	O
the	O
discoveries	O
of	O
the	O
gene	O
for	O
antim1/4llerian	O
hormone	O
as	O
well	O
as	O
the	O
gene	O
for	O
its	O
receptor	O
.	O
However	O
,	O
the	O
etiology	O
of	O
the	O
clinical	O
syndrome	O
of	O
m1/4llerian	O
agenesis	O
remains	O
elusive	O
.	O
We	O
hypothesize	O
that	O
activating	O
mutations	O
of	O
either	O
the	O
antim1/4llerian	O
hormone	O
gene	O
or	O
its	O
receptor	O
gene	O
may	O
cause	O
m1/4llerian	O
duct	O
regression	O
in	O
a	O
genetic	O
female	O
during	O
embryogenesis	O
.	O
This	O
clinical	O
commentary	O
discusses	O
the	O
current	O
management	O
of	O
the	O
syndrome	O
including	O
the	O
Abbe-McIndoe	SYMP
procedure	SYMP
,	O
the	O
most	O
commonly	O
used	O
method	O
of	O
surgical	SYMP
correction	SYMP
,	O
and	O
the	O
Frank	SYMP
vaginal	SYMP
dilation	SYMP
method	SYMP
,	O
the	O
most	O
common	O
nonsurgical	O
method	O
of	O
correction	O
.	O
YES	O
YES	O
This	O
article	O
discusses	O
dental	O
anxiety	O
and	O
phobia	O
.	O
The	O
author	O
presents	O
background	O
information	O
,	O
including	O
incidence	O
and	O
etiology	O
.	O
A	O
discussion	O
of	O
evaluative	O
techniques	O
for	O
assessing	O
anxiety	O
levels	O
follows	O
.	O
Examination	O
and	O
treatment	O
planning	O
are	O
considered	O
in	O
relation	O
to	O
this	O
patient	O
's	O
special	O
needs	O
.	O
The	O
article	O
stresses	O
behavioral	O
treatment	O
modalities	O
that	O
eliminate	O
the	O
debilitating	O
phobia	O
.	O
In	O
closing	O
,	O
the	O
author	O
presents	O
practical	O
information	O
regarding	O
prevention	O
of	O
dental	O
phobia	O
and	O
the	O
merits	O
of	O
incorporating	O
this	O
type	O
of	O
patient	O
into	O
a	O
dental	O
practice	O
.	O
YES	O
In	O
patients	O
with	O
chronic	SYMP
myeloid	SYMP
leukemia	SYMP
(	SYMP
CML	SYMP
)	SYMP
,	O
the	O
neoplastic	O
(	O
BCR-ABL+	O
)	O
progenitor	O
cells	O
are	O
characterized	O
by	O
an	O
increased	O
proliferative	O
activity	O
.	O
Whether	O
these	O
cells	O
are	O
also	O
resistant	O
to	O
apoptosis	O
and	O
if	O
so	O
,	O
under	O
what	O
conditions	O
remains	O
controversial	O
.	O
We	O
now	O
show	O
that	O
highly	O
purified	O
populations	O
of	O
very	O
primitive	O
neoplastic	O
progenitor	O
cells	O
obtained	O
directly	O
from	O
CML	O
patients	O
survive	O
and	O
proliferate	O
in	O
vitro	O
for	O
several	O
weeks	O
in	O
the	O
absence	O
of	O
any	O
added	O
growth	O
factors	O
(	O
except	O
insulin	O
)	O
.	O
In	O
contrast	O
,	O
purified	O
primary	O
normal	O
progenitors	O
maintained	O
under	O
the	O
same	O
conditions	O
die	O
rapidly	O
.	O
Nevertheless	O
,	O
both	O
primary	O
CML	O
cells	O
and	O
BCR-ABL+	O
BAF3	O
cells	O
show	O
the	O
same	O
dose-dependent	O
sensitivity	O
to	O
TNF-alpha	O
or	O
ceramide-induced	O
apoptosis	O
as	O
their	O
respective	O
normal	O
counterparts	O
.	O
In	O
fact	O
,	O
time	O
course	O
studies	O
demonstrated	O
an	O
even	O
faster	O
onset	O
of	O
apoptosis	O
in	O
ceramide-treated	O
BCR-ABL+	O
BAF3	O
cells	O
as	O
compared	O
to	O
normal	O
controls	O
.	O
BCR-ABL+	O
cells	O
treated	O
with	O
ceramide	O
also	O
showed	O
a	O
rapid	O
and	O
sequential	O
increase	O
in	O
the	O
tyrosine	O
phosphorylation	O
of	O
p210	O
(	O
BCR-ABL	O
)	O
,	O
p46-56SHC	O
and	O
p120Cbl	O
.	O
These	O
findings	O
suggest	O
growth	O
factor	O
deprivation	O
and	O
treatment	O
with	O
TNF-alpha	O
or	O
ceramide	O
trigger	O
different	O
initial	O
events	O
both	O
of	O
which	O
can	O
lead	O
to	O
apoptosis	O
in	O
factor-dependent	O
hematopoietic	O
cells	O
.	O
However	O
,	O
in	O
the	O
first	O
case	O
,	O
activation	O
of	O
apoptosis	O
is	O
blocked	O
by	O
the	O
basal	O
activity	O
of	O
p210	O
(	O
BCR-ABL	O
)	O
,	O
whereas	O
in	O
the	O
second	O
,	O
the	O
presence	O
of	O
p210	O
(	O
BCR-ABL	O
)	O
appears	O
to	O
accelerate	O
the	O
onset	O
of	O
apoptosis	O
by	O
a	O
mechanism	O
that	O
may	O
involve	O
an	O
activation	O
of	O
its	O
kinase	O
function	O
.	O
Clinically	O
,	O
the	O
hallmark	O
of	O
the	O
human	SYMP
amnesic	SYMP
syndrome	SYMP
is	O
an	O
impaired	O
ability	O
to	O
consciously	O
recollect	O
or	O
remember	O
daily	O
events	O
.	O
If	O
the	O
medial	O
region	O
of	O
the	O
temporal	O
lobes	O
,	O
including	O
the	O
hippocampus	O
and	O
related	O
structures	O
,	O
is	O
critical	O
for	O
establishing	O
these	O
new	O
memories	O
,	O
then	O
this	O
brain	O
region	O
should	O
be	O
active	O
whenever	O
events	O
are	O
experienced	O
,	O
regardless	O
of	O
whether	O
subjects	O
are	O
asked	O
explicitly	O
to	O
learn	O
and	O
remember	O
.	O
Here	O
we	O
show	O
that	O
the	O
medial	O
temporal	O
region	O
is	O
active	O
during	O
encoding	O
and	O
that	O
the	O
hemisphere	O
activated	O
and	O
the	O
amount	O
of	O
activation	O
depend	O
on	O
the	O
type	O
of	O
stimulus	O
presented	O
(	O
objects	O
or	O
words	O
)	O
,	O
whether	O
the	O
stimulus	O
can	O
be	O
encoded	O
for	O
meaning	O
(	O
real	O
objects	O
and	O
words	O
versus	O
nonsense	O
objects	O
and	O
words	O
)	O
,	O
and	O
task	O
experience	O
(	O
first	O
versus	O
the	O
second	O
time	O
a	O
task	O
is	O
performed	O
)	O
.	O
These	O
findings	O
demonstrate	O
that	O
the	O
medial	O
temporal	O
lobe	O
memory	O
system	O
is	O
engaged	O
automatically	O
when	O
we	O
attend	O
to	O
a	O
perceptual	O
event	O
and	O
that	O
the	O
location	O
and	O
amount	O
of	O
activation	O
depend	O
on	O
stimulus	O
characteristics	O
(	O
physical	O
form	O
,	O
meaning	O
)	O
and	O
experience	O
.	O
The	O
involvement	O
of	O
structures	O
in	O
the	O
medial	O
temporal	O
lobe	O
during	O
the	O
encoding	O
of	O
visual	O
associations	O
was	O
studied	O
with	O
functional	O
magnetic	O
resonance	O
imaging	O
.	O
In	O
11	O
out	O
of	O
12	O
normal	O
healthy	O
volunteers	O
this	O
task	O
resulted	O
in	O
activation	O
in	O
posterior	O
portions	O
of	O
the	O
parahippocampal	O
region	O
,	O
close	O
to	O
the	O
collateral	O
sulcus	O
.	O
In	O
seven	O
subjects	O
activation	O
was	O
encountered	O
in	O
the	O
hippocampal	O
formation	O
.	O
The	O
visual	O
association	O
task	O
as	O
adapted	O
for	O
this	O
study	O
may	O
provide	O
a	O
sensitive	O
measure	O
to	O
study	O
anterograde	O
amnesia	O
prevalent	O
in	O
Alzheimer	O
's	O
disease	O
.	O
Therefore	O
,	O
the	O
present	O
paradigm	O
enables	O
the	O
study	O
of	O
individual	O
changes	O
in	O
learning	O
and	O
memory	O
capacities	O
over	O
time	O
.	O
Altered	O
calcium	O
(	O
Ca2+	O
)	O
homeostasis	O
is	O
thought	O
to	O
play	O
a	O
key	O
role	O
in	O
aging	O
and	O
neuropathology	O
resulting	O
in	O
memory	O
deficits	O
.	O
Several	O
forms	O
of	O
hippocampal	O
synaptic	O
plasticity	O
are	O
dependent	O
on	O
Ca2+	O
,	O
providing	O
a	O
potential	O
link	O
between	O
altered	O
Ca2+	O
homeostasis	O
and	O
memory	O
deficits	O
associated	O
with	O
aging	O
.	O
The	O
current	O
study	O
reviews	O
evidence	O
for	O
Ca2+	O
dysregulation	O
during	O
aging	O
which	O
could	O
interact	O
with	O
Ca	O
(	O
2+	O
)	O
-dependent	O
synaptic	O
plasticity	O
.	O
The	O
authors	O
suggest	O
that	O
changes	O
in	O
Ca2+	O
regulation	O
could	O
adjust	O
the	O
thresholds	O
for	O
synaptic	O
modification	O
,	O
favoring	O
processes	O
for	O
depression	O
of	O
synaptic	O
strength	O
during	O
aging	O
.	O
Transiently	O
evolked	O
otoacoustic	O
emissions	O
(	O
TEOAE	O
)	O
have	O
been	O
reported	O
in	O
several	O
studies	O
as	O
absent	O
in	O
a	O
small	O
minority	O
of	O
normal	O
ears	O
.	O
Other	O
studies	O
have	O
reported	O
TEOAEs	O
in	O
all	O
normal	O
ears	O
.	O
Differences	O
between	O
studies	O
may	O
arise	O
directly	O
from	O
criteria	O
for	O
TEOAE	O
identification	O
,	O
criteria	O
for	O
selection	O
of	O
normals	O
,	O
or	O
statistically	O
due	O
to	O
limited	O
sample	O
sizes	O
.	O
In	O
order	O
to	O
understand	O
and	O
model	O
cochlear	O
processes	O
involved	O
in	O
TEOAE	O
generation	O
,	O
it	O
needs	O
to	O
be	O
known	O
whether	O
the	O
presence	O
of	O
normal	O
hearing	O
leads	O
automatically	O
to	O
generation	O
of	O
TEOAEs	O
.	O
The	O
present	O
study	O
set	O
out	O
to	O
establish	O
in	O
a	O
large	O
sample	O
if	O
any	O
ears	O
could	O
be	O
found	O
that	O
lacked	O
TEOAEs	O
despite	O
normal	O
hearing	O
threshold	O
levels	O
(	O
HTL	O
)	O
.	O
A	O
total	O
of	O
397	O
ears	O
from	O
highly	O
cooperative	O
adult	O
subjects	O
were	O
examined	O
under	O
laboratory	O
conditions	O
.	O
Using	O
cross	O
correlation	O
between	O
replicate	O
nonlinear	O
waveforms	O
as	O
the	O
criterion	O
,	O
TEOAEs	O
were	O
present	O
in	O
99.2	O
%	O
of	O
the	O
sample	O
(	O
lower	O
CI	O
98.1	O
%	O
)	O
.	O
However	O
,	O
careful	O
visual	O
assessment	O
of	O
the	O
recorded	O
waveforms	O
for	O
the	O
remaining	O
ears	O
did	O
not	O
unequivocally	O
show	O
absence	O
of	O
TEOAE	O
characteristics	O
in	O
any	O
ear	O
with	O
normal	O
HTLs	O
.	O
While	O
TEOAE	O
strength	O
varies	O
widely	O
among	O
ears	O
,	O
no	O
clear	O
evidence	O
was	O
found	O
to	O
show	O
that	O
TEOAEs	O
can	O
be	O
absent	O
when	O
HTLs	O
are	O
normal	O
.	O
In	O
addition	O
to	O
a	O
long	O
form	O
of	O
591	O
amino	O
acids	O
(	O
aa	O
)	O
,	O
two	O
other	O
forms	O
of	O
PRL	O
receptor	O
(	O
PRLR	O
)	O
,	O
differing	O
in	O
the	O
length	O
of	O
their	O
cytoplasmic	O
domains	O
,	O
have	O
been	O
identified	O
in	O
the	O
rat	O
.	O
The	O
Nb2	O
form	O
,	O
lacking	O
198	O
aa	O
in	O
the	O
cytoplasmic	O
domain	O
,	O
is	O
able	O
to	O
transmit	O
a	O
lactogenic	O
signal	O
similar	O
to	O
the	O
long	O
form	O
,	O
whereas	O
the	O
short	O
form	O
of	O
291	O
aa	O
is	O
inactive	O
.	O
The	O
ability	O
of	O
PRL	O
to	O
activate	O
the	O
promoter	O
of	O
the	O
beta-casein	O
gene	O
or	O
the	O
lactogenic	O
hormone	O
responsive	O
element	O
fused	O
to	O
the	O
luciferase	O
reporter	O
was	O
assessed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
or	O
293	O
fibroblasts	O
transiently	O
transfected	O
with	O
PRLR	O
cDNAs	O
.	O
The	O
function	O
of	O
the	O
short	O
form	O
was	O
examined	O
after	O
cotransfection	O
of	O
both	O
the	O
long	O
and	O
short	O
forms	O
.	O
These	O
results	O
clearly	O
show	O
that	O
the	O
short	O
form	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
through	O
the	O
formation	O
of	O
inactive	O
heterodimers	O
,	O
resulting	O
in	O
an	O
inhibition	O
of	O
Janus	O
kinase	O
2	O
(	O
JAK2	O
)	O
activation	O
.	O
The	O
present	O
study	O
also	O
investigates	O
the	O
possible	O
participation	O
of	O
cytoplasmic	O
receptors	O
in	O
the	O
signal	O
transduction	O
pathway	O
,	O
using	O
cotransfection	O
experiments	O
and	O
a	O
new	O
approach	O
that	O
selectively	O
determines	O
the	O
contribution	O
of	O
cytoplasmic	O
receptors	O
in	O
the	O
process	O
of	O
signal	O
transduction	O
.	O
We	O
cotransfected	O
Chinese	O
hamster	O
ovary	O
cells	O
with	O
two	O
cDNA	O
constructs	O
:	O
a	O
cytoplasmic	O
(	O
soluble	O
)	O
form	O
of	O
the	O
receptor	O
with	O
a	O
deleted	O
signal	O
peptide	O
(	O
delta-19	O
)	O
,	O
which	O
is	O
unable	O
to	O
bind	O
PRL	O
,	O
and	O
a	O
functionally	O
inactive	O
receptor	O
mutant	O
(	O
lacking	O
box	O
1	O
)	O
,	O
which	O
is	O
anchored	O
in	O
the	O
plasma	O
membrane	O
and	O
able	O
to	O
bind	O
PRL	O
.	O
This	O
approach	O
has	O
allowed	O
us	O
to	O
show	O
that	O
delta-19	O
,	O
lacking	O
expression	O
at	O
the	O
plasma	O
membrane	O
,	O
can	O
transduce	O
the	O
hormonal	O
message	O
,	O
at	O
least	O
to	O
a	O
limited	O
extent	O
(	O
up	O
to	O
30	O
%	O
of	O
wild	O
type	O
efficiency	O
)	O
,	O
providing	O
that	O
association/activation	O
occurs	O
with	O
a	O
PRL-PRLR	O
complex	O
initiated	O
at	O
the	O
cell	O
surface	O
level	O
;	O
box	O
1	O
of	O
the	O
cytoplasmic	O
form	O
is	O
necessary	O
to	O
rescue	O
this	O
partial	O
transcriptional	O
activity	O
of	O
the	O
inactive	O
mutant	O
.	O
This	O
partial	O
recovery	O
is	O
also	O
parallel	O
to	O
the	O
partial	O
activation	O
of	O
JAK2	O
,	O
indicating	O
that	O
the	O
signal	O
transduction	O
pathway	O
implicated	O
JAK2	O
.	O
Our	O
results	O
provide	O
evidence	O
that	O
heterodimerization	O
of	O
receptors	O
can	O
be	O
implicated	O
either	O
in	O
the	O
positive	O
or	O
in	O
negative	O
activation	O
of	O
gene	O
transcription	O
.	O
BACKGROUND	O
:	O
Inadequate	O
dietary	O
intake	O
of	O
calcium	O
and	O
vitamin	O
D	O
may	O
contribute	O
to	O
the	O
high	O
prevalence	O
of	O
osteoporosis	SYMP
among	O
older	O
persons	O
.	O
METHODS	O
:	O
We	O
studied	O
the	O
effects	O
of	O
three	O
years	O
of	O
dietary	O
supplementation	O
with	O
calcium	O
and	O
vitamin	O
D	O
on	O
bone	O
mineral	O
density	O
,	O
biochemical	O
measures	O
of	O
bone	O
metabolism	O
,	O
and	O
the	O
incidence	O
of	O
nonvertebral	O
fractures	O
in	O
176	O
men	O
and	O
213	O
women	O
65	O
years	O
of	O
age	O
or	O
older	O
who	O
were	O
living	O
at	O
home	O
.	O
They	O
received	O
either	O
500	O
mg	O
of	O
calcium	O
plus	O
700	O
IU	O
of	O
vitamin	O
D3	O
(	O
cholecalciferol	O
)	O
per	O
day	O
or	O
placebo	O
.	O
Bone	O
mineral	O
density	O
was	O
measured	O
by	O
dual-energy	O
x-ray	O
absorptiometry	O
,	O
blood	O
and	O
urine	O
were	O
analyzed	O
every	O
six	O
months	O
,	O
and	O
cases	O
of	O
nonvertebral	O
fracture	O
were	O
ascertained	O
by	O
means	O
of	O
interviews	O
and	O
verified	O
with	O
use	O
of	O
hospital	O
records	O
.	O
RESULTS	O
:	O
The	O
mean	O
(	O
+/-SD	O
)	O
changes	O
in	O
bone	O
mineral	O
density	O
in	O
the	O
calcium-vitamin	O
D	O
and	O
placebo	O
groups	O
were	O
as	O
follows	O
:	O
femoral	O
neck	O
,	O
+0.50+/-4.80	O
and	O
-0.70+/-5.03	O
percent	O
,	O
respectively	O
(	O
P=0.02	O
)	O
;	O
spine	O
,	O
+2.12+/-4.06	O
and	O
+1.22+/-4.25	O
percent	O
(	O
P=0.04	O
)	O
;	O
and	O
total	O
body	O
,	O
+0.06+/-1.83	O
and	O
-1.09+/-1.71	O
percent	O
(	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O
.	O
The	O
difference	O
between	O
the	O
calcium-vitamin	O
D	O
and	O
placebo	O
groups	O
was	O
significant	O
at	O
all	O
skeletal	O
sites	O
after	O
one	O
year	O
,	O
but	O
it	O
was	O
significant	O
only	O
for	O
total-body	O
bone	O
mineral	O
density	O
in	O
the	O
second	O
and	O
third	O
years	O
.	O
Of	O
37	O
subjects	O
who	O
had	O
nonvertebral	O
fractures	O
,	O
26	O
were	O
in	O
the	O
placebo	O
group	O
and	O
11	O
were	O
in	O
the	O
calcium-vitamin	O
D	O
group	O
(	O
P=0.02	O
)	O
.	O
CONCLUSIONS	O
:	O
In	O
men	O
and	O
women	O
65	O
years	O
of	O
age	O
or	O
older	O
who	O
are	O
living	O
in	O
the	O
community	O
,	O
dietary	SYMP
supplementation	SYMP
with	SYMP
calcium	SYMP
and	SYMP
vitamin	SYMP
D	SYMP
moderately	O
reduced	O
bone	SYMP
loss	SYMP
measured	O
in	O
the	O
femoral	O
neck	O
,	O
spine	O
,	O
and	O
total	O
body	O
over	O
the	O
three-year	O
study	O
period	O
and	O
reduced	O
the	O
incidence	O
of	O
nonvertebral	SYMP
fractures	SYMP
.	O
The	O
sterilization	O
and	O
contaminated	O
waste	O
disposal	O
practices	O
in	O
all	O
14	O
dental	O
clinics	O
operated	O
by	O
the	O
Southern	O
Sydney	O
Area	O
Health	O
Service	O
were	O
surveyed	O
.	O
All	O
of	O
the	O
clinics	O
used	O
autoclaves	O
for	O
sterilization	O
.	O
All	O
hand	O
instruments	O
,	O
handpieces	O
and	O
triplex	O
syringes	O
were	O
autoclaved	O
between	O
patients	O
.	O
Chemical	O
disinfection	O
solutions	O
were	O
used	O
in	O
12	O
of	O
the	O
14	O
dental	O
clinics	O
,	O
mainly	O
for	O
surface	O
decontamination	O
.	O
Five	O
dental	O
clinics	O
had	O
separate	O
storage	O
areas	O
for	O
contaminated	O
waste	O
which	O
compiled	O
with	O
contaminated	O
waste	O
separation	O
and	O
disposal	O
guidelines	O
.	O
The	O
practice	O
of	O
recapping	O
needles	O
with	O
fingers	O
and	O
some	O
inadequate	O
washing	O
facilities	O
are	O
areas	O
that	O
require	O
particular	O
attention	O
.	O
Safety	O
and	O
efficacy	O
are	O
crucial	O
but	O
separate	O
issues	O
for	O
vitamin	O
and	O
mineral	O
supplements	O
.	O
Misinterpretation	O
of	O
``	O
safe	O
and	O
adequate	O
''	O
to	O
mean	O
``	O
safety	O
limit	O
''	O
would	O
impose	O
restrictions	O
on	O
vitamin	O
and	O
mineral	O
intakes	O
that	O
are	O
not	O
needed	O
to	O
ensure	O
safety	O
.	O
Substantial	O
evidence	O
indicates	O
that	O
intakes	O
greater	O
than	O
the	O
recommended	O
dietary	O
allowances	O
(	O
RDAs	O
)	O
of	O
certain	O
vitamins	O
and	O
minerals	O
such	O
as	O
calcium	O
,	O
folic	O
acid	O
,	O
vitamin	O
E	O
,	O
selenium	O
,	O
and	O
chromium	O
reduce	O
the	O
risk	O
of	O
certain	O
diseases	O
for	O
some	O
people	O
.	O
Limitation	O
of	O
intakes	O
to	O
the	O
RDAs	O
would	O
preclude	O
reductions	O
in	O
disease	O
risk	O
from	O
these	O
nutrients	O
.	O
The	O
margin	O
of	O
safety	O
between	O
the	O
usual	O
dietary	O
intake	O
and	O
the	O
intake	O
that	O
would	O
produce	O
adverse	O
effects	O
varies	O
greatly	O
among	O
the	O
different	O
nutrients	O
.	O
Very	O
high	O
intakes	O
of	O
vitamins	O
A	O
and	O
D	O
,	O
niacin	O
,	O
pyridoxine	O
,	O
and	O
selenium	O
have	O
produced	O
adverse	O
effects	O
.	O
Many	O
widely	O
discussed	O
putative	O
adverse	O
effects	O
of	O
vitamin	O
C	O
,	O
vitamin	O
E	O
,	O
and	O
trivalent	O
chromium	O
have	O
little	O
factual	O
basis	O
.	O
There	O
is	O
no	O
evidence	O
of	O
adverse	O
effects	O
from	O
beta-carotene	O
supplements	O
except	O
in	O
current	O
heavy	O
smokers	O
.	O
The	O
mutator	O
hypothesis	O
of	O
tumorigenesis	O
suggests	O
that	O
loss	O
of	O
chromosomal	O
stability	O
or	O
maintenance	O
functions	O
results	O
in	O
elevated	O
mutation	O
rates	O
,	O
leading	O
to	O
the	O
accumulation	O
of	O
the	O
numerous	O
mutations	O
required	O
for	O
multistep	O
carcinogenesis	O
.	O
The	O
human	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
are	O
highly	O
conserved	O
homologues	O
of	O
the	O
Escherichia	O
coli	O
MutHLS	O
system	O
,	O
which	O
contribute	O
to	O
genomic	O
stability	O
by	O
surveillance	O
and	O
repair	O
of	O
replication	O
misincorporation	O
errors	O
and	O
exogenous	O
DNA	O
damage	O
.	O
Mutations	O
in	O
one	O
of	O
these	O
MMR	O
genes	O
,	O
hMSH2	O
,	O
account	O
for	O
about	O
half	O
of	O
all	O
cases	O
of	O
genetically	O
linked	O
hereditary	O
non-polyposis	O
colorectal	O
cancer	O
.	O
Loss	O
of	O
function	O
of	O
p53	O
has	O
also	O
been	O
proposed	O
to	O
increase	O
cellular	O
hypermutability	O
,	O
thereby	O
accelerating	O
carcinogenesis	O
,	O
although	O
a	O
clear	O
role	O
for	O
p53	O
in	O
genomic	O
instability	O
remains	O
controversial	O
.	O
p53	O
is	O
mutated	O
frequently	O
in	O
a	O
wide	O
range	O
of	O
human	O
cancers	SYMP
,	O
including	O
colonic	SYMP
tumours	SYMP
.	O
Both	O
Msh2-	O
and	O
p53-targeted	O
knockout	O
mice	O
are	O
viable	O
and	O
susceptible	O
to	O
cancer	SYMP
.	O
Here	O
we	O
demonstrate	O
that	O
combined	O
Msh2	O
and	O
p53	O
ablation	O
(	O
Msh2-/-p53-/-	O
)	O
results	O
in	O
developmental	O
arrest	O
of	O
all	O
female	O
embryos	O
at	O
9.5	O
days	O
.	O
In	O
contrast	O
,	O
male	O
Msh2-/-p53-/-	O
mice	O
are	O
viable	O
,	O
but	O
succumb	O
to	O
tumours	SYMP
significantly	O
earlier	O
(	O
t1-2	O
is	O
73	O
days	O
)	O
than	O
either	O
Msh2-/-	O
or	O
p53-/-	O
littermates	O
.	O
Furthermore	O
,	O
the	O
frequency	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
in	O
tumours	O
from	O
Msh2-/-p53-/-	O
mice	O
is	O
not	O
significantly	O
different	O
than	O
in	O
Msh2-/-	O
mice	O
.	O
Synergism	O
in	O
tumorigenesis	O
and	O
independent	O
segregation	O
of	O
the	O
MSI	O
phenotype	O
suggest	O
that	O
Msh2	O
and	O
p53	O
are	O
not	O
genetically	O
epistatic	O
.	O
Our	O
data	O
(	O
Reddy	O
et	O
al.	O
,	O
Radiat	O
.	O
Res	O
.	O
141	O
,	O
252-258	O
,	O
1995	O
)	O
on	O
the	O
kinetics	O
of	O
the	O
repair	O
of	O
potentially	O
lethal	O
damage	O
in	O
log-phase	O
Chinese	O
hamster	O
V79	O
cells	O
are	O
used	O
to	O
test	O
some	O
predictions	O
which	O
arise	O
from	O
the	O
different	O
assumptions	O
of	O
the	O
repair-misrepair	O
(	O
RMR	O
)	O
(	O
C.	O
A.	O
Tobias	O
,	O
Radiat	O
.	O
Res	O
.	O
104	O
,	O
S77-S95	O
,	O
1985	O
)	O
,	O
lethal-potentially	O
lethal	O
(	O
LPL	O
)	O
(	O
S.	O
B.	O
Curtis	O
,	O
Radiat	O
.	O
Res	O
.	O
106	O
,	O
252-270	O
,	O
1986	O
)	O
and	O
double-strand	O
break	O
(	O
DSB	O
)	O
(	O
J.	O
Y.	O
Ostashevsky	O
,	O
Radiat	O
.	O
Res	O
.	O
118	O
,	O
437-466	O
,	O
1989	O
)	O
models	O
.	O
The	O
LPL	O
model	O
defines	O
the	O
time	O
available	O
for	O
repair	O
of	O
PLD	O
(	O
t	O
(	O
rep	O
)	O
)	O
as	O
the	O
time	O
taken	O
to	O
reach	O
maximal	O
survival	O
in	O
a	O
delayed-plating	O
recovery	O
experiment	O
.	O
Those	O
data	O
show	O
that	O
after	O
this	O
time	O
has	O
elapsed	O
,	O
contrary	O
to	O
the	O
expectation	O
of	O
the	O
LPL	O
model	O
,	O
survival	O
can	O
be	O
increased	O
by	O
changing	O
the	O
medium	O
used	O
for	O
delayed	O
plating	O
from	O
fresh	O
growth	O
medium	O
to	O
conditioned	O
medium	O
.	O
According	O
to	O
the	O
RMR	O
model	O
,	O
all	O
potentially	O
lethal	O
lesions	O
should	O
also	O
be	O
committed	O
by	O
that	O
time	O
and	O
be	O
unavailable	O
for	O
repair	O
in	O
the	O
new	O
medium	O
.	O
Only	O
the	O
DSB	O
model	O
correctly	O
predicted	O
that	O
PLD	O
(	O
=	O
DSBs	O
)	O
would	O
still	O
be	O
available	O
for	O
repair	O
after	O
that	O
time	O
.	O
Second	O
,	O
data	O
for	O
split-dose	O
recovery	O
are	O
used	O
to	O
predict	O
the	O
first-order	O
kinetics	O
time	O
constant	O
for	O
DSB	O
repair	O
(	O
tau	O
(	O
DSBR	O
)	O
)	O
using	O
the	O
DSB	O
model	O
(	O
24	O
+/-	O
1.5	O
min	O
)	O
.	O
This	O
value	O
is	O
nearly	O
identical	O
to	O
the	O
value	O
of	O
27	O
+/-	O
1	O
min	O
determined	O
from	O
the	O
data	O
obtained	O
by	O
Cheong	O
et	O
al	O
.	O
using	O
pulsed-field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
(	O
Mutat	O
.	O
Res	O
.	O
274	O
,	O
111-122	O
,	O
1992	O
)	O
.	O
The	O
value	O
based	O
on	O
PFGE	O
is	O
used	O
to	O
calculate	O
the	O
value	O
of	O
t	O
(	O
rep	O
)	O
predicted	O
by	O
the	O
DSB	O
model	O
(	O
2.6	O
+/-	O
0.1	O
h	O
)	O
,	O
which	O
agrees	O
with	O
the	O
value	O
determined	O
experimentally	O
as	O
the	O
time	O
when	O
changing	O
the	O
delayed-plating	O
medium	O
from	O
growth	O
medium	O
to	O
conditioned	O
medium	O
no	O
longer	O
gives	O
the	O
full	O
recovery	O
seen	O
with	O
delayed	O
plating	O
in	O
conditioned	O
medium	O
(	O
2.5	O
h	O
)	O
.	O
However	O
,	O
some	O
recovery	O
was	O
seen	O
for	O
a	O
change	O
in	O
the	O
medium	O
(	O
growth	O
medium	O
to	O
conditioned	O
medium	O
)	O
up	O
to	O
5-6	O
h	O
postirradiation	O
.	O
Reanalysis	O
of	O
the	O
original	O
data	O
on	O
DSB	O
repair	O
shows	O
that	O
they	O
are	O
consistent	O
with	O
two	O
first-order	O
repair	O
rates	O
(	O
18	O
+/-	O
7	O
min	O
and	O
about	O
52	O
min	O
)	O
.	O
These	O
results	O
are	O
consistent	O
with	O
two	O
pools	O
of	O
DSBs	O
(	O
or	O
cells	O
)	O
,	O
each	O
with	O
their	O
own	O
t	O
(	O
rep	O
)	O
.	O
The	O
early	O
t	O
(	O
rep	O
)	O
,	O
associated	O
with	O
tau	O
(	O
fast	O
)	O
,	O
is	O
predicted	O
to	O
be	O
1.7	O
+/-	O
0.7	O
h	O
,	O
and	O
the	O
late	O
t	O
(	O
rep	O
)	O
,	O
associated	O
with	O
tau	O
(	O
slow	O
)	O
,	O
is	O
predicted	O
to	O
be	O
about	O
5	O
h.	O
Both	O
values	O
are	O
in	O
excellent	O
agreement	O
with	O
the	O
times	O
at	O
which	O
changing	O
from	O
growth	O
medium	O
to	O
conditioned	O
medium	O
no	O
longer	O
gives	O
the	O
full	O
recovery	O
seen	O
in	O
conditioned	O
medium	O
only	O
(	O
the	O
early	O
t	O
(	O
rep	O
)	O
)	O
,	O
and	O
the	O
time	O
when	O
changing	O
from	O
growth	O
medium	O
to	O
conditioned	O
medium	O
produces	O
no	O
further	O
increase	O
in	O
survival	O
(	O
the	O
late	O
t	O
(	O
rep	O
)	O
)	O
,	O
respectively	O
.	O
It	O
is	O
noted	O
that	O
attempts	O
to	O
correlate	O
radiosensitivity	O
with	O
the	O
rates	O
of	O
DSB	O
repair	O
,	O
rather	O
than	O
using	O
an	O
explicit	O
model	O
such	O
as	O
the	O
DSB	O
model	O
,	O
are	O
unlikely	O
to	O
be	O
productive	O
since	O
survival	O
depends	O
on	O
both	O
tau	O
(	O
DSBR	O
)	O
and	O
t	O
(	O
rep	O
)	O
(	O
as	O
defined	O
in	O
the	O
DSB	O
model	O
)	O
and	O
the	O
latter	O
may	O
be	O
the	O
more	O
important	O
determinant	O
of	O
radiosensitivity	O
(	O
as	O
it	O
appears	O
to	O
be	O
for	O
ataxia	O
telangiectasia	O
cells	O
compared	O
to	O
normal	O
fibroblasts	O
and	O
for	O
irs	O
compared	O
to	O
V79	O
cells	O
)	O
.	O
CONTEXT	O
:	O
Adolescents	O
'	O
concerns	O
about	O
privacy	O
in	O
clinical	O
settings	O
decrease	O
their	O
willingness	O
to	O
seek	O
health	O
care	O
for	O
sensitive	O
problems	O
and	O
may	O
inhibit	O
their	O
communication	O
with	O
physicians	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
influence	O
of	O
physicians	O
'	O
assurances	O
of	O
confidentiality	O
on	O
adolescents	O
'	O
willingness	O
to	O
disclose	O
information	O
and	O
seek	O
future	O
health	O
care	O
.	O
DESIGN	O
:	O
Randomized	O
controlled	O
trial	O
.	O
SETTING	O
:	O
Three	O
suburban	O
public	O
high	O
schools	O
in	O
California	O
.	O
PARTICIPANTS	O
:	O
The	O
562	O
participating	O
adolescents	O
represented	O
92	O
%	O
of	O
students	O
in	O
mandatory	O
classes	O
.	O
INTERVENTION	O
:	O
After	O
random	O
assignment	O
to	O
1	O
of	O
3	O
groups	O
,	O
the	O
adolescents	O
listened	O
to	O
a	O
standardized	O
audiotape	O
depiction	O
of	O
an	O
office	O
visit	O
during	O
which	O
they	O
heard	O
a	O
physician	O
who	O
assured	O
unconditional	O
confidentiality	O
,	O
a	O
physician	O
who	O
assured	O
conditional	O
confidentiality	O
,	O
or	O
a	O
physician	O
who	O
did	O
not	O
mention	O
confidentiality	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Adolescents	O
'	O
willingness	O
to	O
disclose	O
general	O
information	O
,	O
willingness	O
to	O
disclose	O
information	O
about	O
sensitive	O
topics	O
,	O
intended	O
honesty	O
,	O
and	O
likelihood	O
of	O
return	O
visits	O
to	O
the	O
physician	O
depicted	O
in	O
the	O
scenario	O
were	O
assessed	O
by	O
anonymous	O
written	O
questionnaire	O
.	O
RESULTS	O
:	O
Assurances	O
of	O
confidentiality	O
increased	O
the	O
number	O
of	O
adolescents	O
willing	O
to	O
disclose	O
sensitive	O
information	O
about	O
sexuality	O
,	O
substance	O
use	O
,	O
and	O
mental	O
health	O
from	O
39	O
%	O
(	O
68/175	O
)	O
to	O
46.5	O
%	O
(	O
178/383	O
)	O
(	O
beta=.10	O
,	O
P=.02	O
)	O
and	O
increased	O
the	O
number	O
willing	O
to	O
seek	O
future	O
health	O
care	O
from	O
53	O
%	O
(	O
93/175	O
)	O
to	O
67	O
%	O
(	O
259/386	O
)	O
(	O
beta=.17	O
,	O
P	O
&	O
#	O
60	O
;	O
.001	O
)	O
.	O
When	O
comparing	O
the	O
unconditional	O
with	O
the	O
conditional	O
groups	O
,	O
assurances	O
of	O
unconditional	O
confidentiality	O
increased	O
the	O
number	O
of	O
adolescents	O
willing	O
to	O
return	O
for	O
a	O
future	O
visit	O
by	O
10	O
percentage	O
points	O
,	O
from	O
62	O
%	O
(	O
122/196	O
)	O
to	O
72	O
%	O
(	O
137/190	O
)	O
(	O
beta=.14	O
,	O
P=.001	O
)	O
.	O
CONCLUSIONS	O
:	O
Adolescents	O
are	O
more	O
willing	O
to	O
communicate	O
with	O
and	O
seek	O
health	O
care	O
from	O
physicians	O
who	O
assure	O
confidentiality	O
.	O
Further	O
investigation	O
is	O
needed	O
to	O
identify	O
a	O
confidentiality	O
assurance	O
statement	O
that	O
explains	O
the	O
legal	O
and	O
ethical	O
limitations	O
of	O
confidentiality	O
without	O
decreasing	O
adolescents	O
'	O
likelihood	O
of	O
seeking	O
future	O
health	O
care	O
for	O
routine	O
and	O
nonreportable	O
sensitive	O
health	O
concerns	O
.	O
YES	O
YES	O
TO_SEE	O
TO_SEE	O
OBJECTIVE	O
:	O
To	O
estimate	O
the	O
crude	O
incidence	O
rates	O
of	O
cerebrovascular	SYMP
accidents	SYMP
among	O
the	O
black	O
residents	O
of	O
Harare	O
.	O
DESIGN	O
:	O
Prospective	O
community-based	O
study	O
.	O
SETTING	O
:	O
Black	O
residents	O
of	O
Harare	O
,	O
Zimbabwe	O
.	O
PARTICIPANTS	O
:	O
Two	O
hundred	O
and	O
seventy-three	O
'first-ever	O
'	O
strokes	SYMP
prospectively	O
identified	O
over	O
a	O
12-month	O
period	O
.	O
MAIN	O
OUTCOME	O
STUDY	O
FACTORS	O
:	O
Cerebrovascular	SYMP
accident	SYMP
first-week	O
fatality	O
rate	O
;	O
age-	O
and	O
sex-related	O
incidence	O
.	O
RESULTS	O
:	O
The	O
crude	O
incidence	O
rate	O
was	O
estimated	O
to	O
be	O
30.7	O
per	O
100000	O
(	O
95	O
%	O
confidence	O
interval	O
27.1-34.4	O
)	O
and	O
the	O
standardised	O
rate	O
was	O
68	O
per	O
100000	O
.	O
Fifty-one	O
per	O
cent	O
of	O
stroke	SYMP
victims	O
were	O
below	O
the	O
age	O
of	O
54	O
years	O
.	O
Thirty-five	O
per	O
cent	O
of	O
patients	O
died	O
within	O
1	O
week	O
of	O
the	O
stroke	O
.	O
Overall	O
,	O
the	O
age-specific	O
rates	O
for	O
both	O
sexes	O
rose	O
with	O
age	O
,	O
with	O
the	O
rates	O
for	O
women	O
being	O
higher	O
at	O
all	O
age	O
strata	O
except	O
for	O
the	O
group	O
45-54	O
years	O
.	O
CONCLUSION	O
:	O
With	O
a	O
standardised	O
rate	O
of	O
68	O
per	O
100000	O
and	O
a	O
first-week	O
mortality	O
rate	O
of	O
35	O
%	O
,	O
stroke	SYMP
must	O
now	O
be	O
considered	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
the	O
population	O
.	O
OBJECTIVE	O
:	O
To	O
explore	O
the	O
long-term	O
effect	O
of	O
calcium	SYMP
supplementation	SYMP
during	O
pregnancy	O
on	O
the	O
offspring	O
's	O
blood	O
pressure	O
during	O
childhood	O
.	O
DESIGN	O
:	O
Follow	O
up	O
of	O
a	O
population	O
enrolled	O
in	O
a	O
double	O
blind	O
,	O
randomised	O
,	O
placebo	O
controlled	O
trial	O
.	O
SETTING	O
:	O
Perinatal	O
research	O
unit	O
,	O
World	O
Health	O
Organisation	O
's	O
collaborative	O
research	O
centre	O
.	O
SUBJECTS	O
:	O
591	O
children	O
at	O
a	O
mean	O
age	O
of	O
7	O
years	O
whose	O
mothers	O
were	O
randomly	O
assigned	O
during	O
pregnancy	O
to	O
receive	O
2	O
g/day	O
of	O
elemental	O
calcium	O
(	O
n	O
=	O
298	O
)	O
or	O
placebo	O
(	O
n	O
=	O
293	O
)	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Mean	O
blood	O
pressure	O
and	O
rate	O
of	O
high	SYMP
blood	SYMP
pressure	SYMP
of	O
children	O
.	O
RESULTS	O
:	O
Overall	O
,	O
systolic	O
blood	O
pressure	O
was	O
lower	O
in	O
the	O
calcium	O
group	O
(	O
mean	O
difference	O
-1.4	O
mm	O
Hg	O
;	O
95	O
%	O
confidence	O
interval	O
-3.2	O
to	O
0.5	O
)	O
than	O
in	O
the	O
placebo	O
group	O
.	O
The	O
effect	O
was	O
found	O
predominantly	O
among	O
children	O
whose	O
body	O
mass	O
index	O
at	O
assessment	O
was	O
above	O
the	O
median	O
for	O
this	O
population	O
(	O
mean	O
difference	O
in	O
systolic	O
blood	O
pressure	O
-5.8	O
mm	O
Hg	O
(	O
-9.8	O
mm	O
Hg	O
to	O
-1.7	O
mm	O
Hg	O
)	O
for	O
children	O
with	O
an	O
index	O
greater	O
than	O
17.5	O
and	O
-3.2	O
mm	O
Hg	O
(	O
-6.3	O
mm	O
Hg	O
to	O
-0.1	O
mm	O
Hg	O
)	O
for	O
those	O
with	O
an	O
index	O
of	O
greater	O
than	O
15.7	O
to	O
17.5	O
)	O
.	O
The	O
risk	O
of	O
high	O
systolic	O
blood	O
pressure	O
was	O
also	O
lower	O
in	O
the	O
calcium	O
group	O
than	O
in	O
the	O
placebo	O
group	O
(	O
relative	O
risk	O
0.59	O
;	O
0.39	O
to	O
0.90	O
)	O
and	O
particularly	O
among	O
children	O
in	O
the	O
highest	O
fourth	O
of	O
body	O
mass	O
index	O
(	O
0.43	O
;	O
0.26	O
to	O
0.71	O
)	O
.	O
CONCLUSION	O
:	O
Calcium	SYMP
supplementation	SYMP
during	O
pregnancy	O
is	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
in	O
the	O
offspring	O
,	O
particularly	O
among	O
overweight	O
children	O
.	O
The	O
fast	O
reaction	O
of	O
peroxynitrite	O
with	O
CO2	O
and	O
the	O
high	O
concentration	O
of	O
dissolved	O
CO2	O
in	O
vivo	O
(	O
ca	O
.	O
1	O
mM	O
)	O
suggest	O
that	O
CO2	O
modulates	O
most	O
of	O
the	O
reactions	O
of	O
peroxynitrite	O
in	O
biological	O
systems	O
.	O
The	O
addition	O
of	O
peroxynitrite	O
to	O
CO2	O
produces	O
of	O
the	O
adduct	O
ONOO-CO2-	O
(	O
1	O
)	O
.	O
The	O
production	O
of	O
1	O
greatly	O
accelerates	O
the	O
decomposition	O
of	O
peroxynitrite	O
to	O
give	O
nitrate	O
.	O
We	O
now	O
show	O
that	O
the	O
formation	O
of	O
1	O
is	O
followed	O
by	O
reformation	O
of	O
CO2	O
(	O
rather	O
than	O
another	O
carbonate	O
species	O
such	O
as	O
CO3	O
=	O
or	O
HCO3-	O
)	O
.	O
To	O
show	O
this	O
,	O
it	O
is	O
necessary	O
to	O
study	O
systems	O
with	O
limiting	O
concentrations	O
of	O
CO2	O
.	O
(	O
When	O
CO2	O
is	O
present	O
in	O
excess	O
,	O
its	O
concentration	O
remains	O
nearly	O
constant	O
during	O
the	O
decomposition	O
of	O
peroxynitrite	O
,	O
and	O
the	O
recycling	O
of	O
CO2	O
,	O
although	O
it	O
occurs	O
,	O
can	O
not	O
be	O
detected	O
kinetically	O
)	O
.	O
We	O
find	O
that	O
CO2	O
is	O
a	O
true	O
catalyst	O
of	O
the	O
decomposition	O
of	O
peroxynitrite	O
,	O
and	O
this	O
fundamental	O
insight	O
into	O
its	O
action	O
must	O
be	O
rationalized	O
by	O
any	O
in	O
vivo	O
or	O
in	O
vitro	O
reaction	O
mechanism	O
that	O
is	O
proposed	O
.	O
When	O
the	O
concentration	O
of	O
CO2	O
is	O
lower	O
than	O
that	O
of	O
peroxynitrite	O
,	O
the	O
reformation	O
of	O
CO2	O
amplifies	O
the	O
fraction	O
of	O
peroxynitrite	O
that	O
reacts	O
with	O
CO2	O
.	O
Even	O
low	O
concentrations	O
of	O
CO2	O
that	O
result	O
from	O
the	O
dissolution	O
of	O
ambient	O
CO2	O
can	O
have	O
pronounced	O
catalytic	O
effects	O
.	O
These	O
effects	O
can	O
cause	O
deviations	O
from	O
predicted	O
kinetic	O
behavior	O
in	O
studies	O
of	O
peroxynitrite	O
in	O
noncarbonate	O
buffers	O
in	O
vitro	O
,	O
and	O
since	O
1	O
and	O
other	O
intermediates	O
derived	O
from	O
it	O
are	O
oxidants	O
and/or	O
nitrating	O
agents	O
,	O
some	O
of	O
the	O
reactions	O
attributed	O
to	O
peroxynitrite	O
may	O
depend	O
on	O
the	O
availability	O
of	O
CO2	O
.	O
YES	O
Starfish	O
oocytes	O
can	O
be	O
fertilized	O
after	O
germinal	O
vesicle	O
breakdown	O
(	O
GVBD	O
)	O
and	O
artificial	O
parthenogenesis	O
can	O
be	O
induced	O
by	O
activating	O
the	O
oocytes	O
after	O
GVBD	O
(	O
post-GVBD	O
activation	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
parthenogenotes	O
were	O
obtained	O
by	O
the	O
activation	O
of	O
immature	O
oocytes	O
with	O
caffeine	O
before	O
treatment	O
with	O
1-methyladenine	SYMP
(	SYMP
1-MeAde	SYMP
)	SYMP
to	O
induce	O
oocyte	O
maturation	O
.	O
Most	O
of	O
the	O
caffeine-treated	O
eggs	O
developed	O
as	O
tetraploids	O
,	O
as	O
parthenogenotes	O
produced	O
by	O
the	O
post-GVBD	O
activation	O
.	O
The	O
parthengenotes	O
were	O
derived	O
only	O
from	O
eggs	O
that	O
failed	O
to	O
extrude	O
polar	O
bodies	O
,	O
mostly	O
from	O
eggs	O
failing	O
to	O
extrude	O
a	O
second	O
polar	O
body	O
.	O
Eggs	O
derived	O
from	O
immature	O
oocytes	O
activated	O
by	O
A23187	O
,	O
treated	O
with	O
1-MeAde	SYMP
and	O
post-treated	O
with	O
cytochalasin	SYMP
B	SYMP
failed	O
to	O
extrude	O
polar	O
bodies	O
,	O
and	O
eventually	O
developed	O
into	O
parthenogenetic	O
embryos	O
.	O
These	O
results	O
indicate	O
that	O
the	O
present	O
parthenogenesis	O
mechanism	O
shares	O
the	O
same	O
characteristics	O
as	O
that	O
achieved	O
by	O
post-GVBD	O
activation	O
in	O
the	O
suppression	O
of	O
polar	O
body	O
formation	O
as	O
a	O
key	O
means	O
for	O
successful	O
starfish	O
parthenogenesis	O
.	O
We	O
hypothesized	O
that	O
fluoride	SYMP
partly	O
acts	O
by	O
changing	O
the	O
levels	O
of	O
circulating	O
calcium-regulating	O
hormones	O
and	O
skeletal	O
growth	O
factors	O
.	O
The	O
effects	O
of	O
oral	SYMP
fluoride	SYMP
on	O
24	O
female	O
,	O
Dutch-Belted	O
,	O
young	O
adult	O
rabbits	O
were	O
studied	O
.	O
The	O
rabbits	O
were	O
divided	O
into	O
two	O
study	O
groups	O
,	O
one	O
control	O
and	O
the	O
other	O
receiving	O
about	O
16	O
mg	O
fluoride/rabbit/day	O
in	O
their	O
drinking	O
water	O
.	O
After	O
6	O
months	O
of	O
fluoride	SYMP
dosing	SYMP
,	O
all	O
rabbits	O
were	O
euthanized	O
and	O
bone	O
and	O
blood	O
samples	O
were	O
taken	O
for	O
analyses	O
.	O
Fluoride	SYMP
treatment	SYMP
increased	O
serum	O
and	O
bone	O
fluoride	O
levels	O
by	O
over	O
an	O
order	O
of	O
magnitude	O
(	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O
,	O
but	O
did	O
not	O
affect	O
body	O
weight	O
or	O
the	O
following	O
serum	O
biochemical	O
variables	O
:	O
urea	O
,	O
creatinine	O
,	O
phosphorus	O
,	O
total	O
protein	O
,	O
albumin	O
,	O
bilirubin	O
,	O
SGOT	O
,	O
or	O
total	O
alkaline	O
phosphatase	O
.	O
No	O
skeletal	SYMP
fluorosis	SYMP
or	O
osteomalacia	SYMP
was	O
observed	O
histologically	O
,	O
nor	O
did	O
fluoride	SYMP
affect	O
serum	O
PTH	O
or	O
Vitamin	O
D	O
metabolites	O
(	O
P	O
greater	O
than	O
0.4	O
)	O
.	O
BAP	O
was	O
increased	O
37	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
by	O
fluoride	O
;	O
serum	O
TRAP	O
was	O
increased	O
42	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
;	O
serum	O
IGF-1	O
was	O
increased	O
40	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
.	O
Fluoride	SYMP
increased	O
the	O
vertebral	O
BV/TV	O
by	O
35	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
and	O
tibial	O
ash	O
weight	O
by	O
10	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
.	O
However	O
,	O
the	O
increases	O
in	O
bone	O
mass	O
and	O
bone	O
formation	O
were	O
not	O
reflected	O
in	O
improved	O
bone	O
strength	O
.	O
Fluoride	O
decreased	O
bone	O
strength	O
by	O
about	O
19	O
%	O
in	O
the	O
L5	O
vertebra	O
(	O
P	O
&	O
#	O
60	O
;	O
0.01	O
)	O
and	O
25	O
%	O
in	O
the	O
femoral	O
neck	O
(	O
P	O
&	O
#	O
60	O
;	O
0	O
.	O
05	O
)	O
.	O
X-ray	O
diffraction	O
showed	O
altered	O
mineral	O
crystal	O
thickness	O
in	O
fluoride-treated	O
bones	O
(	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O
,	O
and	O
there	O
was	O
a	O
negative	O
association	O
between	O
crystal	O
width	O
and	O
fracture	O
stress	O
of	O
the	O
femur	O
(	O
P	O
&	O
#	O
60	O
;	O
0.02	O
)	O
.	O
In	O
conclusion	O
,	O
fluoride	O
's	O
effects	O
on	O
bone	O
mass	O
and	O
bone	O
turnover	O
were	O
not	O
mediated	O
by	O
PTH	O
.	O
IGF-1	O
was	O
increased	O
by	O
fluoride	O
and	O
was	O
associated	O
with	O
increased	O
bone	O
turnover	O
,	O
but	O
was	O
not	O
correlated	O
with	O
bone	O
formation	O
markers	O
.	O
High-dose	O
fluoride	SYMP
treatment	SYMP
did	O
not	O
improve	O
,	O
but	O
decreased	O
,	O
bone	O
strength	O
in	O
rabbits	O
,	O
even	O
in	O
the	O
absence	O
of	O
impaired	O
mineralization	O
.	O
YES	O
Evidence	O
for	O
the	O
presence	O
of	O
a	O
serotonin1A	O
(	O
5-HT1A	O
)	O
receptor	O
subtype	O
in	O
the	O
salmonid	O
fish	O
brain	O
has	O
recently	O
been	O
presented	O
.	O
In	O
the	O
present	O
study	O
the	O
potent	O
5-HT1A	O
receptor	O
agonist	O
,	O
8-hydroxy-2-	O
(	O
di-n-propylamino	O
)	O
-tetralin	O
(	O
8-OH-DPAT	O
)	O
was	O
tested	O
for	O
its	O
effect	O
on	O
plasma	O
cortisol	O
concentrations	O
in	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
.	O
Blood	O
was	O
sampled	O
and	O
8-OH-DPAT	O
administered	O
through	O
a	O
catheter	O
in	O
the	O
dorsal	O
aorta	O
.	O
Thirty	O
minutes	O
after	O
the	O
injection	O
of	O
40	O
microg	O
of	O
8-OH-DPAT/kg	O
,	O
plasma	O
cortisol	O
levels	O
had	O
increased	O
from	O
12	O
to	O
149	O
ng/ml	O
,	O
whereupon	O
they	O
fell	O
,	O
reaching	O
baseline	O
levels	O
after	O
4	O
h.	O
The	O
effect	O
of	O
1-40	O
microg	O
8-OH-DPAT/kg	O
on	O
plasma	O
cortisol	O
concentrations	O
was	O
dose-dependent	O
.	O
The	O
results	O
lends	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
the	O
brain	O
serotonergic	O
system	O
plays	O
a	O
key	O
role	O
in	O
integrating	O
autonomic	O
,	O
behavioral	O
and	O
neuroendocrine	O
stress-responses	O
in	O
fish	O
as	O
well	O
as	O
mammals	O
,	O
suggesting	O
that	O
not	O
only	O
the	O
structural	O
and	O
biochemical	O
organization	O
,	O
but	O
also	O
the	O
function	O
of	O
the	O
serotonergic	O
system	O
has	O
been	O
conserved	O
during	O
vertebrate	O
evolution	O
.	O
YES	O
YES	O
We	O
describe	O
2	O
cases	O
in	O
which	O
intraoperative	O
transesophageal	O
echocardiography	O
detected	O
complications	O
related	O
to	O
the	O
proximal	O
coronary	O
arteries	O
during	O
homograft	SYMP
aortic	SYMP
valve	SYMP
and	SYMP
root	SYMP
replacement	SYMP
.	O
In	O
both	O
cases	O
,	O
cardiopulmonary	SYMP
bypass	SYMP
could	O
not	O
be	O
discontinued	O
despite	O
the	O
use	O
of	O
large	O
doses	O
of	O
inotropic	SYMP
drugs	SYMP
.	O
Transesophageal	O
echocardiography	O
demonstrated	O
aliasing	O
on	O
color	O
flow	O
mapping	O
in	O
the	O
left	O
main	O
coronary	O
artery	O
in	O
1	O
case	O
and	O
proximal	O
right	O
coronary	O
artery	O
in	O
the	O
other	O
,	O
along	O
with	O
severely	O
depressed	O
left	O
ventricular	O
anterior	O
wall	O
and	O
right	O
ventricular	O
function	O
,	O
respectively	O
.	O
Coronary	SYMP
artery	SYMP
bypass	SYMP
grafting	SYMP
was	O
performed	O
in	O
both	O
cases	O
,	O
and	O
the	O
outcome	O
was	O
successful	O
.	O
TO_SEE	O
Evidence-based	O
medicine	O
(	O
EBM	O
)	O
aids	O
clinical	O
decision	O
making	O
in	O
all	O
fields	O
of	O
medicine	O
,	O
including	O
primary	O
care	O
.	O
General	O
practice	O
is	O
characterized	O
by	O
particular	O
emphasis	O
on	O
the	O
doctor-patient	O
relationship	O
and	O
on	O
biomedical	O
,	O
personal	O
and	O
contextual	O
perspectives	O
in	O
diagnosis	O
.	O
Most	O
evidence	O
available	O
to	O
general	O
practitioners	O
(	O
GPs	O
)	O
addresses	O
only	O
the	O
bio-medical	O
perspective	O
and	O
is	O
often	O
not	O
directly	O
applicable	O
to	O
primary	O
care	O
,	O
as	O
it	O
derives	O
from	O
secondary	O
or	O
tertiary	O
care	O
.	O
Emphasis	O
on	O
the	O
biomedical	O
domain	O
and	O
the	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
alone	O
reflects	O
a	O
reductionist	O
approach	O
that	O
fails	O
to	O
do	O
justice	O
to	O
the	O
philosophy	O
of	O
general	O
practice	O
.	O
The	O
art	O
of	O
medicine	O
is	O
founded	O
on	O
context	O
,	O
anecdote	O
,	O
patient	O
stories	O
of	O
illness	O
and	O
personal	O
experience	O
,	O
and	O
we	O
should	O
continue	O
to	O
blend	O
this	O
with	O
good	O
quality	O
and	O
appropriate	O
research	O
findings	O
in	O
patient	O
care	O
.	O
TO_SEE	O
YES	O
A	O
55-year-old	O
lady	O
underwent	O
repeat	O
aortic	SYMP
valve	SYMP
replacement	SYMP
using	O
a	O
16-mm	O
Carbomedics	O
prosthesis	O
.	O
She	O
made	O
an	O
uneventful	O
postoperative	O
recovery	O
and	O
now	O
leads	O
an	O
unrestricted	O
life	O
.	O
Doppler	O
echocardiography	O
reveals	O
a	O
21-mm	O
Hg	O
gradient	O
across	O
the	O
valve	O
at	O
rest	O
.	O
This	O
did	O
not	O
increase	O
with	O
an	O
infusion	O
of	O
30	O
mcg/kg	O
per	O
min	O
of	O
dobutamine	O
,	O
which	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
cardiac	O
output	O
from	O
1.96	O
to	O
5.46	O
l/min	O
.	O
BACKGROUND	O
:	O
For	O
more	O
than	O
30	O
years	O
it	O
has	O
been	O
known	O
that	O
gastric	O
acid	O
secretion	O
is	O
inversely	O
related	O
to	O
the	O
extent	O
and	O
severity	O
of	O
corpal	SYMP
gastritis	SYMP
.	O
We	O
therefore	O
evaluated	O
the	O
effect	O
of	O
cure	O
of	O
Helicobacter	SYMP
pylori	SYMP
infection	SYMP
on	O
basal	O
and	O
pentagastrin-stimulated	O
acid	O
secretion	O
.	O
METHODS	O
:	O
Basal	O
acid	O
output	O
(	O
BAO	O
)	O
and	O
maximal	O
acid	O
output	O
(	O
MAO	O
)	O
were	O
assessed	O
in	O
11	O
H.	O
pylori-infected	O
dyspeptic	O
patients	O
(	O
8	O
women	O
and	O
3	O
men	O
;	O
mean	O
age	O
,	O
28	O
years	O
)	O
before	O
and	O
after	O
successful	O
anti-H.	O
pylori	O
therapy	O
.	O
RESULTS	O
:	O
The	O
gastritis	O
index	O
was	O
significantly	O
lower	O
after	O
therapy	O
and	O
was	O
associated	O
with	O
an	O
increase	O
in	O
both	O
BAO	O
and	O
MAO	O
after	O
cure	O
of	O
the	O
H	SYMP
.	SYMP
pylori	SYMP
infection	SYMP
(	O
BAO	O
from	O
0.3	O
mmol/h	O
and	O
MAO	O
from	O
4.8	O
mmol/h	O
to	O
19	O
mmol/	O
h	O
)	O
.	O
Basal	O
and	O
stimulated	O
acid	O
concentrations	O
also	O
increased	O
(	O
29.1	O
+/-	O
36.6	O
to	O
54	O
+/-	O
31	O
mmol/l	O
and	O
72.5	O
+/-	O
46	O
to	O
120.1	O
+/-	O
30	O
mmol/l	O
,	O
respectively	O
,	O
for	O
basal	O
and	O
stimulated	O
acid	O
concentrations	O
;	O
P	O
&	O
#	O
60	O
;	O
0.05	O
for	O
peak	O
and	O
MAO	O
,	O
P	O
=	O
0.07	O
for	O
BAO	O
)	O
.	O
CONCLUSION	O
:	O
Gastric	O
acid	O
secretion	O
increased	O
into	O
the	O
normal	O
range	O
after	O
successful	O
treatment	O
of	O
H	SYMP
.	SYMP
pylori	SYMP
infection	SYMP
,	O
suggesting	O
that	O
gastric	O
function	O
can	O
recover	O
to	O
normal	O
or	O
almost	O
normal	O
after	O
cure	O
of	O
H	SYMP
.	SYMP
pylori	SYMP
infection	SYMP
.	O
YES	O
After	O
a	O
rapid	O
examination	O
of	O
a	O
few	O
basic	O
concepts	O
concerning	O
cellular	O
aging	O
and	O
programmed	O
cell	O
death	O
,	O
the	O
aging	O
of	O
the	O
tissues	O
and	O
organs	O
,	O
the	O
authors	O
discuss	O
the	O
principal	O
theories	O
on	O
senescence	O
.	O
They	O
underline	O
that	O
it	O
is	O
necessary	O
to	O
agree	O
in	O
considering	O
the	O
various	O
genetic	O
and	O
epigenetic	O
,	O
endogenous	O
and	O
exogenous	O
mechanisms	O
that	O
lead	O
to	O
the	O
complex	O
aging	O
phenomenon	O
multiple	O
and	O
interrelated	O
.	O
In	O
particular	O
they	O
stress	O
the	O
hypothesis	O
that	O
senescence	O
can	O
be	O
due	O
to	O
a	O
sum	O
of	O
molecular	O
damages	O
caused	O
by	O
free	O
radicals	O
,	O
and	O
to	O
the	O
loss	O
of	O
telomeric	O
DNA	O
.	O
Radical	O
reactions	O
can	O
cause	O
mutations	O
,	O
inactivation	O
or	O
a	O
decrease	O
in	O
the	O
turnover	O
of	O
mitochondrial	O
DNA	O
which	O
is	O
more	O
vulnerable	O
than	O
the	O
nuclear	O
genoma	O
to	O
the	O
attack	O
of	O
mutagenic	O
agents	O
,	O
acting	O
also	O
as	O
a	O
continuous	O
source	O
of	O
initial	O
and/or	O
promoting	O
factors	O
of	O
the	O
carcinogenetic	O
process	O
.	O
The	O
somatic	O
cells	O
become	O
senescent	O
because	O
during	O
cell	O
division	O
,	O
they	O
lose	O
the	O
mechanisms	O
for	O
the	O
lengthening	O
of	O
the	O
telomere	O
.	O
The	O
telomerase	O
prevents	O
the	O
shortening	O
of	O
telomeres	O
in	O
neoplastic	O
cells	O
and	O
therefore	O
renders	O
them	O
immortal	O
.	O
Paradoxically	O
the	O
protection	O
of	O
the	O
telomere	O
is	O
exactly	O
what	O
must	O
be	O
avoided	O
in	O
the	O
case	O
of	O
tumor	O
cells	O
.	O
Recently	O
the	O
demonstration	O
that	O
telomerase	O
is	O
not	O
always	O
involved	O
in	O
the	O
restoration	O
of	O
telomere	O
length	O
shows	O
the	O
complexity	O
of	O
the	O
problems	O
connected	O
to	O
the	O
cause	O
of	O
senescence	O
.	O
Chromosomally	O
integrated	O
retroviral	O
switch	O
(	O
S	O
)	O
substrates	O
have	O
been	O
developed	O
to	O
reveal	O
switch	O
recombinase-like	O
activities	O
(	O
SRLA	O
)	O
in	O
pre-B	O
and	O
mature	O
B	O
cell	O
lines	O
.	O
Switch	O
substrate	O
retrovectors	O
(	O
SSR	O
)	O
contain	O
a	O
long-terminal	O
repeat-driven	O
neomycin	O
(	O
Neo	O
)	O
gene	O
for	O
proviral	O
chromosomal	O
maintenance	O
(	O
pre-	O
and	O
post-S	O
recombination	O
)	O
and	O
a	O
CMV	O
promoter-driven	O
,	O
chimeric	O
hygromycin-thymidine	O
kinase	O
(	O
Hytk	O
)	O
gene	O
(	O
flanked	O
by	O
S	O
mu	O
and	O
S	O
gamma	O
2b	O
recombination	O
targets	O
)	O
to	O
select	O
for	O
(	O
ganciclovir	O
)	O
and	O
against	O
(	O
hygromycin	O
B	O
)	O
S	O
region	O
recombination	O
.	O
The	O
retro-substrates	O
'	O
strong	O
,	O
constitutive	O
promoters	O
ensure	O
that	O
variations	O
in	O
cellular	O
switch	O
recombinase	O
activities	O
are	O
independent	O
of	O
S	O
region	O
accessibility	O
control	O
.	O
By	O
initially	O
selecting	O
for	O
proviral	O
integrants	O
in	O
hygromycin	O
followed	O
by	O
shifting	O
into	O
neomycin	O
+	O
ganciclovir	O
to	O
select	O
for	O
S	O
sequence-mediated	O
deletions	O
,	O
switch	O
recombinations	O
can	O
be	O
specifically	O
forestalled	O
in	O
B	O
cell	O
lines	O
whilst	O
most	O
switch-incompetent	O
cells	O
do	O
not	O
survive	O
secondary	O
selection	O
.	O
A	O
qualitative	O
,	O
direct	O
PCR	O
assay	O
reveals	O
that	O
SSR	O
recombinations	O
are	O
stochastic	O
in	O
B	O
cell	O
lines	O
generating	O
a	O
product	O
array	O
akin	O
to	O
natural	O
GH	O
class	O
switching	O
.	O
A	O
semi-quantitative	O
DC-PCR	O
assay	O
detects	O
a	O
significant	O
recombinase	O
activity	O
only	O
in	O
a	O
restricted	O
set	O
of	O
late	O
stage	O
pre-B	O
and	O
mature	O
B	O
cell	O
lines	O
.	O
BCL1B1	O
mature	O
B	O
cells	O
have	O
the	O
highest	O
level	O
of	O
recombinase	O
activity	O
with	O
25	O
%	O
or	O
more	O
of	O
proviral	O
integrants	O
accumulating	O
S	O
mu/S	O
gamma	O
2b	O
substrate	O
recombinations	O
within	O
10-14	O
cell	O
generations	O
.	O
The	O
SSR	O
recombinase	O
assay	O
can	O
be	O
performed	O
in	O
a	O
transient	O
fashion	O
wherein	O
extensive	O
,	O
B	O
cell-specific	O
recombination	O
can	O
be	O
visualized	O
within	O
only	O
a	O
few	O
cell	O
divisions	O
post	O
proviral	O
integration	O
.	O
We	O
propose	O
that	O
switch	O
recombinase	O
activity	O
becomes	O
activated	O
during	O
B	O
cell	O
ontogeny	O
independent	O
of	O
or	O
prior	O
to	O
the	O
acquisition	O
of	O
CH	O
locus	O
accessibility	O
and	O
that	O
endogenous	O
S	O
segment	O
targeting	O
to	O
pre-existing	O
recombinase	O
requires	O
a	O
level	O
of	O
accessibility	O
beyond	O
transcriptional	O
activation	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
prevalence	O
of	O
illicit	O
drug	O
abuse	O
and	O
alcohol	O
use	O
in	O
an	O
obstetric	O
population	O
based	O
in	O
an	O
urban	O
maternity	O
hospital	O
.	O
SETTING	O
:	O
A	O
collaborative	O
study	O
between	O
the	O
Rotunda	O
Hospital	O
,	O
Dublin	O
and	O
the	O
Irish	O
National	O
Drug	O
Advisory	O
&	O
#	O
38	O
;	O
Treatment	O
Centre	O
.	O
DESIGN	O
:	O
A	O
prospective	O
study	O
consisting	O
of	O
anonymous	O
,	O
unlinked	O
urine	O
testing	O
of	O
504	O
'first	O
visit	O
'	O
antenatal	O
patients	O
and	O
a	O
separate	O
group	O
of	O
515	O
patients	O
six	O
weeks	O
after	O
delivery	O
.	O
METHODS	O
&	O
#	O
38	O
;	O
OUTCOME	O
MEASURES	O
:	O
Toxicological	O
screening	O
using	O
enzyme-linked	O
immunoassay	O
techniques	O
,	O
with	O
all	O
positive	O
samples	O
being	O
reanalysed	O
.	O
Drug	O
histories	O
were	O
taken	O
and	O
samples	O
were	O
tested	O
for	O
alcohol	O
and	O
six	O
of	O
the	O
most	O
commonly	O
abused	O
drugs	O
.	O
The	O
pre-	O
and	O
postnatal	O
prevalence	O
of	O
abuse	O
was	O
matched	O
with	O
demographic	O
data	O
.	O
RESULTS	O
:	O
The	O
prevalence	O
of	O
chemical	O
substance	O
misuse	O
in	O
the	O
antenatal	O
population	O
was	O
2.8	O
%	O
and	O
5.6	O
%	O
in	O
the	O
postnatal	O
population	O
.	O
Substances	O
identified	O
included	O
benzodiazepines	O
,	O
cannabis	O
,	O
amphetamines	O
,	O
opiates	O
and	O
cocaine	O
.	O
Less	O
than	O
2	O
%	O
of	O
samples	O
tested	O
positive	O
for	O
alcohol	O
.	O
None	O
of	O
the	O
women	O
yielding	O
positive	O
samples	O
had	O
been	O
pre-identified	O
on	O
the	O
basis	O
of	O
history	O
.	O
A	O
significant	O
proportion	O
of	O
the	O
women	O
were	O
in	O
the	O
high	O
risk	O
categories	O
with	O
regard	O
to	O
age	O
and	O
socio-economic	O
status	O
.	O
CONCLUSION	O
:	O
The	O
prevalence	O
of	O
drug	O
misuse	O
antenatally	O
was	O
nearly	O
3	O
%	O
and	O
postnatally	O
almost	O
6	O
%	O
.	O
Substance	O
abusers	O
in	O
pregnancy	O
are	O
more	O
likely	O
to	O
be	O
single	O
,	O
unemployed	O
,	O
and	O
to	O
have	O
had	O
a	O
previous	O
pregnancy	O
.	O
Schizophrenic	SYMP
illnesses	SYMP
occur	O
with	O
approximately	O
the	O
same	O
incidence	O
in	O
all	O
human	O
populations	O
with	O
a	O
characteristic	O
distribution	O
(	O
slightly	O
earlier	O
in	O
males	O
)	O
of	O
ages	O
of	O
onset	O
.	O
Given	O
that	O
the	O
predisposition	O
(	O
which	O
presumably	O
is	O
genetic	O
)	O
is	O
associated	O
with	O
a	O
procreative	O
disadvantage	O
why	O
do	O
such	O
illnesses	O
persist	O
?	O
Here	O
it	O
is	O
suggested	O
that	O
these	O
conditions	O
are	O
a	O
manifestation	O
of	O
genetic	O
diversity	O
in	O
the	O
evolution	O
of	O
the	O
specifically	O
human	O
characteristic	O
of	O
language	O
,	O
an	O
innovation	O
that	O
has	O
occurred	O
by	O
a	O
process	O
of	O
progressive	O
hemispheric	O
specialization-the	O
establishment	O
of	O
dominance	O
for	O
some	O
critical	O
component	O
of	O
language	O
in	O
one	O
or	O
the	O
other	O
hemisphere	O
.	O
Individuals	O
who	O
develop	O
schizophrenic	SYMP
symptoms	SYMP
show	O
lesser	O
anatomical	O
and	O
functional	O
asymmetries	O
than	O
the	O
population	O
as	O
a	O
whole	O
;	O
such	O
symptoms	O
may	O
reflect	O
'dominance	O
failure	O
'	O
for	O
language	O
.	O
Cloacal	SYMP
anomalies	SYMP
are	O
extremely	O
rare	O
and	O
have	O
variable	O
presentations	O
.	O
Prenatal	O
diagnosis	O
can	O
be	O
difficult	O
especially	O
if	O
they	O
present	O
in	O
late	O
gestation	O
.	O
Here	O
we	O
present	O
two	O
cases	O
diagnosed	O
in	O
the	O
late	O
third	O
trimester	O
and	O
review	O
the	O
literature	O
regarding	O
prenatal	O
diagnosis	O
of	O
cloacal	SYMP
anomalies	SYMP
.	O
OBJECTIVE	O
:	O
To	O
determine	O
whether	O
patients	O
with	O
myocardial	SYMP
amyloidosis	SYMP
due	O
either	O
to	O
AL	O
(	O
primary	O
)	O
amyloid	O
or	O
familial	O
amyloid	O
have	O
distinguishing	O
echocardiographic	O
or	O
electrocardiographic	O
features	O
;	O
and	O
to	O
compare	O
the	O
prevalence	O
of	O
heart	SYMP
failure	SYMP
and	O
survival	O
in	O
the	O
two	O
types	O
of	O
amyloidosis	SYMP
in	O
relation	O
to	O
echocardiographic	O
findings	O
.	O
DESIGN	O
:	O
Blinded	O
group	O
comparison	O
of	O
randomly	O
selected	O
cases	O
of	O
cardiac	SYMP
amyloidosis	SYMP
.	O
SETTING	O
:	O
International	O
referral	O
centre	O
for	O
amyloid	O
research	O
and	O
treatment	O
.	O
PATIENTS	O
:	O
36	O
patients	O
with	O
cardiac	SYMP
amyloid	SYMP
heart	SYMP
disease	SYMP
,	O
of	O
whom	O
12	O
had	O
familial	O
and	O
24	O
had	O
primary	O
AL	O
amyloidosis	SYMP
.	O
RESULTS	O
:	O
Familial	O
and	O
AL	O
echocardiograms	O
were	O
morphologically	O
indistinguishable	O
,	O
with	O
similar	O
left	O
ventricular	O
wall	O
thickness	O
,	O
mean	O
(	O
SD	O
)	O
15.4	O
(	O
2.3	O
)	O
nu	O
15.8	O
(	O
2.5	O
)	O
mm	O
,	O
respectively	O
;	O
right	O
ventricular	O
wall	O
thickness	O
was	O
also	O
similar	O
between	O
amyloid	O
types	O
:	O
9.6	O
(	O
2.8	O
)	O
nu	O
9.7	O
(	O
6.5	O
)	O
mm	O
,	O
respectively	O
.	O
Doppler	O
indices	O
of	O
left	O
and	O
right	O
ventricular	O
function	O
,	O
left	O
ventricular	O
volume	O
,	O
and	O
ejection	O
fraction	O
were	O
also	O
similar	O
.	O
Low	O
voltage	O
electrocardiograms	O
(	O
&	O
#	O
60	O
;	O
0.5	O
mV	O
)	O
were	O
more	O
common	O
in	O
the	O
AL	O
(	O
16/24	O
,	O
67	O
%	O
)	O
than	O
in	O
the	O
familial	O
group	O
(	O
4/12	O
,	O
25	O
%	O
)	O
,	O
P	O
&	O
#	O
60	O
;	O
0.05	O
.	O
The	O
one	O
year	O
survival	O
for	O
familial	O
and	O
AL	O
forms	O
was	O
92	O
%	O
(	O
11/12	O
)	O
nu	O
38	O
%	O
(	O
6/24	O
)	O
,	O
respectively	O
,	O
with	O
virtually	O
all	O
deaths	O
due	O
to	O
cardiac	O
causes	O
.	O
CONCLUSIONS	O
:	O
Although	O
cardiac	O
involvement	O
is	O
echocardiographically	O
indistinguishable	O
,	O
cardiac	O
mortality	O
is	O
very	O
different	O
between	O
the	O
two	O
forms	O
of	O
amyloidosis	SYMP
.	O
Preservation	O
of	O
electrocardiographic	O
voltage	O
in	O
familial	O
amyloidosis	SYMP
suggests	O
that	O
the	O
particular	O
biochemical	O
characteristics	O
of	O
distinct	O
types	O
of	O
amyloid	O
fibril	O
have	O
different	O
pathological	O
effects	O
on	O
the	O
myocardium	O
.	O
This	O
distinction	O
becomes	O
critical	O
in	O
the	O
evaluation	O
,	O
treatment	O
,	O
and	O
management	O
of	O
patients	O
who	O
have	O
a	O
diagnosis	O
within	O
the	O
spectrum	O
of	O
the	O
protein	SYMP
deposition	SYMP
diseases	SYMP
.	O
OBJECTIVE	O
:	O
To	O
examine	O
the	O
relationship	O
between	O
plasma	O
plasminogen	O
activator	O
inhibitor	O
1	O
(	O
PAI-1	O
)	O
activity	O
and	O
PAI-1	O
gene	O
(	O
4G/5G	O
)	O
polymorphism	O
and	O
diabetic	SYMP
retinopathy	SYMP
in	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	SYMP
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
We	O
studied	O
171	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	SYMP
between	O
the	O
ages	O
of	O
30-70	O
years	O
in	O
a	O
population-based	O
epidemiological	O
survey	O
.	O
Plasma	O
PAI-1	O
activity	O
was	O
measured	O
by	O
a	O
spectrophotometric	O
assay	O
and	O
PAI-1	O
4G/5G	O
promoter	O
genotype	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
allele-specific	O
primers	O
.	O
Retinopathy	SYMP
was	O
assessed	O
by	O
ophthalmoscopy	O
after	O
pupillary	O
dilation	O
and	O
classified	O
as	O
any	O
retinopathy	SYMP
or	O
as	O
nonproliferative	O
and	O
proliferative	O
.	O
RESULTS	O
:	O
Retinopathy	SYMP
was	O
present	O
in	O
70	O
(	O
41	O
%	O
)	O
subjects	O
,	O
and	O
4	O
(	O
2.3	O
%	O
)	O
subjects	O
had	O
proliferative	O
retinopathy	SYMP
.	O
Plasma	O
PAI-1	O
activity	O
was	O
not	O
significantly	O
different	O
among	O
subjects	O
with	O
and	O
without	O
retinopathy	SYMP
(	O
17.1	O
+/-	O
vs.	O
19.7	O
+/-	O
9.1	O
arbitrary	O
units	O
(	O
AU	O
)	O
/ml	O
,	O
P	O
=	O
0.09	O
)	O
.	O
PAI-1	O
activity	O
was	O
negatively	O
correlated	O
with	O
duration	O
of	O
diabetes	SYMP
(	O
rs	O
=	O
-0.18	O
,	O
P	O
=	O
0.02	O
)	O
.	O
In	O
a	O
logistic	O
regression	O
analysis	O
controlled	O
for	O
age	O
,	O
sex	O
,	O
BMI	O
,	O
and	O
duration	O
of	O
diabetes	SYMP
,	O
any	O
retinopathy	SYMP
was	O
significantly	O
associated	O
with	O
fasting	O
plasma	O
glucose	O
concentrations	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
,	O
2-h	O
postload	O
glucose	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
HbA1c	O
(	O
P	O
=	O
0.008	O
)	O
,	O
but	O
not	O
with	O
PAI-1	O
activity	O
(	O
P	O
=	O
0.48	O
)	O
.	O
The	O
prevalence	O
of	O
retinopathy	SYMP
in	O
the	O
three	O
genotype	O
groups	O
differed	O
significantly	O
(	O
4G/4G	O
,	O
4G/5G	O
,	O
and	O
5G/5G	O
were	O
44	O
,	O
49	O
,	O
and	O
24	O
%	O
,	O
respectively	O
;	O
chi	O
2	O
=	O
8.22	O
,	O
df	O
=	O
2	O
,	O
P	O
=	O
0.016	O
)	O
and	O
remained	O
significant	O
after	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
BMI	O
,	O
duration	O
of	O
diabetes	SYMP
,	O
glycated	O
hemoglobin	O
,	O
and	O
urine	O
albumin-to-creatine	O
ratio	O
in	O
a	O
logistic	O
regression	O
analysis	O
.	O
The	O
odds	O
ratios	O
for	O
retinopathy	SYMP
in	O
subjects	O
with	O
4G/4G	O
and	O
4G/5G	O
,	O
compared	O
with	O
the	O
5G/5G	O
genotype	O
,	O
were	O
2.0	O
and	O
3.1	O
,	O
respectively	O
.	O
CONCLUSIONS	O
:	O
Although	O
diabetic	SYMP
retinopathy	SYMP
in	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	SYMP
is	O
not	O
associated	O
with	O
PAI-1	O
activity	O
,	O
subjects	O
with	O
the	O
4G/4G	O
and	O
4G/5G	O
genotype	O
had	O
a	O
higher	O
prevalence	O
of	O
retinopathy	SYMP
compared	O
with	O
5G/5G	O
PAI-1genotype	O
.	O
These	O
preliminary	O
findings	O
indicate	O
that	O
in	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	SYMP
,	O
presence	O
of	O
the	O
4G	O
allele	O
of	O
the	O
PAI-1	O
gene	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
diabetic	SYMP
retinopathy	SYMP
.	O
YES	O
BACKGROUND	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
Blastocystis	SYMP
hominis	SYMP
parasitation	SYMP
and	O
to	O
ascertain	O
its	O
role	O
as	O
an	O
intestinal	O
a	O
prospective	O
study	O
during	O
18	O
months	O
pathogen	O
has	O
been	O
carried	O
out	O
.	O
SUBJECTS	O
AND	O
METHODS	O
:	O
The	O
study	O
included	O
2,039	O
patients	O
,	O
which	O
were	O
classified	O
in	O
three	O
groups	O
(	O
asymptomatic	O
[	O
group	O
A	O
]	O
,	O
with	O
suspicion	O
of	O
parasitosis	SYMP
[	O
group	O
B	O
]	O
,	O
with	O
diarrhoea	SYMP
[	O
group	O
C	O
]	O
)	O
.	O
In	O
all	O
cases	O
a	O
coproparasitological	O
study	O
was	O
performed	O
.	O
In	O
the	O
group	O
C	O
the	O
presence	O
of	O
non-parasitic	O
enteropathogens	O
was	O
also	O
investigated	O
.	O
In	O
patients	O
with	O
B.	O
hominis	O
in	O
the	O
absence	O
of	O
other	O
pathogens	O
clinical	O
and	O
epidemiological	O
characteristics	O
were	O
evaluated	O
.	O
Also	O
,	O
its	O
was	O
determined	O
the	O
morphology	O
and	O
quantification	O
of	O
parasites	O
.	O
RESULTS	O
:	O
Parasites	O
were	O
identified	O
in	O
26.2	O
%	O
of	O
population	O
.	O
B.	O
hominis	O
was	O
identified	O
in	O
336	O
patients	O
(	O
16.5	O
%	O
)	O
.	O
The	O
frequency	O
of	O
parasitation	SYMP
was	O
superior	O
in	O
adults	O
(	O
p	O
&	O
#	O
60	O
;	O
0.0001	O
)	O
,	O
with	O
a	O
slight	O
predominance	O
in	O
the	O
female	O
sex	O
.	O
The	O
rate	O
of	O
asymptomatic	O
carriers	O
was	O
3.3	O
%	O
.	O
In	O
21	O
patients	O
B.	O
hominis	O
(	O
group	O
C	O
)	O
was	O
observed	O
in	O
absence	O
of	O
other	O
enteropathogens	O
.	O
Statistical	O
significant	O
association	O
was	O
found	O
between	O
B.	O
hominis	O
,	O
in	O
absence	O
of	O
other	O
pathogens	O
and	O
the	O
presence	O
of	O
clinical	O
manifestations	O
(	O
p	O
&	O
#	O
60	O
;	O
0.0001	O
)	O
,	O
the	O
most	O
common	O
of	O
which	O
were	O
diarrhoea	SYMP
and	O
abdominal	SYMP
pain	SYMP
.	O
We	O
did	O
not	O
find	O
a	O
statistically	O
significant	O
association	O
between	O
the	O
number	O
of	O
B.	O
hominis	O
present	O
and	O
stool	O
characteristics	O
.	O
The	O
vacuolar	O
form	O
was	O
the	O
predominant	O
morphological	O
type	O
.	O
The	O
ameboid	O
form	O
was	O
observed	O
only	O
in	O
diarrhoeal	O
stools	O
.	O
CONCLUSIONS	O
:	O
B.	O
hominis	O
is	O
the	O
most	O
frequent	O
parasite	O
found	O
in	O
faecal	O
parasitological	O
investigation	O
.	O
In	O
absence	O
of	O
other	O
causes	O
,	O
B.	O
hominis	O
must	O
be	O
considered	O
as	O
a	O
pathogen	O
.	O
TO_SEE	O
Postnatal	O
growth	O
was	O
prospectively	O
measured	O
from	O
birth	O
to	O
1	O
y	O
in	O
54	O
term	O
infants	O
born	O
small	O
for	O
gestational	O
age	O
(	O
SGA	O
)	O
,	O
fed	O
either	O
breast	O
milk	O
or	O
a	O
standard	O
term	O
infant	O
formula	O
.	O
Breastfeeding	O
was	O
associated	O
with	O
a	O
0.36	O
and	O
0.64	O
standard	O
deviation	O
(	O
SD	O
)	O
increase	O
in	O
weight	O
at	O
2	O
weeks	O
and	O
3	O
months	O
of	O
age	O
,	O
respectively	O
,	O
which	O
persisted	O
beyond	O
the	O
breastfeeding	O
period	O
(	O
0.64	O
SD	O
at	O
1	O
y	O
)	O
.	O
Breastfed	O
infants	O
also	O
showed	O
greater	O
catch-up	O
growth	O
in	O
head	O
circumference	O
[	O
SD	O
score	O
(	O
SDS	O
)	O
0.53	O
higher	O
at	O
3	O
months	O
]	O
,	O
and	O
greater	O
body	O
length	O
gain	O
(	O
SDS	O
0.68	O
higher	O
at	O
6	O
months	O
)	O
.	O
This	O
increased	O
growth	O
was	O
independent	O
of	O
potentially	O
confounding	O
obstetric	O
,	O
social	O
and	O
demographic	O
factors	O
.	O
Our	O
findings	O
suggest	O
that	O
breastfeeding	O
may	O
promote	O
faster	O
growth	O
in	O
infants	O
compromised	O
by	O
poor	O
growth	O
in	O
utero	O
.	O
SGA	O
infants	O
may	O
be	O
programmed	O
for	O
a	O
number	O
of	O
adverse	O
outcomes	O
;	O
the	O
possibility	O
that	O
such	O
events	O
are	O
altered	O
by	O
choice	O
of	O
postnatal	O
diet	O
is	O
a	O
key	O
issue	O
for	O
future	O
research	O
.	O
BACKGROUND	O
:	O
Few	O
studies	O
have	O
explored	O
the	O
health	O
practices	O
of	O
critical	O
care	O
nurses	O
.	O
Critical	O
care	O
nurses	O
routinely	O
teach	O
patients	O
about	O
using	O
healthy	O
practices	O
such	O
as	O
low-fat	O
diets	O
,	O
exercise	O
,	O
and	O
routine	O
screening	O
examinations	O
.	O
However	O
,	O
it	O
may	O
be	O
even	O
more	O
important	O
that	O
the	O
nurses	O
themselves	O
have	O
a	O
healthy	O
lifestyle	O
,	O
thus	O
serving	O
as	O
role	O
models	O
for	O
patients	O
.	O
Nurses	O
are	O
selling	O
a	O
product	O
,	O
and	O
that	O
product	O
is	O
health	O
.	O
The	O
best	O
salespersons	O
are	O
those	O
who	O
are	O
genuinely	O
committed	O
to	O
their	O
product	O
and	O
model	O
its	O
benefits	O
.	O
Therefore	O
,	O
critical	O
care	O
nurses	O
'	O
healthful	O
practices	O
can	O
have	O
a	O
profound	O
effect	O
on	O
their	O
patients	O
.	O
OBJECTIVES	O
:	O
The	O
purpose	O
of	O
this	O
descriptive	O
exploratory	O
study	O
was	O
to	O
examine	O
critical	O
care	O
nurses	O
'	O
responses	O
to	O
three	O
questions	O
about	O
health	O
practices	O
in	O
their	O
daily	O
lives	O
:	O
(	O
1	O
)	O
What	O
are	O
critical	O
care	O
nurses	O
doing	O
currently	O
to	O
stay	O
healthy	O
?	O
(	O
2	O
)	O
Do	O
they	O
anticipate	O
making	O
any	O
changes	O
in	O
their	O
lifestyle	O
in	O
the	O
future	O
?	O
(	O
3	O
)	O
Would	O
they	O
recommend	O
their	O
lifestyle	O
to	O
their	O
patients	O
?	O
METHODS	O
:	O
One	O
hundred	O
twenty-seven	O
critical	O
care	O
nurses	O
attending	O
a	O
midwestern	O
critical	O
care	O
conference	O
completed	O
a	O
two-part	O
questionnaire	O
designed	O
to	O
produce	O
a	O
health	O
profile	O
.	O
In	O
a	O
man-on-the-street	O
approach	O
,	O
23	O
nurses	O
participated	O
in	O
an	O
interview	O
via	O
video	O
camera	O
.	O
Descriptive	O
statistics	O
were	O
used	O
to	O
analyze	O
the	O
data	O
retrieved	O
from	O
the	O
questionnaires	O
.	O
Interviews	O
were	O
transcribed	O
verbatim	O
and	O
analyzed	O
for	O
themes	O
with	O
a	O
constant	O
comparative	O
method	O
.	O
RESULTS	O
:	O
More	O
than	O
70	O
%	O
of	O
the	O
critical	O
care	O
nurses	O
who	O
responded	O
engage	O
in	O
exercise	O
and	O
follow	O
a	O
healthy	O
,	O
low-fat	O
diet	O
.	O
Seventy-one	O
percent	O
said	O
that	O
they	O
anticipate	O
making	O
a	O
change	O
in	O
their	O
lifestyle	O
in	O
the	O
future	O
,	O
and	O
70	O
%	O
said	O
that	O
they	O
would	O
recommend	O
their	O
lifestyle	O
to	O
their	O
patients	O
.	O
Five	O
themes	O
emerged	O
from	O
the	O
videotaped	O
interviews	O
:	O
(	O
1	O
)	O
Heart-healthy	O
practices	O
predominated	O
the	O
responses	O
.	O
(	O
2	O
)	O
Incorporating	O
a	O
healthy	O
lifestyle	O
was	O
easy	O
for	O
some	O
and	O
a	O
struggle	O
for	O
others	O
.	O
(	O
3	O
)	O
Critical	O
care	O
nurses	O
readily	O
listed	O
barriers	O
to	O
healthy	O
living	O
.	O
(	O
4	O
)	O
The	O
nurses	O
had	O
a	O
positive	O
attitude	O
about	O
their	O
healthy	O
lifestyles	O
and	O
felt	O
optimistic	O
about	O
being	O
role	O
models	O
for	O
their	O
patients	O
.	O
(	O
5	O
)	O
Future	O
plans	O
were	O
either	O
singular	O
in	O
focus	O
or	O
limited	O
to	O
maintenance	O
of	O
current	O
health	O
habits	O
.	O
CONCLUSIONS	O
:	O
The	O
majority	O
of	O
the	O
nurses	O
reported	O
practicing	O
a	O
healthy	O
lifestyle	O
and	O
thought	O
that	O
they	O
were	O
good	O
role	O
models	O
for	O
patients	O
.	O
Cytochrome	O
P450	O
1A1	O
(	O
CYP1A1	O
)	O
and	O
glutathione	O
S-transferase	O
M1	O
(	O
GSTM1	O
)	O
genetic	O
polymorphisms	O
are	O
involved	O
in	O
the	O
activation	O
and	O
detoxification	O
of	O
chemical	O
carcinogens	O
found	O
in	O
tobacco	O
smoke	O
;	O
thus	O
they	O
may	O
influence	O
host	O
susceptibility	O
to	O
lung	SYMP
cancer	SYMP
.	O
In	O
this	O
study	O
at	O
Massachusetts	O
General	O
Hospital	O
(	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
of	O
416	O
cases	O
and	O
446	O
controls	O
(	O
mostly	O
White	O
)	O
we	O
evaluated	O
the	O
association	O
between	O
the	O
CYP1A1	O
MspI	O
and	O
GSTM1	O
polymorphisms	O
and	O
lung	SYMP
cancer	SYMP
risk	O
,	O
and	O
their	O
interaction	O
with	O
cigarette	O
smoke	O
.	O
The	O
CYP1A1	O
MspI	O
heterozygous	O
genotype	O
was	O
present	O
in	O
18	O
percent	O
of	O
cases	O
and	O
16	O
percent	O
of	O
controls	O
,	O
and	O
one	O
percent	O
of	O
cases	O
and	O
controls	O
were	O
CYP1A1	O
MspI	O
homozygous	O
variant	O
.	O
The	O
GSTM1	O
null	O
genotype	O
was	O
detected	O
in	O
54	O
percent	O
of	O
cases	O
and	O
52	O
percent	O
of	O
controls	O
.	O
After	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
pack-years	O
of	O
smoking	O
,	O
and	O
years	O
since	O
quitting	O
smoking	O
,	O
while	O
neither	O
the	O
CYP1A1	O
MspI	O
heterozygous	O
genotype	O
alone	O
nor	O
the	O
GSTM1	O
null	O
genotype	O
alone	O
were	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
lung	SYMP
cancer	SYMP
risk	O
,	O
having	O
both	O
genetic	O
traits	O
was	O
associated	O
with	O
a	O
twofold	O
increase	O
in	O
risk	O
(	O
95	O
percent	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
1.0-3.4	O
)	O
.	O
Our	O
data	O
did	O
not	O
provide	O
enough	O
evidence	O
for	O
a	O
substantial	O
modification	O
of	O
the	O
effect	O
of	O
pack-years	O
on	O
lung	SYMP
cancer	SYMP
risk	O
by	O
the	O
CYP1A1	O
MspI	O
and	O
GSTM1	O
genotypes	O
.	O
However	O
,	O
limitations	O
of	O
our	O
study	O
preclude	O
a	O
conclusion	O
about	O
this	O
potential	O
interaction	O
.	O
YES	O
YES	O
YES	O
A	O
commercially	O
available	O
health	O
food	O
product	O
of	O
cold-pressed	O
hemp	O
seed	O
oil	O
ingested	O
by	O
one	O
volunteer	O
twice	O
a	O
day	O
for	O
4	O
1/2	O
days	O
(	O
135	O
mL	O
total	O
)	O
.	O
Urine	O
specimens	O
collected	O
from	O
the	O
volunteer	O
were	O
subjected	O
to	O
standard	O
workplace	O
urine	O
drug	O
testing	O
procedures	O
,	O
and	O
the	O
following	O
concentrations	O
of	O
11-nor-delta9-	O
tetrahydrocannabinol	O
carboxylic	O
acid	O
(	O
9-THCA	O
)	O
were	O
detected	O
:	O
41	O
ng/mL	O
9-THCA	O
at	O
45	O
h	O
,	O
49	O
ng/mL	O
at	O
69	O
h	O
,	O
and	O
55	O
ng/mL	O
at	O
93	O
h.	O
Ingestion	O
was	O
discontinued	O
after	O
93	O
h	O
,	O
and	O
the	O
following	O
concentrations	O
were	O
detected	O
:	O
68	O
ng/mL	O
at	O
108	O
h	O
,	O
57	O
ng/mL	O
at	O
117	O
h	O
,	O
31	O
ng/mL	O
at	O
126	O
h	O
,	O
and	O
20	O
ng/mL	O
at	O
142	O
h.	O
The	O
first	O
specimen	O
that	O
tested	O
negative	O
(	O
50	O
ng/mL	O
initial	O
immunoassay	O
test	O
,	O
15	O
ng/mL	O
confirmatory	O
gas	O
chromatographic-mass	O
spectrometric	O
test	O
)	O
was	O
at	O
146	O
h	O
,	O
which	O
was	O
53	O
h	O
after	O
the	O
last	O
hemp	O
seed	O
oil	O
ingestion	O
.	O
Four	O
subsequent	O
specimens	O
taken	O
to	O
177	O
h	O
were	O
also	O
negative	O
.	O
This	O
study	O
indicates	O
that	O
a	O
workplace	O
urine	O
drug	O
test	O
positive	O
for	O
cannabinoids	O
may	O
arise	O
from	O
the	O
consumption	O
of	O
commercially	O
available	O
cold-pressed	O
hemp	O
seed	O
oil	O
.	O
OBJECTIVE	O
:	O
We	O
determined	O
the	O
sensitivity	O
and	O
specificity	O
of	O
neonatal	O
brain-stem	O
auditory	O
evoked	O
potentials	O
(	O
BAEP	O
)	O
as	O
markers	O
for	O
subsequent	O
hearing	SYMP
impairment	SYMP
and	O
for	O
developmental	SYMP
problems	SYMP
found	O
later	O
in	O
infancy	O
and	O
childhood	O
.	O
METHODS	O
:	O
BAEP	O
studies	O
were	O
performed	O
before	O
discharge	O
in	O
infants	O
treated	O
with	O
extracorporeal	SYMP
membrane	SYMP
oxygenation	SYMP
(	SYMP
ECMO	SYMP
)	SYMP
,	O
and	O
two	O
specific	O
abnormalities	O
were	O
analyzed	O
:	O
elevated	O
threshold	O
and	O
delayed	O
central	O
auditory	O
conduction	O
.	O
Behavioral	O
audiometry	O
was	O
repeated	O
during	O
periodic	O
follow-up	O
until	O
reliable	O
responses	O
were	O
obtained	O
for	O
all	O
frequencies	O
,	O
and	O
standardized	O
developmental	O
testing	O
was	O
also	O
conducted	O
.	O
The	O
sensitivity	O
and	O
specificity	O
of	O
an	O
elevated	O
threshold	O
on	O
the	O
neonatal	O
BAEP	O
for	O
detecting	O
subsequent	O
hearing	O
loss	O
,	O
and	O
the	O
relationship	O
of	O
any	O
neonatal	O
BAEP	O
abnormality	O
to	O
language	O
or	O
developmental	O
disorders	O
in	O
infancy	O
,	O
were	O
calculated	O
.	O
RESULTS	O
:	O
Test	O
results	O
for	O
46	O
ECMO-treated	O
infants	O
(	O
57.5	O
%	O
)	O
were	O
normal	O
,	O
and	O
those	O
for	O
34	O
infants	O
(	O
42.5	O
%	O
)	O
were	O
abnormal	O
,	O
with	O
either	O
elevated	O
wave	O
V	O
threshold	O
,	O
prolonged	O
wave	O
I-V	O
interval	O
,	O
or	O
both	O
on	O
neonatal	O
BAEP	O
recordings	O
.	O
Most	O
significantly	O
,	O
7	O
(	O
58	O
%	O
)	O
of	O
the	O
12	O
children	O
with	O
subsequent	O
sensorineural	SYMP
hearing	SYMP
loss	SYMP
had	O
left	O
the	O
hospital	O
after	O
showing	O
normal	O
results	O
on	O
threshold	O
tests	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
hearing	SYMP
loss	SYMP
between	O
subjects	O
with	O
abnormal	O
(	O
5/21	O
,	O
or	O
24	O
%	O
)	O
and	O
those	O
with	O
normal	O
BAEP	O
thresholds	O
(	O
7/59	O
,	O
or	O
12	O
%	O
;	O
Fisher	O
Exact	O
Test	O
,	O
p	O
=	O
0.28	O
)	O
.	O
Therefore	O
the	O
sensitivity	O
of	O
neonatal	O
BAEP	O
testing	O
for	O
predicting	O
subsequent	O
hearing	SYMP
loss	SYMP
was	O
only	O
42	O
%	O
.	O
Neonatal	O
BAEP	O
specificity	O
for	O
excluding	O
subsequent	O
hearing	SYMP
loss	SYMP
was	O
76	O
%	O
.	O
In	O
contrast	O
,	O
on	O
language	O
development	O
testing	O
,	O
19	O
children	O
demonstrated	O
receptive	O
language	O
delay	O
.	O
Of	O
these	O
children	O
,	O
12	O
(	O
63	O
%	O
)	O
had	O
abnormal	O
neonatal	O
BAEP	O
recordings	O
and	O
7	O
(	O
37	O
%	O
)	O
had	O
a	O
normal	O
BAEP	O
threshold	O
,	O
normal	O
central	O
auditory	O
conduction	O
test	O
results	O
,	O
or	O
both	O
(	O
p	O
=	O
0.04	O
)	O
.	O
CONCLUSIONS	O
:	O
Neonatal	O
BAEP	O
threshold	O
recordings	O
were	O
of	O
limited	O
value	O
for	O
predicting	O
subsequent	O
hearing	SYMP
loss	SYMP
common	O
in	O
ECMO	SYMP
-treated	O
survivors	O
.	O
However	O
,	O
an	O
abnormal	O
neonatal	O
BAEP	O
significantly	O
increased	O
the	O
probability	O
of	O
finding	O
a	O
receptive	O
language	O
delay	O
during	O
early	O
childhood	O
,	O
even	O
in	O
those	O
with	O
subsequently	O
normal	O
audiometry	O
findings	O
.	O
Because	O
neonatal	O
ECMO	SYMP
is	O
associated	O
with	O
a	O
high	O
risk	O
of	O
hearing	SYMP
and	SYMP
receptive	SYMP
language	SYMP
disorders	SYMP
,	O
parents	O
should	O
be	O
counseled	O
that	O
audiologic	O
and	O
developmental	O
follow-up	O
evaluations	O
in	O
surviving	O
children	O
are	O
essential	O
regardless	O
of	O
the	O
results	O
of	O
neonatal	O
BAEP	O
testing	O
.	O
The	O
Federated	O
Council	O
of	O
Internal	O
Medicine	O
has	O
developed	O
a	O
resource	O
guide	O
to	O
help	O
internal	O
medicine	O
residency	O
programs	O
produce	O
internists	O
who	O
are	O
prepared	O
for	O
today	O
's	O
practice	O
of	O
internal	O
medicine	O
and	O
the	O
challenges	O
of	O
practice	O
in	O
the	O
future	O
.	O
The	O
guide	O
situates	O
general	O
internal	O
medicine	O
as	O
the	O
primary	O
care	O
profession	O
that	O
focuses	O
on	O
preventive	O
,	O
short-term	O
,	O
and	O
long-term	O
care	O
of	O
adult	O
patients	O
.	O
It	O
assumes	O
that	O
a	O
single	O
pathway	O
is	O
sufficient	O
for	O
educating	O
general	O
internists	O
and	O
subspecialty-bound	O
trainees	O
.	O
It	O
identifies	O
the	O
learning	O
experiences	O
that	O
should	O
be	O
part	O
of	O
general	O
internal	O
medicine	O
residency	O
training	O
,	O
lists	O
the	O
clinical	O
competencies	O
that	O
are	O
important	O
for	O
primary	O
care	O
practice	O
,	O
and	O
describes	O
the	O
role	O
of	O
the	O
integrative	O
disciplines	O
that	O
should	O
inform	O
the	O
care	O
of	O
every	O
patient	O
.	O
It	O
also	O
describes	O
a	O
process	O
that	O
program	O
directors	O
and	O
local	O
program	O
committees	O
can	O
use	O
to	O
develop	O
competency-based	O
curricula	O
.	O
BACKGROUND	O
:	O
Darier	SYMP
disease	SYMP
is	O
an	O
uncommon	O
genodermatosis	SYMP
characterized	O
by	O
the	O
symmetrical	O
eruption	O
of	O
keratotic	O
reddish-brown	O
papules	O
occurring	O
in	O
the	O
seborrheic	O
areas	O
of	O
the	O
body	O
.	O
A	O
unilateral	O
,	O
or	O
localized	O
,	O
variant	O
has	O
been	O
identified	O
.	O
We	O
report	O
4	O
new	O
cases	O
of	O
localized	O
Darier	SYMP
disease	SYMP
and	O
review	O
the	O
English-language	O
literature	O
.	O
The	O
implications	O
of	O
these	O
cases	O
on	O
future	O
genetic	O
studies	O
are	O
also	O
discussed	O
.	O
OBSERVATIONS	O
:	O
Localized	O
Darier	SYMP
disease	SYMP
occurred	O
with	O
equal	O
frequency	O
in	O
males	O
and	O
females	O
.	O
The	O
average	O
age	O
at	O
onset	O
was	O
27	O
years	O
.	O
The	O
most	O
frequent	O
site	O
of	O
involvement	O
was	O
the	O
trunk	O
(	O
40	O
%	O
[	O
16/40	O
]	O
)	O
.	O
This	O
condition	O
was	O
aggravated	O
by	O
sunlight	O
,	O
heat	O
,	O
or	O
sweating	O
in	O
42	O
%	O
(	O
19/40	O
)	O
of	O
reported	O
cases	O
,	O
and	O
38	O
%	O
(	O
15/40	O
)	O
of	O
the	O
patients	O
responded	O
to	O
treatment	O
with	O
topical	O
tretinoin	SYMP
.	O
CONCLUSIONS	O
:	O
Many	O
of	O
the	O
clinical	O
features	O
of	O
localized	O
Darier	SYMP
disease	SYMP
suggest	O
that	O
it	O
is	O
a	O
genetic	O
mosaic	O
of	O
generalized	O
Darier	SYMP
disease	SYMP
.	O
Further	O
studies	O
of	O
localized	O
Darier	SYMP
disease	SYMP
may	O
therefore	O
prove	O
to	O
be	O
instrumental	O
in	O
the	O
search	O
for	O
the	O
Darier	SYMP
disease	SYMP
gene	O
.	O
UV	O
radiation	O
induces	O
two	O
major	O
DNA	O
damage	O
products	O
,	O
the	O
cyclobutane	O
pyrimidine	O
dimer	O
(	O
CPD	O
)	O
and	O
,	O
at	O
a	O
lower	O
frequency	O
,	O
the	O
pyrimidine	O
(	O
6-4	O
)	O
pyrimidinone	O
dimer	O
(	O
6-4	O
product	O
)	O
.	O
Although	O
Escherichia	O
coli	O
and	O
Saccharomyes	O
cerevisiae	O
produce	O
a	O
CPD-specific	O
photolyase	O
that	O
eliminates	O
only	O
this	O
class	O
of	O
dimer	O
,	O
Arabidopsis	O
thaliana	O
,	O
Drosphila	O
melanogaster	O
,	O
Crotalus	O
atrox	O
,	O
and	O
Xenopus	O
laevis	O
have	O
recently	O
been	O
shown	O
to	O
photoreactivate	O
both	O
CPDs	O
and	O
6-4	O
products	O
.	O
We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
two	O
new	O
classes	O
of	O
mutants	O
of	O
Arabidopsis	O
,	O
termed	O
uvr2	O
and	O
uvr3	O
,	O
that	O
are	O
defective	O
in	O
the	O
photoreactivation	O
of	O
CPDs	O
and	O
6-4	O
products	O
,	O
respectively	O
.	O
We	O
demonstrate	O
that	O
the	O
CPD	O
photolyase	O
mutation	O
is	O
genetically	O
linked	O
to	O
a	O
DNA	O
sequence	O
encoding	O
a	O
type	O
II	O
(	O
metazoan	O
)	O
CPD	O
photolyase	O
.	O
In	O
addition	O
,	O
we	O
are	O
able	O
to	O
generate	O
plants	O
in	O
which	O
only	O
CPDs	O
or	O
6-4	O
products	O
are	O
photoreactivated	O
in	O
the	O
nuclear	O
genome	O
by	O
exposing	O
these	O
mutants	O
to	O
UV	O
light	O
and	O
then	O
allowing	O
them	O
to	O
repair	O
one	O
or	O
the	O
other	O
class	O
of	O
dimers	O
.	O
This	O
provides	O
us	O
with	O
a	O
unique	O
opportunity	O
to	O
study	O
the	O
biological	O
consequences	O
of	O
each	O
of	O
these	O
two	O
major	O
UV-induced	O
photoproducts	O
in	O
an	O
intact	O
living	O
system	O
.	O
A	O
diffuse	O
macular	SYMP
erythroderma	SYMP
and	O
subsequent	O
desquamation	SYMP
after	O
1	O
to	O
2	O
weeks	O
are	O
two	O
of	O
the	O
five	O
major	O
diagnostic	O
criteria	O
of	O
toxic	SYMP
shock	SYMP
syndrome	SYMP
(	SYMP
TSS	SYMP
)	SYMP
.	O
We	O
present	O
the	O
case	O
of	O
a	O
15-month-old	O
girl	O
with	O
TSS	SYMP
,	O
but	O
without	O
erythroderma	SYMP
or	O
desquamation	SYMP
.	O
She	O
was	O
admitted	O
with	O
high	SYMP
fever	SYMP
,	O
shock	SYMP
,	O
and	O
multiorgan	O
involvement	O
.	O
Minimal	O
or	O
no	O
cutaneous	O
signs	O
were	O
present	O
.	O
Initially	O
the	O
diagnosis	O
of	O
the	O
syndrome	O
of	O
hemorrhagic	SYMP
shock	SYMP
and	O
encephalopathy	SYMP
was	O
made	O
.	O
After	O
7	O
days	O
,	O
a	O
TSS	SYMP
toxin	O
1-producing	O
strain	O
of	O
Staphylococcus	O
aureus	O
was	O
cultured	O
from	O
an	O
inguinal	O
lymph	O
node	O
,	O
where	O
inflammation	SYMP
had	O
already	O
been	O
noticed	O
on	O
admission	O
.	O
Moreover	O
,	O
the	O
girl	O
had	O
no	O
antibodies	O
against	O
this	O
toxin	O
.	O
The	O
serum	O
cytokine	O
profile	O
during	O
the	O
acute	O
phase	O
of	O
her	O
illness	O
showed	O
high	O
levels	O
of	O
tumor	O
necrosis	O
factor-alpha	O
,	O
interleukin-6	O
and	O
interferon-gamma	O
,	O
as	O
is	O
seen	O
during	O
activation	O
of	O
the	O
immune	O
system	O
by	O
TSS	SYMP
toxin	O
1	O
.	O
Other	O
possible	O
causes	O
for	O
the	O
patient	O
's	O
illness	O
were	O
excluded	O
.	O
We	O
conclude	O
that	O
the	O
patient	O
had	O
TSS	SYMP
without	O
rash	SYMP
.	O
Without	O
the	O
evidence	O
implicating	O
a	O
TSS	SYMP
toxin	O
1-producing	O
strain	O
of	O
S.	O
aureus	O
as	O
the	O
cause	O
of	O
her	O
disease	O
,	O
a	O
diagnosis	O
of	O
syndrome	O
of	O
hemorrhagic	SYMP
shock	SYMP
and	O
encephalopathy	SYMP
would	O
have	O
been	O
made	O
.	O
It	O
is	O
possible	O
that	O
some	O
cases	O
of	O
syndrome	O
of	O
hemorrhagic	SYMP
shock	SYMP
and	O
encephalopathy	SYMP
represent	O
a	O
variant	O
of	O
TSS	SYMP
in	O
small	O
children	O
.	O
TO_SEE	O
The	O
chicken	O
calmodulin	O
I	O
(	O
CaMI	O
)	O
gene	O
has	O
been	O
isolated	O
and	O
characterized	O
on	O
the	O
level	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
.	O
The	O
deduced	O
amino	O
acid	O
(	O
aa	O
)	O
sequence	O
is	O
identical	O
to	O
the	O
one	O
of	O
chicken	O
CaMII	O
which	O
consists	O
of	O
148	O
aa	O
.	O
The	O
CaMI	O
gene	O
contains	O
six	O
exons	O
.	O
Its	O
intron/exon	O
organization	O
is	O
identical	O
to	O
that	O
of	O
the	O
chicken	O
CaMII	O
and	O
the	O
CaMI	O
and	O
CaMIII	O
genes	O
of	O
rat	O
and	O
human	O
.	O
Expression	O
of	O
the	O
CaMI	O
gene	O
was	O
detected	O
in	O
all	O
chicken	O
tissues	O
examined	O
,	O
although	O
at	O
varying	O
levels	O
.	O
The	O
gene	O
is	O
transcribed	O
into	O
four	O
mRNAs	O
of	O
0.8	O
,	O
1.4	O
,	O
1.7	O
and	O
4.4	O
kb	O
as	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O
Our	O
results	O
demonstrate	O
that	O
the	O
``	O
multigene-one-protein	O
''	O
principle	O
of	O
CaM	O
synthesis	O
is	O
not	O
only	O
applicable	O
to	O
mammals	O
whose	O
CaM	O
is	O
encoded	O
by	O
three	O
different	O
genes	O
,	O
but	O
also	O
to	O
chickens	O
.	O
BACKGROUND	O
:	O
We	O
assessed	O
the	O
accuracy	O
of	O
two	O
electron	O
beam	O
computed	O
tomography	O
(	O
EBCT	O
)	O
protocols	O
for	O
predicting	O
coronary	SYMP
events	SYMP
.	O
METHODS	O
AND	O
RESULTS	O
:	O
In	O
1994	O
,	O
24	O
months	O
after	O
enrollment	O
in	O
a	O
longitudinal	O
study	O
,	O
326	O
high-risk	O
adults	O
underwent	O
both	O
3-	O
and	O
6-mm	O
image-slice	O
thickness	O
EBCT	O
scanning	O
and	O
were	O
followed	O
up	O
for	O
32.0+/-4.0	O
additional	O
months	O
.	O
Events	O
were	O
defined	O
as	O
either	O
coronary	O
death	O
,	O
myocardial	SYMP
infarction	SYMP
than	O
,	O
or	O
revascularization	SYMP
.	O
We	O
monitored	O
these	O
subjects	O
for	O
the	O
32-month	O
postscanning	O
period	O
with	O
yearly	O
phone	O
calls	O
and	O
acquisition	O
of	O
records	O
for	O
all	O
hospital	O
admissions	O
.	O
At	O
the	O
time	O
of	O
scanning	O
,	O
11	O
subjects	O
(	O
3	O
%	O
)	O
had	O
already	O
suffered	O
12	O
events	O
(	O
5	O
infarctions	SYMP
and	O
7	O
revascularizations	SYMP
)	O
during	O
the	O
24-month	O
prescanning	O
period	O
.	O
During	O
the	O
postscanning	O
period	O
,	O
18	O
subjects	O
(	O
6	O
%	O
)	O
suffered	O
23	O
events	O
(	O
5	O
coronary	O
deaths	O
,	O
6	O
infarctions	SYMP
,	O
and	O
12	O
revascularizations	SYMP
)	O
.	O
Thus	O
,	O
28	O
subjects	O
(	O
9	O
%	O
)	O
suffered	O
35	O
events	O
.	O
Calcium	O
quantities	O
calculated	O
for	O
both	O
protocols	O
,	O
performed	O
on	O
the	O
same	O
subjects	O
,	O
were	O
sorted	O
in	O
ascending	O
order	O
and	O
divided	O
into	O
equal	O
quartiles	O
.	O
When	O
revascularizations	SYMP
were	O
included	O
,	O
there	O
was	O
a	O
significant	O
trend	O
toward	O
higher	O
frequencies	O
of	O
events	O
with	O
increasing	O
calcium	O
quantity	O
(	O
P	O
&	O
#	O
60	O
;	O
.01	O
)	O
.	O
However	O
,	O
coronary	O
death	O
and	O
infarction	SYMP
were	O
not	O
significantly	O
more	O
frequent	O
in	O
higher	O
quartiles	O
.	O
These	O
relationships	O
were	O
preserved	O
in	O
the	O
subjects	O
without	O
prior	O
events	O
at	O
the	O
time	O
of	O
scanning	O
.	O
CONCLUSIONS	O
:	O
Calcium	O
quantities	O
from	O
the	O
3-mm	O
and	O
the	O
more	O
reproducible	O
6-mm	O
scanning	O
are	O
equally	O
accurate	O
for	O
predicting	O
events	O
.	O
Coronary	O
calcium	O
amount	O
appears	O
to	O
be	O
a	O
weak	O
predictor	O
of	O
coronary	O
death	O
and	O
infarction	SYMP
.	O
Its	O
predictive	O
accuracy	O
is	O
superior	O
for	O
predicting	O
revascularization	SYMP
.	O
Research	O
into	O
the	O
genetic	O
component	O
of	O
some	O
complex	O
behaviors	O
often	O
causes	O
controversy	O
,	O
depending	O
on	O
the	O
social	O
meaning	O
and	O
significance	O
of	O
the	O
behavior	O
under	O
study	O
.	O
Research	O
into	O
sexual	O
orientation-simplistically	O
referred	O
to	O
as	O
``	O
gay	O
gene	O
''	O
research-is	O
an	O
example	O
of	O
research	O
that	O
provokes	O
intense	O
controversy	O
.	O
This	O
research	O
is	O
worrisome	O
for	O
many	O
reasons	O
,	O
including	O
the	O
fact	O
that	O
it	O
has	O
been	O
used	O
to	O
harm	O
lesbians	O
and	O
gay	O
men	O
.	O
Many	O
homosexual	O
people	O
have	O
been	O
forced	O
to	O
undergo	O
``	O
treatments	O
''	O
to	O
change	O
their	O
sexual	O
orientation	O
.	O
Other	O
chose	O
to	O
undergo	O
them	O
to	O
escape	O
discrimination	O
and	O
social	O
disapprobation	O
.	O
But	O
there	O
are	O
other	O
reasons	O
to	O
worry	O
about	O
such	O
research	O
.	O
The	O
very	O
motivation	O
for	O
seeking	O
an	O
``	O
origin	O
''	O
of	O
homosexuality	O
reveals	O
homophobia	O
.	O
Moreover	O
,	O
such	O
research	O
may	O
lead	O
to	O
prenatal	O
tests	O
that	O
claim	O
to	O
predict	O
for	O
homosexuality	O
.	O
For	O
homosexual	O
people	O
who	O
live	O
in	O
countries	O
with	O
no	O
legal	O
protections	O
these	O
dangers	O
are	O
particularly	O
serious	O
.	O
YES	O
Cyclin	O
D1	O
,	O
the	O
regulatory	O
subunit	O
of	O
certain	O
protein	O
kinases	O
thought	O
to	O
advance	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
is	O
now	O
established	O
as	O
a	O
proto-oncogene	O
,	O
with	O
evidence	O
indicating	O
that	O
its	O
derangement	O
may	O
contribute	O
to	O
the	O
uncontrolled	O
cell	O
growth	O
characteristic	O
of	O
tumors	SYMP
.	O
The	O
chromosomal	O
translocation	O
t	O
(	O
11	O
;	O
14	O
)	O
(	O
q13	O
:	O
q32	O
)	O
,	O
involving	O
rearrangement	O
of	O
the	O
BCL-1	O
locus	O
,	O
is	O
closely	O
associated	O
with	O
human	SYMP
lymphoid	SYMP
neoplasia	SYMP
affecting	O
mantle	SYMP
cell	SYMP
lymphomas	SYMP
(	SYMP
MCL	SYMP
)	SYMP
.	O
Recently	O
,	O
the	O
putative	O
BCL-1	O
proto-oncogene	O
turned	O
out	O
to	O
be	O
none	O
other	O
than	O
the	O
cyclin	O
D1	O
gene	O
.	O
Although	O
the	O
observed	O
break	O
points	O
in	O
the	O
BCL-1	O
locus	O
are	O
not	O
tightly	O
clustered	O
,	O
its	O
rearrangement	O
has	O
been	O
documented	O
in	O
40-70	O
%	O
of	O
cases	O
of	O
mantle	SYMP
cell	SYMP
lymphoma	SYMP
,	O
whereas	O
it	O
only	O
rarely	O
occurs	O
in	O
other	O
B	SYMP
cell	SYMP
lymphomas	SYMP
.	O
Of	O
note	O
,	O
all	O
of	O
the	O
known	O
break	O
points	O
leave	O
the	O
cyclin	O
D1	O
coding	O
region	O
structurally	O
intact	O
and	O
result	O
in	O
increased	O
protein	O
expression	O
,	O
implying	O
that	O
this	O
may	O
provide	O
a	O
highly	O
sensitive	O
and	O
specific	O
marker	O
for	O
MCL	SYMP
.	O
Recent	O
studies	O
demonstrated	O
that	O
immunohistochemical	O
detection	O
in	O
paraffin-embedded	O
material	O
,	O
using	O
a	O
monoclonal	O
antibody	O
,	O
is	O
very	O
useful	O
for	O
routine	O
diagnosis	O
.	O
Current	O
knowledge	O
of	O
cyclin	O
D1	O
overexpression	O
in	O
malignant	SYMP
lymphomas	SYMP
,	O
with	O
emphasis	O
on	O
its	O
clinicopathologic	O
significance	O
,	O
is	O
reviewed	O
.	O
In	O
the	O
mammalian	O
central	O
nervous	O
system	O
,	O
a	O
diverse	O
group	O
of	O
basic	O
helix-loop-helix	O
(	O
bHLH	O
)	O
proteins	O
is	O
involved	O
in	O
the	O
determination	O
of	O
progenitor	O
cells	O
and	O
,	O
subsequently	O
,	O
in	O
regulating	O
neuronal	O
differentiation	O
.	O
Here	O
we	O
report	O
the	O
identification	O
of	O
a	O
novel	O
subfamily	O
of	O
bHLH	O
proteins	O
,	O
defined	O
by	O
two	O
mammalian	O
enhancer-of-split-	O
and	O
hairy-related	O
proteins	O
,	O
termed	O
SHARP-1	O
and	O
SHARP-2	O
.	O
In	O
contrast	O
to	O
known	O
bHLH	O
genes	O
,	O
detectable	O
transcription	O
of	O
SHARP	O
genes	O
begins	O
at	O
the	O
end	O
of	O
embryonic	O
development	O
marking	O
differentiated	O
neurons	O
that	O
have	O
reached	O
a	O
final	O
position	O
,	O
and	O
increases	O
as	O
postnatal	O
development	O
proceeds	O
.	O
In	O
the	O
adult	O
,	O
SHARP	O
genes	O
are	O
expressed	O
in	O
subregions	O
of	O
the	O
CNS	O
that	O
have	O
been	O
associated	O
with	O
adult	O
plasticity	O
.	O
In	O
PC12	O
cells	O
,	O
a	O
model	O
system	O
to	O
study	O
neurite	O
outgrowth	O
,	O
SHARP	O
genes	O
can	O
be	O
induced	O
by	O
NGF	O
with	O
the	O
kinetics	O
of	O
an	O
immediate-early	O
gene	O
.	O
Similarly	O
,	O
within	O
1	O
h	O
after	O
the	O
administration	O
of	O
kainic	O
acid	O
in	O
vivo	O
,	O
SHARP-2	O
is	O
induced	O
in	O
neurons	O
throughout	O
the	O
rat	O
cerebral	O
cortex	O
.	O
This	O
suggests	O
that	O
neuronal	O
bHLH	O
proteins	O
are	O
also	O
involved	O
in	O
the	O
``	O
adaptive	O
''	O
changes	O
of	O
mature	O
CNS	O
neurons	O
which	O
are	O
coupled	O
to	O
glutamatergic	O
stimulation	O
.	O
The	O
embryonic	O
development	O
of	O
the	O
face	O
has	O
been	O
studied	O
in	O
many	O
reviews	O
,	O
this	O
work	O
purposes	O
only	O
to	O
clear	O
up	O
some	O
points	O
which	O
remain	O
obscure	O
concerning	O
cervico-facial	O
morphogenesis	O
.	O
In	O
the	O
first	O
part	O
of	O
this	O
study	O
only	O
the	O
facial	O
development	O
,	O
properly	O
speaking	O
,	O
is	O
considered	O
,	O
although	O
it	O
can	O
not	O
be	O
separate	O
of	O
cervical	O
development	O
to	O
which	O
a	O
second	O
study	O
will	O
be	O
reserved	O
.	O
In	O
the	O
present	O
study	O
we	O
recall	O
the	O
particular	O
aspects	O
of	O
the	O
neurulation	O
in	O
the	O
cephalic	O
area	O
,	O
then	O
the	O
establishment	O
of	O
the	O
facial	O
processes	O
.	O
Then	O
we	O
approach	O
among	O
other	O
things	O
the	O
way	O
to	O
consider	O
the	O
maxillary	O
process	O
with	O
regard	O
to	O
the	O
other	O
facial	O
processes	O
.	O
After	O
is	O
considered	O
constitution	O
and	O
natured	O
of	O
the	O
prechordal	O
plate	O
which	O
has	O
been	O
diversely	O
explained	O
.	O
Finally	O
,	O
the	O
modelling	O
of	O
the	O
face	O
is	O
evocated	O
,	O
in	O
which	O
the	O
dissociation	O
between	O
the	O
olfactive	O
and	O
buccal	O
spheres	O
is	O
pointed	O
out	O
,	O
with	O
the	O
disparition	O
of	O
the	O
muzzle	O
,	O
as	O
it	O
is	O
established	O
in	O
the	O
haplorhinae	O
,	O
a	O
class	O
of	O
primates	O
in	O
which	O
the	O
human	O
being	O
is	O
involved	O
.	O
This	O
phenomenon	O
raises	O
different	O
questions	O
,	O
in	O
particular	O
about	O
the	O
relation	O
of	O
this	O
disposition	O
with	O
the	O
nasoseptal	O
center	O
,	O
the	O
medial	O
part	O
of	O
the	O
nasodorsal	O
center	O
.	O
A	O
case-control	O
study	O
was	O
performed	O
in	O
eight	O
pairs	O
of	O
women	O
to	O
determine	O
whether	O
preeclamptic	O
women	O
developed	O
abnormalities	O
in	O
minor	O
hemoglobins	O
,	O
glycolytic	O
enzymes	O
,	O
or	O
other	O
blood	O
components	O
that	O
might	O
provide	O
insight	O
into	O
the	O
pathophysiology	O
of	O
preeclampsia	SYMP
,	O
or	O
that	O
in	O
combination	O
might	O
be	O
used	O
as	O
a	O
marker	O
for	O
the	O
condition	O
.	O
These	O
variables	O
and	O
standard	O
clinical	O
tests	O
were	O
analyzed	O
as	O
discriminators	O
between	O
preeclamptic	O
and	O
control	O
women	O
.	O
The	O
subjects	O
were	O
matched	O
for	O
age	O
,	O
ethnicity	O
,	O
parity	O
,	O
and	O
gestational	O
age	O
.	O
Blood	O
samples	O
were	O
taken	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
preeclampsia	SYMP
and	O
at	O
comparable	O
gestational	O
ages	O
for	O
matched	O
normal	O
controls	O
.	O
Variables	O
differing	O
significantly	O
between	O
groups	O
included	O
increases	O
in	O
uric	O
acid	O
(	O
UA	O
)	O
,	O
low-density	O
lipoproteins	O
(	O
LDL	O
)	O
,	O
phosphoglycerate	O
kinase	O
(	O
PGK	O
)	O
,	O
and	O
mean	O
platelet	O
volume	O
(	O
MPV	O
)	O
,	O
and	O
decreases	O
in	O
glyceraldehyde	O
phosphate	O
dehydrogenase	O
(	O
G3PD	O
)	O
in	O
preeclamptic	O
women	O
compared	O
to	O
normal	O
controls	O
.	O
Discriminant	O
analysis	O
revealed	O
the	O
following	O
function	O
to	O
separate	O
the	O
groups	O
:	O
0.7764	O
(	O
UA	O
)	O
+	O
0.8086	O
(	O
PGK	O
)	O
-0.7032	O
(	O
G3PD	O
)	O
+	O
0.1399	O
(	O
LDL	O
)	O
-0.2386	O
(	O
MPV	O
)	O
.	O
A	O
discriminant	O
score	O
of	O
greater	O
than	O
or	O
=	O
275	O
indicated	O
a	O
greater	O
than	O
or	O
=	O
90	O
%	O
probability	O
of	O
preeclampsia	SYMP
.	O
The	O
results	O
are	O
consistent	O
with	O
perturbations	O
in	O
red	O
cell	O
glycolysis	O
in	O
preeclampsia	SYMP
.	O
Further	O
prospective	O
studies	O
are	O
warranted	O
to	O
test	O
the	O
efficacy	O
of	O
this	O
discriminant	O
function	O
in	O
predicting	O
preeclampsia	SYMP
.	O
A	O
novel	O
technique	O
for	O
patterning	O
immobilized	O
antibody	O
layers	O
based	O
upon	O
photolithography	O
and	O
oxygen	O
plasma	O
exposure	O
has	O
been	O
developed	O
.	O
Mouse	O
monoclonal	O
antibodies	O
specific	O
for	O
thiabendazole	SYMP
(	O
a	O
post-harvest	O
fungicide	O
and	O
veterinary	O
anthelmintic	O
)	O
were	O
covalently	O
linked	O
through	O
free	O
amine	O
groups	O
to	O
aminosilanized	O
silicon	O
dioxide	O
films	O
using	O
glutaraldehyde	O
.	O
Immobilized	O
antibody	O
layers	O
were	O
stabilized	O
with	O
sucrose	O
,	O
dehydrated	O
,	O
and	O
stored	O
refrigerated	O
with	O
desiccant	O
.	O
Photolithographic	O
patterning	O
was	O
performed	O
with	O
a	O
positive	O
photoresist	O
with	O
modified	O
bake	O
temperatures	O
and	O
times	O
,	O
selective	O
UV	O
exposure	O
with	O
a	O
contact	O
mask	O
,	O
and	O
aqueous	O
alkaline	O
solubilization	O
of	O
exposed	O
resist	O
.	O
Exposed	O
regions	O
of	O
immobilized	O
antibody	O
were	O
then	O
removed	O
by	O
exposure	O
to	O
a	O
low	O
power	O
,	O
radio	O
frequency	O
oxygen	O
discharge	O
.	O
Residual	O
resist	O
was	O
stripped	O
with	O
acetone	O
.	O
Successful	O
patterning	O
was	O
demonstrated	O
by	O
challenging	O
surfaces	O
with	O
goat	O
anti-mouse	O
antibody	O
conjugated	O
to	O
tetramethylrhodamine	O
isothiocyanate	O
.	O
Sucrose	O
stabilization	O
was	O
necessary	O
for	O
antibody	O
to	O
undergo	O
photoresist	O
processing	O
without	O
loss	O
of	O
binding	O
activity	O
.	O
Challenge	O
with	O
enzyme	O
linked	O
antigen	O
of	O
oxygen	O
plasma	O
exposed	O
antibody	O
layers	O
demonstrated	O
that	O
plasma	O
treatment	O
completely	O
neutralized	O
antibody	O
capture	O
ability	O
.	O
Ellipsometry	O
measurements	O
of	O
oxygen	O
plasma	O
exposed	O
antibody	O
layers	O
indicated	O
complete	O
removal	O
of	O
immobilized	O
antibodies	O
.	O
Fluorescent	O
imaging	O
demonstrated	O
smallest	O
line	O
widths	O
of	O
2-3	O
microns	O
.	O
Immune	O
cells	O
in	O
vivo	O
routinely	O
perform	O
highly	O
selective	O
immunosensing	O
in	O
blood	O
and	O
tissues	O
as	O
part	O
of	O
their	O
normal	O
immune	O
surveillance	O
functions	O
.	O
We	O
have	O
been	O
investigating	O
the	O
potential	O
of	O
exploiting	O
the	O
immunosensing	O
detection	O
abilities	O
of	O
excitable	O
immune	O
cells	O
(	O
i.e	O
.	O
the	O
mast	O
cell	O
)	O
for	O
the	O
development	O
of	O
whole	O
cell	O
immunobiosensors	O
.	O
A	O
key	O
feature	O
is	O
that	O
these	O
immune	O
cells	O
can	O
be	O
selectively	O
engineered	O
to	O
recognize	O
specific	O
antigens	O
in	O
vitro	O
.	O
In	O
the	O
presence	O
of	O
antigen	O
,	O
these	O
cells	O
undergo	O
excitable	O
activation	O
responses	O
which	O
result	O
in	O
increased	O
metabolism	O
and	O
the	O
exocytosis	O
of	O
stored	O
intracellular	O
mediators	O
.	O
We	O
have	O
previously	O
determined	O
that	O
mast	O
cell	O
metabolic	O
responses	O
can	O
be	O
thermally	O
transduced	O
in	O
real	O
time	O
,	O
thus	O
indicating	O
the	O
possibility	O
of	O
whole	O
cell	O
thermoelectric	O
immunobiosensing	O
.	O
In	O
this	O
work	O
we	O
investigated	O
the	O
use	O
of	O
enzyme	O
amplification	O
systems	O
to	O
enhance	O
the	O
direct	O
transduction	O
of	O
immune	O
cell	O
responses	O
to	O
analyte	O
.	O
It	O
was	O
found	O
that	O
with	O
appropriate	O
enzymes	O
,	O
peak	O
outputs	O
occurred	O
within	O
approximately	O
5	O
min	O
(	O
4-20	O
times	O
faster	O
than	O
without	O
enzymes	O
)	O
and	O
peak	O
response	O
magnitudes	O
were	O
up	O
to	O
nine-fold	O
greater	O
than	O
without	O
enzymes	O
.	O
An	O
easy-to-use	O
technique	O
for	O
detection	O
of	O
antibodies	O
specific	O
for	O
the	O
parasite	O
L.	O
donovani	O
in	O
human	O
serum	O
sample	O
has	O
been	O
developed	O
.	O
The	O
method	O
is	O
based	O
on	O
an	O
evanescent	O
wave	O
generated	O
from	O
a	O
tapered	O
configuration	O
of	O
decladded	O
optical	O
fibre	O
and	O
does	O
not	O
require	O
any	O
volumetric	O
measurement	O
.	O
Tapered	O
fibres	O
are	O
immobilized	O
with	O
the	O
purified	O
cell	O
surface	O
protein	O
of	O
L.	O
donovani	O
by	O
covalent	O
bonding	O
.	O
Treated	O
fibres	O
are	O
incubated	O
with	O
the	O
patient	O
serum	O
for	O
10	O
min	O
followed	O
by	O
incubation	O
with	O
goat	O
anti	O
human	O
IgG	O
tagged	O
FITC	O
.	O
Fluorescent	O
intensity	O
from	O
the	O
fibre	O
has	O
been	O
shown	O
to	O
be	O
proportional	O
to	O
L.	O
donovani	O
specific	O
antibodies	O
present	O
in	O
the	O
test	O
sera	O
.	O
Direct	O
readings	O
can	O
be	O
obtained	O
after	O
signal	O
enhancement	O
through	O
a	O
photomultiplier	O
tube	O
within	O
5	O
min	O
.	O
The	O
system	O
,	O
when	O
tested	O
on	O
12	O
positive	O
sera	O
,	O
did	O
not	O
show	O
any	O
false	O
negative	O
result	O
.	O
Also	O
,	O
no	O
false	O
positive	O
result	O
was	O
obtained	O
with	O
serum	O
samples	O
of	O
patients	O
infected	O
with	O
leprosy	SYMP
,	O
tuberculosis	SYMP
,	O
typhoid	SYMP
and	O
malaria	SYMP
,	O
showing	O
the	O
specificity	O
of	O
the	O
sensor	O
and	O
efficacy	O
of	O
the	O
technique	O
.	O
We	O
present	O
an	O
optical	O
biosensor	O
design	O
that	O
expands	O
the	O
utility	O
of	O
enzyme	O
biosensors	O
.	O
These	O
biosensors	O
are	O
fabricated	O
by	O
site-selective	O
photodeposition	O
of	O
analyte-sensitive	O
polymer	O
matrices	O
on	O
optical	O
imaging	O
fibres	O
.	O
These	O
dual-analyte	O
arrays	O
allow	O
for	O
the	O
simultaneous	O
,	O
independent	O
measurement	O
of	O
the	O
analyte	O
of	O
interest	O
and	O
the	O
transducing	O
analyte	O
.	O
The	O
first	O
integrated	O
optical-biosensors	O
using	O
this	O
design	O
have	O
been	O
prepared	O
that	O
allow	O
both	O
the	O
dependent	O
and	O
independent	O
analytes	O
to	O
be	O
measured	O
simultaneously	O
,	O
for	O
example	O
penicillin	O
and	O
pH	O
(	O
Healey	O
&	O
#	O
38	O
;	O
Walt	O
,	O
1995	O
)	O
or	O
glucose	O
and	O
O2	O
(	O
Li	O
&	O
#	O
38	O
;	O
Walt	O
,	O
1995	O
)	O
.	O
Independent	O
measurement	O
of	O
the	O
transducing	O
analyte	O
allows	O
penicillin	SYMP
or	O
glucose	O
to	O
be	O
quantitated	O
in	O
the	O
presence	O
of	O
a	O
concurrent	O
pH	O
or	O
O2	O
change	O
,	O
respectively	O
.	O
Penicillin	SYMP
can	O
be	O
measured	O
in	O
the	O
range	O
0.25-10.0	O
mM	O
in	O
the	O
pH	O
range	O
6.2-7.5	O
.	O
Glucose	O
can	O
be	O
measured	O
in	O
the	O
range	O
0.6-20.0	O
mM	O
in	O
the	O
O2	O
range	O
20-100	O
%	O
.	O
The	O
utility	O
of	O
the	O
sensor	O
design	O
was	O
demonstrated	O
by	O
using	O
the	O
penicillin-dual-analyte	O
biosensor	O
to	O
quantitate	O
penicillin	SYMP
produced	O
during	O
a	O
Penicillium	O
chrysogenum	O
fermentation	O
.	O
The	O
characterization	O
of	O
low	O
molecular	O
weight	O
ligand	O
interaction	O
with	O
receptor	O
molecules	O
is	O
of	O
importance	O
for	O
the	O
investigation	O
of	O
biological	O
processes	O
and	O
for	O
drug	O
research	O
.	O
We	O
report	O
on	O
the	O
investigation	O
of	O
the	O
binding	O
of	O
low	O
molecular	O
weight	O
ligands	O
to	O
immobilized	O
receptors	O
by	O
label-free	O
detection	O
.	O
Reflectometric	O
interference	O
spectroscopy	O
,	O
an	O
optical	O
transducer	O
which	O
allows	O
the	O
monitoring	O
of	O
a	O
few	O
picograms	O
per	O
square	O
millimetre	O
changes	O
in	O
surface	O
coverage	O
,	O
was	O
used	O
to	O
study	O
two	O
model	O
systems	O
.	O
In	O
both	O
cases	O
detection	O
of	O
the	O
binding	O
event	O
was	O
successful	O
.	O
High	O
affinity	O
binding	O
of	O
biotin	O
to	O
immobilized	O
streptavidin	O
was	O
clearly	O
detectable	O
at	O
receptor	O
surface	O
concentrations	O
as	O
low	O
as	O
1-2	O
x	O
10	O
(	O
10	O
)	O
binding	O
sites/mm2	O
.	O
Linear	O
correlation	O
between	O
the	O
receptor	O
surface	O
concentration	O
and	O
the	O
response	O
to	O
biotin	O
binding	O
was	O
observed	O
.	O
Using	O
immobilized	O
DNA	O
,	O
we	O
investigated	O
the	O
binding	O
of	O
common	O
intercalators	O
with	O
respect	O
to	O
kinetics	O
and	O
thermodynamics	O
by	O
evaluation	O
of	O
the	O
association	O
and	O
the	O
dissociation	O
part	O
of	O
the	O
binding	O
curve	O
.	O
Bi-exponential	O
increase	O
and	O
decrease	O
of	O
intercalator	O
loading	O
was	O
observed	O
,	O
indicating	O
complex	O
interaction	O
kinetics	O
.	O
The	O
four	O
structurally	O
different	O
intercalators	O
showed	O
significant	O
distinction	O
in	O
binding	O
kinetics	O
and	O
equilibrium	O
signals	O
.	O
Improvement	O
of	O
experimental	O
parameters	O
is	O
required	O
to	O
obtain	O
more	O
reliable	O
kinetic	O
data	O
.	O
An	O
amperometric	O
lactate	O
oxidase	O
catheter	O
has	O
been	O
developed	O
for	O
in	O
vivo	O
application	O
to	O
real-time	O
lactate	O
monitoring	O
.	O
The	O
electrochemical	O
behaviour	O
of	O
the	O
1	O
x	O
3	O
mm	O
Pt-Ag/AgCl	O
thin	O
film	O
electrode	O
is	O
not	O
significantly	O
influenced	O
by	O
lactate	O
oxidase-polyurethane	O
covering	O
.	O
Gamma-irradiation	O
(	O
25	O
kGy	O
)	O
is	O
suitable	O
for	O
the	O
sterilization	O
procedure	O
.	O
The	O
final	O
lactate	O
catheter	O
is	O
characterized	O
by	O
a	O
linear	O
concentration	O
range	O
between	O
0.5	O
and	O
20	O
mmol/l	O
lactate	O
with	O
a	O
sensitivity	O
around	O
2	O
nA	O
mmol-1	O
l-1	O
lactate	O
.	O
The	O
accuracy	O
is	O
demonstrated	O
by	O
the	O
measurement	O
of	O
control	O
sera	O
.	O
Both	O
physiological	O
and	O
pathological	O
materials	O
correlate	O
well	O
with	O
the	O
declared	O
values	O
.	O
The	O
dry	O
stored	O
lactate	O
catheter	O
needs	O
about	O
10	O
min	O
for	O
hydration	O
and	O
is	O
characterized	O
by	O
response	O
times	O
t98	O
%	O
of	O
less	O
than	O
2	O
min	O
.	O
Ex	O
vivo	O
whole	O
blood	O
measurements	O
using	O
the	O
lactate	O
catheter	O
(	O
y	O
)	O
give	O
a	O
correlation	O
with	O
the	O
BIOSEN	O
Med	O
L	O
(	O
x	O
)	O
of	O
y	O
=	O
(	O
1.010x	O
+	O
0.513	O
)	O
mmol/l	O
(	O
r	O
=	O
0.9748	O
)	O
.	O
Lactate	O
values	O
obtained	O
by	O
continuous	O
catheter	O
operation	O
ex	O
vivo	O
correlate	O
well	O
with	O
those	O
obtained	O
by	O
BIOSEN	O
Med	O
L.	O
First	O
subcutaneous	O
implantation	O
(	O
dog	O
)	O
underlines	O
the	O
characteristics	O
obtained	O
ex	O
vivo	O
:	O
after	O
30	O
min	O
hydration	O
the	O
lactate	O
catheter	O
follows	O
the	O
lactate	O
concentration	O
measured	O
ex	O
vivo	O
with	O
samples	O
from	O
the	O
leg	O
vein	O
by	O
BIOSEN	O
Med	O
L	O
.	O
The	O
diffusion-limited	O
binding	O
kinetics	O
of	O
antigen	O
(	O
or	O
antibody	O
)	O
in	O
solution	O
to	O
antibody	O
(	O
or	O
antigen	O
)	O
immobilized	O
on	O
a	O
biosensor	O
and	O
other	O
surfaces	O
is	O
analyzed	O
within	O
a	O
fractal	O
framework	O
.	O
Often	O
,	O
the	O
binding	O
kinetics	O
may	O
be	O
described	O
by	O
a	O
single-fractal	O
analysis	O
.	O
In	O
some	O
cases	O
,	O
the	O
binding	O
curve	O
exhibits	O
complexities	O
.	O
Then	O
,	O
for	O
these	O
cases	O
,	O
the	O
dual-fractal	O
analysis	O
provides	O
an	O
improved	O
fit	O
when	O
compared	O
with	O
a	O
single-fractal	O
analysis	O
.	O
This	O
indicates	O
a	O
change	O
in	O
the	O
reaction	O
mechanism	O
on	O
the	O
surface	O
.	O
It	O
is	O
of	O
interest	O
to	O
note	O
that	O
the	O
state	O
of	O
disorder	O
(	O
or	O
the	O
fractal	O
dimension	O
)	O
and	O
the	O
binding	O
rate	O
coefficient	O
both	O
increase	O
as	O
the	O
reaction	O
progresses	O
on	O
the	O
biosensor	O
surface	O
.	O
For	O
example	O
,	O
for	O
the	O
binding	O
of	O
10	O
nM	O
insulin	O
growth	O
factor-1	O
in	O
solution	O
to	O
insulin	O
growth	O
factor	O
binding	O
protein-1	O
immobilized	O
on	O
a	O
biosensor	O
surface	O
,	O
a	O
64	O
%	O
increase	O
in	O
the	O
fractal	O
dimension	O
from	O
1.73	O
(	O
Df1	O
)	O
to	O
2.85	O
(	O
Df2	O
)	O
leads	O
to	O
an	O
increase	O
in	O
the	O
binding	O
rate	O
coefficient	O
by	O
a	O
factor	O
of	O
31.8	O
from	O
3.92	O
(	O
k1	O
)	O
to	O
125	O
(	O
k2	O
)	O
.	O
Furthermore	O
,	O
as	O
the	O
IGF-1	O
concentration	O
in	O
solution	O
increases	O
from	O
10	O
to	O
80	O
nM	O
in	O
solution	O
,	O
k2	O
and	O
Df2	O
exhibit	O
a	O
linear	O
increase	O
.	O
k1	O
and	O
Df1	O
exhibit	O
a	O
linear	O
increase	O
with	O
the	O
reciprocal	O
of	O
the	O
IGF-1	O
concentration	O
in	O
solution	O
.	O
The	O
different	O
examples	O
analyzed	O
and	O
presented	O
together	O
provide	O
a	O
means	O
by	O
which	O
the	O
antigen-antibody	O
reactions	O
may	O
be	O
better	O
controlled	O
by	O
noting	O
the	O
magnitude	O
of	O
the	O
changes	O
in	O
the	O
fractal	O
dimension	O
and	O
in	O
the	O
binding	O
rate	O
coefficient	O
as	O
the	O
reaction	O
progresses	O
on	O
the	O
biosensor	O
surface	O
.	O
Also	O
,	O
the	O
magnitude	O
of	O
the	O
changes	O
in	O
the	O
binding	O
rate	O
coefficients	O
(	O
k1	O
and	O
k2	O
)	O
and	O
in	O
the	O
fractal	O
dimensions	O
(	O
Df1	O
and	O
Df2	O
)	O
as	O
different	O
parameters	O
are	O
changed	O
for	O
the	O
different	O
biosensor	O
applications	O
are	O
of	O
particular	O
value	O
,	O
since	O
they	O
provide	O
us	O
with	O
a	O
measure	O
or	O
extent	O
of	O
changes	O
in	O
the	O
binding	O
rate	O
coefficient	O
on	O
changing	O
different	O
experimental	O
parameter	O
values	O
.	O
It	O
is	O
of	O
interest	O
to	O
note	O
the	O
effect	O
of	O
different	O
parameters	O
on	O
the	O
extent	O
or	O
heterogeneity	O
that	O
exists	O
on	O
the	O
surface	O
and	O
how	O
this	O
influences	O
the	O
binding	O
rate	O
coefficients	O
.	O
This	O
may	O
be	O
one	O
method	O
to	O
help	O
manipulate	O
or	O
control	O
the	O
binding	O
rate	O
coefficients	O
on	O
the	O
reaction	O
surface	O
.	O
To	O
determine	O
if	O
microscopic	O
urinalysis	O
is	O
needed	O
in	O
all	O
pediatric	O
emergency	O
room	O
patients	O
screened	O
for	O
urinary	SYMP
tract	SYMP
infections	SYMP
(	SYMP
UTI	SYMP
)	SYMP
,	O
we	O
compared	O
the	O
dipstick	O
urinalysis	O
and	O
complete	O
urinalysis	O
(	O
dipstick	O
and	O
microscopy	O
)	O
with	O
urine	O
cultures	O
in	O
236	O
children	O
,	O
aged	O
3	O
weeks	O
to	O
21	O
years	O
.	O
The	O
ability	O
to	O
detect	O
UTI	SYMP
by	O
dipstick	O
only	O
and	O
by	O
complete	O
urinalysis	O
was	O
the	O
same	O
,	O
however	O
microscopic	O
evaluation	O
added	O
many	O
false-positive	O
results	O
without	O
detecting	O
additional	O
UTIs	SYMP
.	O
Because	O
the	O
ability	O
to	O
detect	O
UTI	SYMP
(	O
sensitivity	O
)	O
is	O
maintained	O
,	O
we	O
now	O
offer	O
a	O
dipstick	O
only	O
urinalysis	O
to	O
our	O
emergency	O
room	O
for	O
children	O
2	O
years	O
of	O
age	O
or	O
older	O
,	O
with	O
a	O
microscopic	O
analysis	O
performed	O
automatically	O
if	O
dipstick	O
results	O
are	O
positive	O
.	O
If	O
no	O
microscopic	O
urinalysis	O
is	O
required	O
,	O
testing	O
turn-around	O
time	O
is	O
reduced	O
by	O
12.3	O
min/test	O
and	O
the	O
hospital	O
charge	O
is	O
reduced	O
from	O
U.S.	O
$	O
32	O
to	O
U.S.	O
$	O
12	O
.	O
Using	O
video-intensified	O
fluorescence	O
microscopy	O
and	O
a	O
pseudocolor	O
display	O
of	O
fluorescence	O
intensity	O
,	O
we	O
analyzed	O
the	O
distribution	O
of	O
microinjected	O
molecules	O
within	O
the	O
nurse-cell/oocyte	O
syncytium	O
of	O
Drosophila	O
ovarian	O
follicles	O
.	O
We	O
varied	O
the	O
composition	O
and	O
the	O
osmolarity	O
of	O
the	O
culture	O
solution	O
as	O
well	O
as	O
the	O
electrical	O
charge	O
and	O
the	O
molecular	O
mass	O
of	O
the	O
microinjected	O
fluorescent	O
probe	O
.	O
As	O
culture	O
solutions	O
,	O
we	O
used	O
four	O
simple	O
salines	O
(	O
IMADS	O
)	O
and	O
a	O
complex	O
tissue-culture	O
medium	O
(	O
R-14	O
)	O
that	O
matched	O
the	O
osmolarity	O
of	O
adult	O
hemolymph	O
.	O
Small	O
amounts	O
of	O
two	O
anionic	O
dyes	O
(	O
Lucifer	O
Yellow	O
CH	O
and	O
Lucifer	O
Yellow	O
dextran	O
)	O
as	O
well	O
as	O
of	O
two	O
cationic	O
dyes	O
(	O
rhodamine	O
6G	O
and	O
tetramethylrhodamine	O
dextran-lysine	O
)	O
were	O
iontophoretically	O
microinjected	O
either	O
into	O
a	O
nurse	O
cell	O
or	O
into	O
the	O
oocyte	O
of	O
stage-10	O
follicles	O
.	O
In	O
the	O
tissue-culture	O
medium	O
,	O
within	O
a	O
few	O
seconds	O
following	O
microinjection	O
,	O
all	O
tested	O
dyes	O
passed	O
through	O
the	O
intercellular	O
bridges	O
in	O
both	O
the	O
anterior	O
direction	O
(	O
to	O
the	O
nurse	O
cells	O
)	O
and	O
the	O
posterior	O
direction	O
(	O
to	O
the	O
oocyte	O
)	O
,	O
independent	O
of	O
their	O
electrical	O
charge	O
or	O
molecular	O
mass	O
.	O
In	O
all	O
simple	O
salines	O
,	O
irrespective	O
of	O
their	O
osmolarity	O
,	O
Lucifer	O
Yellow	O
CH	O
was	O
found	O
to	O
preferentially	O
migrate	O
in	O
the	O
posterior	O
direction	O
and	O
to	O
accumulate	O
in	O
the	O
oocyte	O
due	O
to	O
progressive	O
binding	O
to	O
yolk	O
spheres	O
.	O
Thus	O
,	O
with	O
this	O
sensitive	O
method	O
,	O
no	O
correlation	O
was	O
detectable	O
between	O
the	O
external	O
osmolarity	O
,	O
the	O
electrical	O
charge	O
and	O
the	O
preferential	O
direction	O
of	O
migration	O
of	O
a	O
microinjected	O
probe	O
.	O
Our	O
results	O
indicate	O
that	O
the	O
electrical	O
gradient	O
described	O
by	O
other	O
authors	O
does	O
not	O
exert	O
significant	O
influence	O
on	O
the	O
migration	O
of	O
charged	O
molecules	O
through	O
intercellular	O
bridges	O
in	O
situ	O
.	O
The	O
AF-4	O
gene	O
on	O
human	O
chromosome	O
4q21	O
is	O
involved	O
in	O
reciprocal	O
translocations	O
to	O
the	O
ALL-1	O
gene	O
on	O
chromosome	O
11q23	O
,	O
which	O
are	O
associated	O
with	O
acute	SYMP
lymphoblastic	SYMP
leukaemias	SYMP
.	O
A	O
set	O
of	O
recombinant	O
phage	O
carrying	O
genomic	O
fragments	O
for	O
the	O
coding	O
region	O
and	O
flanking	O
sequences	O
of	O
the	O
AF-4	O
gene	O
were	O
isolated	O
.	O
Phage	O
inserts	O
were	O
assembled	O
into	O
four	O
contigs	O
with	O
21	O
exons	O
,	O
and	O
an	O
intron	O
phase	O
map	O
was	O
produced	O
enabling	O
the	O
interpretation	O
of	O
translocation-generated	O
fusion	O
proteins	O
.	O
The	O
gene	O
contains	O
two	O
alternative	O
first	O
exons	O
,	O
1a	O
and	O
1b	O
,	O
both	O
including	O
a	O
translation	O
initiation	O
codon	O
.	O
The	O
translocation	O
breakpoint	O
cluster	O
region	O
is	O
flanked	O
by	O
exons	O
3	O
and	O
6	O
and	O
two	O
different	O
polyadenylation	O
signals	O
were	O
identified	O
.	O
Polyclonal	O
antisera	O
directed	O
against	O
three	O
different	O
portions	O
of	O
the	O
AF-4	O
protein	O
were	O
produced	O
and	O
used	O
to	O
detect	O
a	O
116	O
kD	O
protein	O
in	O
cellular	O
extracts	O
of	O
human	O
B-lymphoblastoid	O
and	O
proB	O
cell	O
lines	O
.	O
In	O
mitogen-stimulated	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
the	O
AF-4	O
antigen	O
was	O
predominantly	O
located	O
in	O
the	O
nucleus	O
.	O
The	O
AF-4	O
gene	O
is	O
a	O
member	O
of	O
the	O
AF-4	O
,	O
LAF-4	O
and	O
FMR-2	O
gene	O
family	O
.	O
The	O
members	O
of	O
this	O
family	O
encode	O
serine-proline-rich	O
proteins	O
with	O
properties	O
of	O
nuclear	O
transcription	O
factors	O
.	O
Comparison	O
of	O
AF-4	O
protein	O
coding	O
sequences	O
with	O
the	O
LAF-4	O
and	O
FMR-2	O
sequences	O
revealed	O
five	O
highly	O
conserved	O
domains	O
of	O
potential	O
functional	O
relevance	O
.	O
Immunoglobulin	O
superfamily	O
molecules	O
in	O
the	O
brain	O
are	O
involved	O
in	O
distinct	O
aspects	O
of	O
nervous	O
system	O
histogenesis	O
,	O
for	O
example	O
neuronal	O
migration	O
and	O
axonal	O
growth	O
.	O
To	O
identify	O
novel	O
members	O
of	O
this	O
superfamily	O
in	O
the	O
chick	O
nervous	O
system	O
,	O
we	O
developed	O
a	O
polymerase	O
chain	O
reaction-based	O
approach	O
making	O
use	O
of	O
sequence	O
motifs	O
of	O
immunoglobulin-like	O
domains	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
molecular	O
cloning	O
of	O
three	O
isoforms	O
,	O
the	O
biochemical	O
analysis	O
and	O
the	O
immunohistochemical	O
characterization	O
of	O
one	O
of	O
the	O
proteins	O
identified	O
in	O
this	O
screen	O
.	O
This	O
molecule	O
has	O
91	O
%	O
sequence	O
identity	O
with	O
the	O
limbic	O
system-associated	O
membrane	O
protein	O
(	O
LAMP	O
)	O
characterized	O
in	O
the	O
rat	O
and	O
is	O
therefore	O
referred	O
to	O
as	O
the	O
chicken	O
homologue	O
of	O
the	O
latter	O
(	O
chLAMP	O
)	O
.	O
The	O
molecule	O
is	O
a	O
glycosylphosphatidyl-inositol-anchored	O
60	O
kDa	O
protein	O
with	O
three	O
immunoglobulin-like	O
domains	O
and	O
contains	O
40	O
%	O
N-linked	O
carbohydrate	O
.	O
We	O
identify	O
three	O
different	O
mRNA	O
forms	O
of	O
chLAMP	O
and	O
show	O
that	O
two	O
forms	O
with	O
distinct	O
5'-termini	O
are	O
differentially	O
transcribed	O
in	O
neural	O
development	O
.	O
In	O
addition	O
,	O
we	O
demonstrate	O
using	O
a	O
fusion	O
protein	O
expressed	O
in	O
eukaryotic	O
cells	O
that	O
chLAMP	O
has	O
homophilic	O
binding	O
activity	O
.	O
The	O
protein	O
was	O
found	O
on	O
a	O
subset	O
of	O
axons	O
in	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
and	O
is	O
likely	O
to	O
be	O
involved	O
in	O
specific	O
cell-cell	O
interactions	O
in	O
neurohistogenesis	O
.	O
Two	O
novel	O
cDNAs	O
,	O
DNAS1L2	O
and	O
DNAS1L3	O
,	O
are	O
predicted	O
to	O
encode	O
proteins	O
of	O
299	O
and	O
305	O
amino	O
acids	O
with	O
56	O
and	O
46	O
%	O
residue	O
identity	O
(	O
71	O
and	O
63	O
%	O
similarity	O
)	O
,	O
respectively	O
,	O
to	O
deoxyribonuclease	O
I	O
(	O
DNase	O
I	O
)	O
.	O
DNAS1L2	O
is	O
located	O
on	O
a	O
16p13.3	O
cosmid	O
,	O
while	O
DNAS1L3	O
maps	O
to	O
3p14.3-p21.1	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
and	O
by	O
PCR	O
analysis	O
of	O
a	O
radiation	O
hybrid	O
panel	O
.	O
Northern	O
analysis	O
revealed	O
DNAS1L3	O
expression	O
nearly	O
exclusively	O
in	O
liver	O
,	O
while	O
DNAS1L2	O
expression	O
was	O
detected	O
in	O
brain	O
by	O
RT-PCR	O
.	O
The	O
previously	O
defined	O
DNL1L	O
or	O
DNAS1L1	O
is	O
expressed	O
highest	O
in	O
heart	O
and	O
skeletal	O
muscle	O
,	O
while	O
DNase	O
I	O
is	O
expressed	O
in	O
the	O
pancreas	O
,	O
parotid	O
gland	O
,	O
and	O
kidney	O
.	O
Thus	O
,	O
to	O
date	O
,	O
four	O
DNase	O
I-like	O
genes	O
that	O
show	O
different	O
tissue	O
expression	O
patterns	O
are	O
known	O
.	O
A	O
comparison	O
of	O
DNAS1L1	O
,	O
DNAS1L2	O
,	O
and	O
DNAS1L3	O
with	O
the	O
well-characterized	O
DNase	O
I	O
suggests	O
that	O
the	O
DNAS1L	O
proteins	O
are	O
unlikely	O
to	O
be	O
glycosylated	O
or	O
bind	O
actin	O
;	O
however	O
,	O
catalytic	O
and	O
calcium-	O
and	O
DNA-binding	O
residues	O
are	O
conserved	O
,	O
and	O
potentially	O
cleavable	O
signal	O
peptides	O
are	O
present	O
among	O
all	O
these	O
proteins	O
.	O
This	O
analysis	O
also	O
identifies	O
regions	O
of	O
high	O
conservation	O
among	O
these	O
proteins	O
with	O
no	O
currently	O
assigned	O
function	O
.	O
Two	O
different	O
responses	O
to	O
the	O
therapy	O
were	O
observed	O
in	O
a	O
group	O
of	O
patients	O
receiving	O
the	O
protease	SYMP
inhibitor	SYMP
indinavir	SYMP
.	O
In	O
one	O
,	O
suppression	O
of	O
virus	O
replication	O
occurred	O
and	O
has	O
persisted	O
for	O
90	O
weeks	O
(	O
bDNA	O
,	O
&	O
#	O
60	O
;	O
500	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
[	O
HIV-1	O
]	O
RNA	O
copies/ml	O
)	O
.	O
In	O
the	O
second	O
group	O
,	O
a	O
rebound	O
in	O
virus	O
levels	O
in	O
plasma	O
followed	O
the	O
initial	O
sharp	O
decline	O
observed	O
at	O
the	O
start	O
of	O
therapy	O
.	O
This	O
was	O
associated	O
with	O
the	O
emergence	O
of	O
drug-resistant	O
variants	O
.	O
Sequence	O
analysis	O
of	O
the	O
protease	O
gene	O
during	O
the	O
course	O
of	O
therapy	O
revealed	O
that	O
in	O
this	O
second	O
group	O
there	O
was	O
a	O
sequential	O
acquisition	O
of	O
protease	O
mutations	O
at	O
amino	O
acids	O
46	O
,	O
82	O
,	O
54	O
,	O
71	O
,	O
89	O
,	O
and	O
90	O
.	O
In	O
the	O
six	O
patients	O
in	O
this	O
group	O
,	O
there	O
was	O
also	O
an	O
identical	O
mutation	O
in	O
the	O
gag	O
p7/p1	O
gag	O
protease	O
cleavage	O
site	O
.	O
In	O
three	O
of	O
the	O
patients	O
,	O
this	O
change	O
was	O
seen	O
as	O
early	O
as	O
6	O
to	O
10	O
weeks	O
after	O
the	O
start	O
of	O
therapy	O
.	O
In	O
one	O
patient	O
,	O
a	O
second	O
mutation	O
occurred	O
at	O
the	O
gag	O
p1/p6	O
cleavage	O
site	O
,	O
but	O
it	O
appeared	O
18	O
weeks	O
after	O
the	O
time	O
of	O
appearance	O
of	O
the	O
p7/p1	O
mutation	O
.	O
Recombinant	O
HIV-1	O
variants	O
containing	O
two	O
or	O
three	O
mutations	O
in	O
the	O
protease	O
gene	O
were	O
constructed	O
either	O
with	O
mutations	O
at	O
the	O
p7/p1	O
cleavage	O
site	O
or	O
with	O
wild-type	O
(	O
WT	O
)	O
gag	O
sequences	O
.	O
When	O
recombinant	O
HIV-1-containing	O
protease	O
mutations	O
at	O
46	O
and	O
82	O
was	O
grown	O
in	O
MT2	O
cells	O
,	O
there	O
was	O
a	O
68	O
%	O
reduction	O
in	O
its	O
rate	O
of	O
replication	O
compared	O
to	O
the	O
WT	O
virus	O
.	O
Introduction	O
of	O
an	O
additional	O
mutation	O
at	O
the	O
gag	O
p7/p1	O
protease	O
cleavage	O
site	O
compensated	O
for	O
the	O
partially	O
defective	O
protease	O
gene	O
.	O
Similarly	O
,	O
rates	O
of	O
replication	O
of	O
viruses	O
with	O
mutations	O
M46L/I	O
,	O
I54V	O
,	O
and	O
V82A	O
in	O
protease	O
were	O
enhanced	O
both	O
in	O
the	O
presence	O
and	O
in	O
the	O
absence	O
of	O
Indinavir	O
when	O
combined	O
with	O
mutations	O
in	O
the	O
gag	O
p7/p1	O
and	O
the	O
gag	O
p1/p6	O
cleavage	O
sites	O
.	O
Optimal	O
rates	O
of	O
virus	O
replication	O
require	O
protease	O
cleavage	O
of	O
precursor	O
polyproteins	O
.	O
A	O
mutation	O
in	O
the	O
cleavage	O
site	O
that	O
enhanced	O
the	O
availability	O
of	O
a	O
protein	O
that	O
was	O
rate	O
limiting	O
for	O
virus	O
maturation	O
would	O
confer	O
on	O
that	O
virus	O
a	O
significant	O
growth	O
advantage	O
and	O
may	O
explain	O
the	O
uniform	O
emergence	O
of	O
viruses	O
with	O
alterations	O
at	O
the	O
p7/p1	O
cleavage	O
site	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
the	O
emergence	O
of	O
mutations	O
in	O
the	O
gag	O
p7/p1	O
protease	O
cleavage	O
sites	O
in	O
patients	O
receiving	O
protease	SYMP
therapy	SYMP
and	O
identifies	O
this	O
change	O
as	O
an	O
important	O
determinant	O
of	O
HIV-1	O
resistance	O
to	O
protease	O
inhibitors	O
in	O
patient	O
populations	O
.	O
A	O
novel	O
intracellular	O
calcium-binding	O
protein	O
from	O
Echinococcus	O
granulosus	O
is	O
described	O
in	O
this	O
work	O
.	O
A	O
cDNA	O
was	O
isolated	O
from	O
a	O
lambdagt11	O
protoscolex	O
expression	O
library	O
and	O
the	O
deduced	O
amino	O
acid	O
sequence	O
has	O
at	O
least	O
fifteen	O
sequentially	O
repeated	O
twelve-residue	O
repeats	O
that	O
resemble	O
the	O
calcium-binding	O
loop	O
of	O
EF-hands	O
;	O
however	O
,	O
the	O
dodecamer	O
motif	O
has	O
no	O
flanking	O
helices	O
.	O
The	O
cDNA	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
using	O
the	O
pGEX	O
vector	O
,	O
and	O
a	O
recombinant	O
fusion	O
protein	O
(	O
EgCaBP1-GST	O
)	O
was	O
obtained	O
.	O
The	O
recombinant	O
fusion	O
protein	O
binds	O
calcium	O
when	O
assayed	O
with	O
45Ca	O
.	O
It	O
is	O
possible	O
that	O
the	O
calcium-binding	O
motifs	O
present	O
a	O
secondary	O
structure	O
similar	O
to	O
the	O
parallel	O
beta	O
roll	O
structure	O
described	O
for	O
an	O
alkaline	O
protease	O
from	O
Pseudomonas	O
aeruginosa	O
.	O
A	O
native	O
protein	O
of	O
more	O
than	O
300	O
kDa	O
was	O
recognized	O
by	O
an	O
anti-EgCaBP1	O
monoclonal	O
antibody	O
by	O
Western-blot	O
analysis	O
.	O
Immunohistochemistry	O
using	O
a	O
pool	O
of	O
anti-EgCaBP1-GST	O
mouse	O
sera	O
demonstrated	O
a	O
strong	O
association	O
of	O
the	O
protein	O
with	O
calcareous	O
corpuscles	O
.	O
The	O
possible	O
role	O
of	O
this	O
protein	O
and	O
that	O
of	O
the	O
calcareous	O
corpuscles	O
in	O
the	O
protoscolex	O
are	O
discussed	O
.	O
The	O
enzyme	O
activity	O
of	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAP	O
kinase	O
)	O
increases	O
in	O
response	O
to	O
agents	O
acting	O
on	O
a	O
variety	O
of	O
cell	O
surface	O
receptors	O
,	O
including	O
receptors	O
linked	O
to	O
heterotrimeric	O
G	O
proteins	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrated	O
that	O
Raf-1	O
protein	O
kinase	O
activity	O
in	O
the	O
mouse	O
parotid	O
glands	O
was	O
induced	O
by	O
chronic	O
isoproterenol	O
administration	O
in	O
whole	O
animals	O
.	O
To	O
investigate	O
the	O
molecular	O
nature	O
underlying	O
cellular	O
responses	O
to	O
Raf-1	O
activation	O
,	O
we	O
have	O
stably	O
transfected	O
rat	O
salivary	O
epithelial	O
Pa-4	O
cells	O
with	O
human	O
Raf-1-estrogen	O
receptor	O
fusion	O
gene	O
(	O
DeltaRaf-1	O
:	O
ER	O
)	O
and	O
used	O
mRNA	O
differential	O
display	O
in	O
search	O
of	O
messages	O
induced	O
by	O
DeltaRaf-1	O
:	O
ER	O
activation	O
.	O
Through	O
this	O
approach	O
,	O
the	O
gene	O
encoding	O
non-histone	O
chromosomal	O
protein	O
HMGI-C	O
was	O
identified	O
as	O
one	O
of	O
the	O
target	O
genes	O
activated	O
by	O
oncogenic	O
Raf-1	O
kinase	O
.	O
Activation	O
of	O
Raf-1	O
kinase	O
resulted	O
in	O
a	O
delayed	O
and	O
sustained	O
increase	O
of	O
HMGI-C	O
expression	O
in	O
the	O
Pa-4	O
cells	O
.	O
The	O
induction	O
of	O
HMGI-C	O
mRNA	O
level	O
is	O
sensitive	O
to	O
both	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
and	O
transcription	O
inhibitor	O
actinomycin	O
D.	O
The	O
role	O
of	O
the	O
extracellular	O
signal-related	O
kinase	O
(	O
ERK	O
)	O
signaling	O
pathway	O
in	O
the	O
HMGI-C	O
induction	O
was	O
highlighted	O
by	O
the	O
result	O
that	O
the	O
MAP	O
kinase	O
kinase	O
(	O
MEK	O
)	O
inhibitor	O
,	O
PD	O
98059	O
,	O
blocked	O
DeltaRaf-1	O
:	O
ER-	O
and	O
12-O-tetradecanoylphorbol-13-acetate-stimulated	O
HMGI-C	O
induction	O
.	O
Altogether	O
,	O
these	O
findings	O
support	O
the	O
notion	O
that	O
the	O
Raf/MEK/ERK	O
signaling	O
module	O
,	O
at	O
least	O
in	O
part	O
,	O
regulates	O
transcriptional	O
activation	O
of	O
the	O
chromosomal	O
architectural	O
protein	O
HMGI-C	O
.	O
Pendred	SYMP
syndrome	SYMP
is	O
a	O
recessively	O
inherited	O
disorder	O
with	O
the	O
hallmark	O
features	O
of	O
congenital	SYMP
deafness	SYMP
and	O
thyroid	SYMP
goitre	SYMP
.	O
By	O
some	O
estimates	O
,	O
the	O
disorder	O
may	O
account	O
for	O
upwards	O
of	O
10	O
%	O
of	O
hereditary	SYMP
deafness	SYMP
.	O
Previous	O
genetic	O
linkage	O
studies	O
localized	O
the	O
gene	O
to	O
a	O
broad	O
interval	O
on	O
human	O
chromosome	O
7q22-31.1	O
.	O
Using	O
a	O
positional	O
cloning	O
strategy	O
,	O
we	O
have	O
identified	O
the	O
gene	O
(	O
PDS	O
)	O
mutated	O
in	O
Pendred	SYMP
syndrome	SYMP
and	O
found	O
three	O
apparently	O
deleterious	O
mutations	O
,	O
each	O
segregating	O
with	O
the	O
disease	O
in	O
the	O
respective	O
families	O
in	O
which	O
they	O
occur	O
.	O
PDS	O
produces	O
a	O
transcript	O
of	O
approximately	O
5	O
kb	O
that	O
was	O
found	O
to	O
be	O
expressed	O
at	O
significant	O
levels	O
only	O
in	O
the	O
thyroid	O
.	O
The	O
predicted	O
protein	O
,	O
pendrin	O
,	O
is	O
closely	O
related	O
to	O
a	O
number	O
of	O
known	O
sulphate	O
transporters	O
.	O
These	O
studies	O
provide	O
compelling	O
evidence	O
that	O
defects	O
in	O
pendrin	O
cause	O
Pendred	SYMP
syndrome	SYMP
thereby	O
launching	O
a	O
new	O
area	O
of	O
investigation	O
into	O
thyroid	O
physiology	O
,	O
the	O
pathogenesis	O
of	O
congenital	SYMP
deafness	SYMP
and	O
the	O
role	O
of	O
altered	O
sulphate	O
transport	O
in	O
human	O
disease	O
.	O
We	O
report	O
the	O
cDNA	O
cloning	O
,	O
partial	O
genomic	O
organization	O
,	O
and	O
expression	O
pattern	O
of	O
Stra10	O
,	O
a	O
novel	O
retinoic	O
acid-inducible	O
gene	O
in	O
P19	O
embryonal	SYMP
carcinoma	SYMP
cells	O
.	O
Four	O
murine	O
cDNA	O
isoforms	O
have	O
been	O
isolated	O
,	O
which	O
are	O
likely	O
to	O
result	O
from	O
alternative	O
splicing	O
.	O
The	O
predicted	O
protein	O
sequences	O
exhibit	O
approximately	O
85	O
%	O
identity	O
with	O
the	O
Pbx-related	O
Meis1	O
homeobox	O
gene	O
products	O
,	O
which	O
are	O
involved	O
in	O
myeloid	SYMP
leukemia	SYMP
in	O
BXH-2	O
mice	O
,	O
and	O
one	O
of	O
the	O
Stra10	O
isoforms	O
corresponds	O
to	O
the	O
recently	O
published	O
Meis2	O
sequence	O
(	O
Nakamura	O
et	O
al	O
.	O
[	O
1996	O
]	O
Oncogene	O
13:2235-2242	O
)	O
.	O
The	O
Meis2	O
homeodomain	O
is	O
identical	O
to	O
that	O
of	O
Meis1	O
,	O
and	O
is	O
most	O
closely	O
related	O
to	O
those	O
of	O
the	O
Pbx/TGIF	O
homeobox	O
gene	O
products	O
.	O
By	O
in	O
situ	O
hybridization	O
analysis	O
,	O
we	O
show	O
that	O
the	O
Meis2	O
gene	O
displays	O
spatially	O
restricted	O
expression	O
patterns	O
in	O
the	O
developing	O
nervous	O
system	O
,	O
limbs	O
,	O
face	O
,	O
and	O
in	O
various	O
viscera	O
.	O
In	O
adult	O
mice	O
,	O
Meis2	O
is	O
mainly	O
expressed	O
in	O
the	O
brain	O
and	O
female	O
genital	O
tract	O
,	O
with	O
a	O
different	O
distribution	O
of	O
the	O
alternative	O
splice	O
forms	O
in	O
these	O
organs	O
.	O
A	O
methodical	O
strategy	O
for	O
the	O
isolation	O
of	O
microsatellite	O
markers	O
specific	O
for	O
targeted	O
regions	O
of	O
bovine	O
chromosomes	O
is	O
presented	O
.	O
The	O
procedure	O
involves	O
directed	O
microdissection	O
of	O
one	O
defined	O
subchromosomal	O
area	O
,	O
its	O
DOP-PCR-amplification	O
and	O
cloning	O
.	O
With	O
this	O
approach	O
,	O
a	O
library	O
specific	O
to	O
the	O
BTA	O
6q21-31	O
chromosomal	O
region	O
was	O
constructed	O
.	O
Eleven	O
unique	O
microsatellite-containing	O
sequences	O
were	O
isolated	O
,	O
converted	O
into	O
sequence-tagged	O
microsatellite	O
sites	O
,	O
and	O
characterized	O
concerning	O
their	O
species-specific	O
origin	O
.	O
Seven	O
primer	O
pairs	O
generated	O
bovine-specific	O
PCR	O
products	O
and	O
provided	O
a	O
set	O
of	O
microsatellite	O
markers	O
that	O
generally	O
revealed	O
high	O
informativity	O
in	O
the	O
HF	O
breed	O
.	O
Linkage	O
analysis	O
assigned	O
six	O
of	O
them	O
to	O
their	O
predefined	O
subchromosomal	O
origin	O
on	O
BTA	O
6	O
corresponding	O
to	O
the	O
specific	O
rehybridization	O
signal	O
of	O
the	O
DOP-PCR	O
product	O
generated	O
from	O
the	O
microdissected	O
chromosome	O
area	O
6q21-31	O
.	O
The	O
results	O
underline	O
the	O
usefulness	O
of	O
the	O
BTA	O
6q21-31	O
library	O
for	O
targeted	O
isolation	O
of	O
unique	O
sequences	O
that	O
are	O
specific	O
for	O
the	O
dissected	O
chromosomal	O
region	O
as	O
demonstrated	O
here	O
by	O
the	O
isolation	O
of	O
microsatellite	O
markers	O
.	O
Phylogeographic	O
structure	O
was	O
determined	O
for	O
the	O
yellow	O
mongoose	O
,	O
Cynictis	O
penicillata	O
,	O
using	O
mtDNA	O
RFLPs	O
and	O
control	O
region	O
sequences	O
.	O
The	O
RFLP	O
analysis	O
revealed	O
13	O
haplotypes	O
which	O
showed	O
weak	O
geographical	O
patterning	O
consistent	O
with	O
a	O
recent	O
range	O
expansion	O
from	O
a	O
refugial	O
population	O
(	O
s	O
)	O
.	O
An	O
analysis	O
of	O
molecular	O
variance	O
(	O
AMOVA	O
)	O
revealed	O
no	O
correspondence	O
between	O
mtDNA	O
phylogeography	O
and	O
subspecies	O
delimitation	O
,	O
nor	O
between	O
matrilines	O
and	O
areas	O
characterized	O
by	O
a	O
high	O
incidence	O
of	O
the	O
viverrid-type	SYMP
rabies	SYMP
,	O
of	O
which	O
the	O
yellow	O
mongoose	O
is	O
the	O
principal	O
vector	O
.	O
The	O
lack	O
of	O
structure	O
was	O
also	O
shown	O
by	O
control	O
region	O
sequences	O
although	O
four	O
of	O
the	O
maternal	O
lineages	O
shared	O
a	O
near-perfect	O
81	O
bp	O
repeat	O
.	O
We	O
speculate	O
that	O
regional	O
hot	O
spots	O
of	O
the	O
viverrid	SYMP
rabies	SYMP
biotype	O
reflect	O
population	O
density	O
differences	O
in	O
the	O
yellow	O
mongoose	O
that	O
are	O
not	O
underscored	O
by	O
genetic	O
partitioning	O
,	O
at	O
least	O
at	O
the	O
level	O
of	O
resolution	O
provided	O
by	O
our	O
analyses	O
.	O
The	O
indoor	O
pollution	O
,	O
where	O
the	O
patients	O
pass	O
in	O
general	O
close	O
to	O
90	O
%	O
of	O
their	O
time	O
,	O
is	O
an	O
important	O
factor	O
to	O
take	O
in	O
consideration	O
if	O
one	O
wants	O
to	O
evaluate	O
suitably	O
the	O
effects	O
of	O
the	O
air	O
pollution	O
on	O
the	O
health	O
.	O
Causes	O
of	O
this	O
kind	O
of	O
pollution	O
are	O
partially	O
linked	O
to	O
the	O
external	O
pollution	O
and	O
the	O
outdoor	O
environment	O
and	O
also	O
are	O
function	O
of	O
human	O
activities	O
and	O
introduced	O
products	O
in	O
the	O
habitat	O
(	O
heating	O
,	O
tabagisme	O
,	O
handywork	O
,	O
products	O
of	O
maintenance	O
,	O
coatings	O
,	O
materials	O
of	O
construction	O
,	O
etc.	O
)	O
.	O
The	O
effects	O
on	O
health	O
are	O
as	O
various	O
as	O
the	O
pollutants	O
,	O
going	O
from	O
sharp	O
intoxication	O
to	O
irritations	O
or	O
simply	O
desagreements	O
.	O
In	O
this	O
problem	O
of	O
public	O
health	O
we	O
may	O
not	O
underestimated	O
sensitive	O
persons	O
and	O
risky	O
group	O
as	O
well	O
as	O
long	O
terme	O
effects	O
,	O
and	O
chronic	O
exposition	O
effects	O
.	O
The	O
search	O
of	O
solutions	O
needs	O
multiple	O
competences	O
from	O
the	O
physician	O
,	O
who	O
has	O
to	O
play	O
an	O
essential	O
role	O
.	O
Dioxins	O
are	O
a	O
family	O
of	O
chlorinated	O
aromatic	O
hydrocarbons	O
that	O
are	O
produced	O
during	O
combustion	O
processes	O
in	O
the	O
presence	O
of	O
a	O
chlorine	O
donor	O
and	O
as	O
by-products	O
of	O
the	O
chlorine-processing	O
chemical	O
industries	O
.	O
Several	O
dioxins	O
are	O
extremely	O
stable	O
compounds	O
and	O
persist	O
for	O
years	O
in	O
the	O
environment	O
.	O
Exposure	O
to	O
dioxins	O
occurs	O
mainly	O
via	O
the	O
ingestion	O
of	O
contaminated	O
food	O
.	O
The	O
lipophilic	O
character	O
of	O
dioxins	O
prevents	O
their	O
excretion	O
in	O
the	O
urine	O
and	O
causes	O
their	O
accumulation	O
in	O
body	O
fat	O
.	O
The	O
mechanisms	O
of	O
dioxin	O
action	O
are	O
similar	O
to	O
those	O
of	O
a	O
hormone	O
.	O
Dioxins	O
bind	O
to	O
a	O
specific	O
intracellular	O
receptor	O
and	O
the	O
complex	O
acts	O
as	O
a	O
transcription	O
factor	O
that	O
induces	O
the	O
production	O
of	O
a	O
great	O
number	O
of	O
proteins	O
.	O
Certain	O
dioxins	O
,	O
particularly	O
2,3,7,8-tetrachlorodibenzo-p-dioxin	O
,	O
are	O
very	O
toxic	O
and	O
able	O
to	O
induce	O
numerous	O
clinical	O
conditions	O
.	O
The	O
carcinogenicity	O
of	O
dioxins	O
is	O
well	O
documented	O
in	O
animal	O
models	O
and	O
has	O
been	O
described	O
in	O
humans	O
after	O
professional	O
and	O
accidental	O
exposures	O
.	O
Recent	O
experimental	O
data	O
also	O
indicate	O
that	O
dioxins	O
can	O
cause	O
dysfunction	SYMP
of	SYMP
the	SYMP
sexual	SYMP
and	SYMP
thyroid	SYMP
hormone	SYMP
systems	SYMP
and	O
that	O
the	O
administration	O
of	O
dioxins	O
induces	O
several	O
conditions	O
related	O
to	O
hormonal	SYMP
dysfunction	SYMP
.	O
Chronic	O
exposure	O
of	O
female	O
Rhesus	O
monkeys	O
increases	O
the	O
incidence	O
and	O
severity	O
of	O
endometriosis	SYMP
.	O
The	O
administration	O
of	O
dioxins	O
during	O
pregnancy	O
and	O
nursing	O
causes	O
altered	O
development	O
of	O
the	O
reproductive	O
system	O
,	O
decreased	O
spermatogenesis	O
,	O
hypothyroidism	SYMP
and	O
disturbed	O
psychomotor	O
development	O
in	O
the	O
offspring	O
.	O
The	O
particular	O
sensibility	O
of	O
the	O
fetus	O
and	O
newborn	O
is	O
of	O
concern	O
because	O
the	O
exposition	O
to	O
dioxins	O
is	O
particularly	O
important	O
during	O
those	O
periods	O
of	O
life	O
.	O
In	O
humans	O
a	O
series	O
of	O
conditions	O
related	O
to	O
hormonal	SYMP
dysfunction	SYMP
as	O
undescended	O
testis	O
,	O
decreased	O
spermatogenesis	O
,	O
testicular	SYMP
cancer	SYMP
and	O
endometriosis	SYMP
have	O
increased	O
in	O
incidence	O
during	O
the	O
last	O
decades	O
.	O
The	O
chronological	O
parallelism	O
with	O
the	O
appearance	O
of	O
dioxins	O
in	O
the	O
environment	O
suggests	O
that	O
these	O
might	O
exert	O
biological	O
effects	O
at	O
the	O
prevailing	O
level	O
of	O
exposure	O
.	O
Nevertheless	O
this	O
hypothesis	O
is	O
currently	O
unconfirmed	O
by	O
epidemiological	O
studies	O
.	O
The	O
implications	O
of	O
this	O
scientific	O
incertitude	O
for	O
the	O
implementation	O
of	O
preventive	O
measures	O
are	O
briefly	O
discussed	O
.	O
This	O
presentation	O
summarizes	O
the	O
debate	O
on	O
the	O
suggested	O
progressive	O
impairment	O
of	O
semen	O
quality	O
(	O
the	O
``	O
sperm	O
fall	O
''	O
)	O
in	O
the	O
last	O
forty	O
years	O
in	O
the	O
developed	O
countries	O
.	O
The	O
various	O
available	O
data	O
strongly	O
suggesting	O
an	O
environmental	O
toxic	O
origin	O
for	O
the	O
``	O
sperm	O
fall	O
''	O
will	O
be	O
presented	O
as	O
well	O
as	O
the	O
most	O
frequently	O
suspected	O
class	O
of	O
substances	O
,	O
the	O
xenoestrogens	O
.	O
YES	O
TO_SEE	O
YES	O
YES	O
Fiercer	O
competition	O
between	O
athletes	O
and	O
a	O
wider	O
knowledge	O
of	O
optimal	O
training	O
regimens	O
dramatically	O
influence	O
current	O
training	O
methods	O
.	O
A	O
single	O
training	O
bout	O
per	O
day	O
was	O
previously	O
considered	O
sufficient	O
,	O
whereas	O
today	O
athletes	O
regularly	O
train	O
twice	O
a	O
day	O
or	O
more	O
.	O
Consequently	O
,	O
the	O
number	O
of	O
athletes	O
who	O
are	O
overtraining	O
and	O
have	O
insufficient	O
rest	O
is	O
increasing	O
.	O
Positive	O
overtraining	O
can	O
be	O
regarded	O
as	O
a	O
natural	O
process	O
when	O
the	O
end	O
result	O
is	O
adaptation	O
and	O
improved	O
performance	O
:	O
the	O
supercompensation	O
principle	O
--	O
which	O
includes	O
the	O
breakdown	O
process	O
(	O
training	O
)	O
followed	O
by	O
the	O
recovery	O
process	O
(	O
rest	O
)	O
--	O
is	O
well	O
known	O
in	O
sports	O
.	O
However	O
,	O
negative	O
overtraining	O
,	O
causing	O
maladaptation	O
and	O
other	O
negative	O
consequences	O
such	O
as	O
staleness	O
,	O
can	O
occur	O
.	O
Physiological	O
,	O
psychological	O
,	O
biochemical	O
and	O
immunological	O
symptoms	O
must	O
be	O
considered	O
,	O
both	O
independently	O
and	O
together	O
,	O
to	O
fully	O
understand	O
the	O
'staleness	O
'	O
syndrome	O
.	O
However	O
,	O
psychological	O
testing	O
may	O
reveal	O
early-warning	O
signs	O
more	O
readily	O
than	O
the	O
various	O
physiological	O
or	O
immunological	O
markers	O
.	O
The	O
time	O
frame	O
of	O
training	O
and	O
recovery	O
is	O
also	O
important	O
since	O
the	O
consequences	O
of	O
negative	O
overtraining	O
comprise	O
an	O
overtraining-response	O
continuum	O
from	O
short	O
to	O
long	O
term	O
effects	O
.	O
An	O
athlete	O
failing	O
to	O
recover	O
within	O
72	O
hours	O
has	O
presumably	O
negatively	O
overtrained	O
and	O
is	O
in	O
an	O
overreached	O
state	O
.	O
For	O
an	O
elite	O
athlete	O
to	O
refrain	O
from	O
training	O
for	O
greater	O
than	O
72	O
hours	O
is	O
extremely	O
undesirable	O
,	O
highlighting	O
the	O
importance	O
of	O
a	O
carefully	O
monitored	O
recovery	O
process	O
.	O
There	O
are	O
many	O
methods	O
used	O
to	O
measure	O
the	O
training	O
process	O
but	O
few	O
with	O
which	O
to	O
match	O
the	O
recovery	O
process	O
against	O
it	O
.	O
One	O
such	O
framework	O
for	O
this	O
is	O
referred	O
to	O
as	O
the	O
total	O
quality	O
recovery	O
(	O
TQR	O
)	O
process	O
.	O
By	O
using	O
a	O
TQR	O
scale	O
,	O
structured	O
around	O
the	O
scale	O
developed	O
for	O
ratings	O
of	O
perceived	O
exertion	O
(	O
RPE	O
)	O
,	O
the	O
recovery	O
process	O
can	O
be	O
monitored	O
and	O
matched	O
against	O
the	O
breakdown	O
(	O
training	O
)	O
process	O
(	O
TQR	O
versus	O
RPE	O
)	O
.	O
The	O
TQR	O
scale	O
emphasises	O
both	O
the	O
athlete	O
's	O
perception	O
of	O
recovery	O
and	O
the	O
importance	O
of	O
active	O
measures	O
to	O
improve	O
the	O
recovery	O
process	O
.	O
Furthermore	O
,	O
directing	O
attention	O
to	O
psychophysiological	O
cues	O
serves	O
the	O
same	O
purpose	O
as	O
in	O
RPE	O
,	O
i.e	O
.	O
increasing	O
self-awareness	O
.	O
This	O
article	O
reviews	O
and	O
conceptualises	O
the	O
whole	O
overtraining	O
process	O
.	O
In	O
doing	O
so	O
,	O
it	O
(	O
i	O
)	O
aims	O
to	O
differentiate	O
between	O
the	O
types	O
of	O
stress	O
affecting	O
an	O
athlete	O
's	O
performance	O
:	O
(	O
ii	O
)	O
identifies	O
factors	O
influencing	O
an	O
athlete	O
's	O
ability	O
to	O
adapt	O
to	O
physical	O
training	O
:	O
(	O
iii	O
)	O
structures	O
the	O
recovery	O
process	O
.	O
The	O
TQR	O
method	O
to	O
facilitate	O
monitoring	O
of	O
the	O
recovery	O
process	O
is	O
then	O
suggested	O
and	O
a	O
conceptual	O
model	O
that	O
incorporates	O
all	O
of	O
the	O
important	O
parameters	O
for	O
performance	O
gain	O
(	O
adaptation	O
)	O
and	O
loss	O
(	O
maladaptation	O
)	O
.	O
Little	O
attention	O
has	O
been	O
directed	O
toward	O
identifying	O
the	O
changes	O
which	O
occur	O
in	O
salivary	O
composition	O
in	O
response	O
to	O
exercise	O
.	O
To	O
address	O
this	O
,	O
our	O
article	O
first	O
refers	O
to	O
the	O
main	O
aspects	O
of	O
salivary	O
gland	O
physiology	O
.	O
A	O
knowledge	O
of	O
the	O
neural	O
control	O
of	O
salivary	O
secretion	O
is	O
especially	O
important	O
for	O
the	O
understanding	O
of	O
the	O
effects	O
of	O
exertion	O
on	O
salivary	O
secretion	O
.	O
Both	O
salivary	O
output	O
and	O
composition	O
depend	O
on	O
the	O
activity	O
of	O
the	O
autonomic	O
nervous	O
system	O
and	O
any	O
modification	O
of	O
this	O
activity	O
can	O
be	O
observed	O
indirectly	O
by	O
alternations	O
in	O
the	O
salivary	O
excretion	O
.	O
The	O
effects	O
of	O
physical	O
activity	O
(	O
with	O
reference	O
to	O
factors	O
such	O
as	O
exercise	O
intensity	O
and	O
duration	O
,	O
or	O
type	O
of	O
exercise	O
protocol	O
)	O
on	O
salivary	O
composition	O
are	O
then	O
considered	O
.	O
Exercise	O
might	O
indeed	O
induce	O
changes	O
in	O
several	O
salivary	O
components	O
such	O
as	O
immunoglobulins	O
,	O
hormones	O
,	O
lactate	O
,	O
proteins	O
and	O
electrolytes	O
.	O
Saliva	O
composition	O
might	O
therefore	O
be	O
used	O
as	O
an	O
alternative	O
noninvasive	O
indicator	O
of	O
the	O
response	O
of	O
the	O
different	O
body	O
tissues	O
and	O
systems	O
to	O
physical	O
exertion	O
.	O
In	O
this	O
respect	O
,	O
the	O
response	O
of	O
salivary	O
amylase	O
and	O
salivary	O
electrolytes	O
to	O
incremental	O
levels	O
of	O
exercise	O
is	O
of	O
particular	O
interest	O
.	O
Beyond	O
a	O
certain	O
intensity	O
of	O
exercise	O
,	O
and	O
coinciding	O
with	O
the	O
accumulation	O
of	O
blood	O
lactate	O
(	O
anaerobic	O
threshold	O
or	O
AT	O
)	O
,	O
a	O
'saliva	O
threshold	O
'	O
(	O
Tsa	O
)	O
does	O
indeed	O
exist	O
.	O
Tsa	O
is	O
the	O
point	O
during	O
exercise	O
at	O
which	O
the	O
levels	O
of	O
salivary	O
alpha-amylase	O
and	O
electrolytes	O
(	O
especially	O
Na+	O
)	O
also	O
begin	O
to	O
rise	O
above	O
baseline	O
levels	O
.	O
The	O
occurrence	O
of	O
the	O
2	O
thresholds	O
(	O
AT	O
and	O
Tsa	O
)	O
might	O
,	O
in	O
turn	O
,	O
be	O
attributable	O
to	O
the	O
same	O
underlying	O
mechanism	O
,	O
that	O
of	O
increased	O
adrenal	O
sympathetic	O
activity	O
at	O
high	O
exercise	O
intensities	O
.	O
Fat	O
is	O
an	O
extremely	O
important	O
substrate	O
for	O
muscle	O
contraction	O
,	O
both	O
at	O
rest	O
and	O
during	O
exercise	O
.	O
Triglycerides	O
(	O
TGs	O
)	O
,	O
stored	O
in	O
adipose	O
tissue	O
and	O
within	O
muscle	O
fibres	O
,	O
are	O
considered	O
to	O
be	O
the	O
main	O
source	O
of	O
the	O
free	O
fatty	O
acids	O
(	O
FFAs	O
)	O
oxidised	O
during	O
exercise	O
.	O
It	O
is	O
still	O
unclear	O
,	O
however	O
,	O
how	O
the	O
use	O
of	O
these	O
substrates	O
is	O
regulated	O
during	O
exercise	O
.	O
The	O
regulation	O
seems	O
to	O
be	O
multifactorial	O
and	O
includes	O
:	O
(	O
i	O
)	O
dietary	O
and	O
nutritional	O
status	O
;	O
(	O
ii	O
)	O
hormonal	O
milieu	O
;	O
(	O
iii	O
)	O
exercise	O
mode	O
,	O
intensity	O
and	O
duration	O
;	O
and	O
(	O
iv	O
)	O
training	O
status	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
mechanism	O
for	O
FFA	O
transport	O
from	O
its	O
storage	O
as	O
triglycerides	O
in	O
adipose	O
tissue	O
and	O
muscle	O
to	O
its	O
place	O
of	O
utilisation	O
in	O
heart	O
,	O
skeletal	O
muscle	O
,	O
kidney	O
and	O
liver	O
is	O
more	O
clearly	O
understood	O
.	O
It	O
has	O
been	O
determined	O
that	O
the	O
plasma	O
FFA	O
turnover	O
rate	O
is	O
sufficiently	O
rapid	O
to	O
account	O
for	O
most	O
of	O
the	O
fat	O
metabolised	O
during	O
low	O
intensity	O
exercise	O
(	O
25	O
to	O
40	O
%	O
VO2max	O
)	O
.	O
However	O
,	O
an	O
exercise	O
intensity	O
of	O
65	O
%	O
VO2max	O
results	O
in	O
a	O
slight	O
decrease	O
in	O
the	O
amount	O
of	O
plasma	O
FFA	O
uptake	O
by	O
muscle	O
tissue	O
.	O
Other	O
studies	O
have	O
found	O
that	O
during	O
prolonged	O
exercise	O
,	O
muscle	O
TGs	O
become	O
the	O
predominant	O
source	O
of	O
energy	O
obtained	O
from	O
fat	O
.	O
Furthermore	O
,	O
it	O
is	O
widely	O
documented	O
that	O
endurance	O
activities	O
increase	O
the	O
energy	O
utilisation	O
from	O
fat	O
while	O
sparing	O
carbohydrate	O
sources	O
.	O
For	O
example	O
,	O
during	O
exercise	O
on	O
a	O
cycle	O
ergometer	O
,	O
nonplasma	O
FFAs	O
and	O
plasma	O
FFAs	O
contribute	O
40	O
%	O
,	O
and	O
carbohydrates	O
60	O
%	O
,	O
of	O
the	O
total	O
calculated	O
amount	O
of	O
energy	O
expenditure	O
before	O
exercise	O
and	O
vice	O
versa	O
after	O
exercise	O
(	O
60	O
%	O
nonplasma	O
and	O
plasma	O
FFAs	O
and	O
40	O
%	O
carbohydrates	O
)	O
.	O
Although	O
it	O
was	O
many	O
years	O
before	O
it	O
was	O
fully	O
demonstrated	O
,	O
fat	O
is	O
now	O
known	O
to	O
be	O
transported	O
in	O
the	O
blood	O
as	O
FFA	O
bound	O
to	O
the	O
protein	O
carrier	O
albumin	O
.	O
The	O
mobilisation	O
of	O
FFA	O
is	O
primarily	O
a	O
function	O
of	O
sympathetic	O
nervous	O
activity	O
directed	O
towards	O
the	O
adipocytes	O
,	O
or	O
the	O
'fat	O
pad	O
'	O
.	O
This	O
nervous	O
activity	O
can	O
be	O
direct	O
or	O
may	O
be	O
an	O
effect	O
of	O
circulating	O
catecholamines	O
such	O
as	O
adrenaline	O
(	O
epinephrine	O
)	O
.	O
This	O
article	O
summarises	O
the	O
role	O
of	O
fat	O
metabolism	O
during	O
exercise	O
.	O
As	O
the	O
clinical	O
availability	O
of	O
glycohaemoglobin/GHb	O
measurement	O
increases	O
,	O
so	O
does	O
the	O
need	O
for	O
comparable	O
and	O
accurate	O
values	O
among	O
different	O
laboratories	O
and	O
different	O
methods	O
.	O
At	O
least	O
there	O
should	O
be	O
comparability	O
,	O
i.e.	O
,	O
commutability	O
or	O
feasibility	O
of	O
providing	O
comparable	O
results	O
from	O
different	O
assays	O
in	O
different	O
laboratories	O
.	O
A	O
clinical	O
joint	O
study	O
on	O
insulin	SYMP
therapy	SYMP
,	O
a	O
survey	O
of	O
the	O
actual	O
inter-laboratory	O
differences	O
in	O
GHb	O
measurement	O
among	O
41	O
institutions	O
and	O
an	O
assessment	O
of	O
11	O
assay	O
methods	O
for	O
the	O
determination	O
of	O
GHb	O
were	O
performed	O
using	O
commercial	O
calibrators	O
and	O
fresh	O
blood	O
samples	O
.	O
Data	O
on	O
the	O
actual	O
state	O
of	O
inter-laboratory	O
and	O
inter-assay	O
differences	O
of	O
observed	O
values	O
were	O
useful	O
for	O
comparing	O
results	O
among	O
facilities	O
.	O
The	O
recommendation	O
of	O
the	O
Japan	O
Diabetes	O
Society	O
to	O
measure	O
only	O
the	O
stable	O
GHb	O
component	O
and	O
to	O
correct	O
the	O
GHb	O
percentage	O
by	O
two-point	O
calibration	O
with	O
assigned	O
values	O
,	O
was	O
effective	O
but	O
not	O
sufficient	O
.	O
Even	O
after	O
correction	O
,	O
8	O
out	O
of	O
11	O
methods	O
still	O
remained	O
of	O
little	O
practical	O
use	O
because	O
of	O
their	O
large	O
relative	O
errors	O
.	O
Inter-method	O
differences	O
among	O
11	O
available	O
assay	O
methods	O
were	O
great	O
even	O
after	O
correction	O
and	O
depended	O
on	O
not	O
only	O
the	O
methods	O
but	O
the	O
samples	O
used	O
for	O
the	O
determination	O
.	O
The	O
performance	O
of	O
some	O
methods	O
or	O
instruments	O
used	O
are	O
only	O
poor	O
at	O
distinguishing	O
the	O
stable	O
glycated	O
haemoglobin	O
itself	O
.	O
Some	O
alternative	O
measurement	O
system	O
with	O
comparability	O
,	O
commutability	O
and	O
precision	O
should	O
be	O
established	O
.	O
An	O
urgent	O
and	O
worldwide	O
problem	O
to	O
remove	O
inter-laboratory	O
differences	O
in	O
the	O
measurement	O
of	O
GHb	O
needs	O
to	O
be	O
solved	O
.	O
Users	O
in	O
clinical	O
practice	O
must	O
recognize	O
these	O
problems	O
,	O
and	O
,	O
before	O
supply	O
,	O
the	O
providers	O
should	O
check	O
their	O
method	O
and	O
keep	O
records	O
that	O
are	O
readily	O
traceable	O
.	O
A	O
postal	O
survey	O
was	O
performed	O
to	O
determine	O
the	O
current	O
practices	O
and	O
attitudes	O
of	O
radiologists	O
towards	O
the	O
imaging	O
of	O
suspected	O
lower	O
limb	O
deep	SYMP
vein	SYMP
thrombosis	SYMP
(	SYMP
DVT	SYMP
)	SYMP
.	O
One	O
hundred	O
and	O
twenty-seven	O
departments	O
responded	O
to	O
a	O
questionnaire	O
sent	O
in	O
March	O
1996	O
.	O
The	O
results	O
show	O
that	O
87	O
%	O
of	O
hospitals	O
possess	O
colour	O
Doppler	O
ultrasound	O
(	O
CDUS	O
)	O
machines	O
and	O
that	O
46	O
%	O
of	O
departments	O
perform	O
ultrasound	O
as	O
the	O
first	O
line	O
investigation	O
in	O
over	O
90	O
%	O
of	O
cases	O
.	O
Thirty	O
per	O
cent	O
of	O
departments	O
considered	O
calf	O
vein	O
visualization	O
to	O
be	O
generally	O
adequate	O
and	O
34	O
%	O
thought	O
that	O
clinicians	O
in	O
their	O
hospitals	O
invariably	O
anticoagulated	O
patients	O
with	O
isolated	SYMP
calf	SYMP
thrombus	SYMP
.	O
In	O
hospitals	O
where	O
venography	O
was	O
routinely	O
used	O
as	O
the	O
first	O
line	O
investigation	O
,	O
the	O
most	O
common	O
reasons	O
were	O
:	O
the	O
perceived	O
inferiority	O
of	O
ultrasound	O
(	O
US	O
)	O
in	O
demonstrating	O
below-knee	O
clot	SYMP
,	O
its	O
time-consuming	O
nature	O
and	O
the	O
limited	O
access	O
to	O
suitable	O
ultrasound	O
machines	O
.	O
The	O
widespread	O
use	O
of	O
ultrasound	O
is	O
encouraging	O
,	O
however	O
,	O
there	O
are	O
clearly	O
diverse	O
views	O
.	O
A	O
significant	O
minority	O
of	O
departments	O
depend	O
principally	O
upon	O
venography	O
in	O
the	O
diagnosis	O
of	O
DVT	SYMP
.	O
